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Preface 
 
This PhD thesis has been carried out at the Department of Life Quality Studies, Alma 
Mater Studiorum-University of Bologna (Italy), under the supervision of  Prof. Vincenzo 
Tumiatti and Dr. Andrea Milelli.  
The whole PhD thesis is devoted to the study of new agents for the treatments of chronic 
degenerative diseases, in particulare for the treatment of Alzheimer and  cancer’s diseases. 
This thesis describes four main projects: the first project is focused on the development of 
new non-ATP competitive GSK-3β inhibitors for Alzhimer disease treatment. The second 
was carried out at Barcelona University in Diego Muñoz-Torrero López-Ibarra’s group 
and this project focused on the development of novel family of rhein−huprine hybrids as 
MTDLs for AD. While the third project regards designe and synthesis of new GSK-3 β- 
HDAC inhibitors agents as MTDLs for AD. And the fourth one is the development of 
new topoisomerase inhibitors as potential for the treatment of cancer diseases. 
The thesis is organized in different chapters: the first chapter is a brief introduction about 
Alzheimer’s disease. Chapters 2 describes design, synthesis and the bilogical studies for 
the new non-ATP competitive GSK-3β inhibitors. While chapter 3 and 4 contain the drug 
design approaches used in each project of the new MTDLs agents for AD, including the 
synthetic methods and the biological evaluation assays of the new synthesized 
compounds. Results and discussions section and experimental procedures are also 
reported. Finally chapter 5 describes the drug design approache for the new topoisomerase 
inhibitors, and explaines the synthetic methods and experimental procedures. 
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Abstract 
 
Alzheimer’s disease (AD) is the most common form of dementia, and the one with the 
strongest societal impact for what concerns incidence, prevalence, and cost of care, it is 
the sixth leading cause of death, currently it affecting more than 44 million people 
worldwide, due to its debilitating nature it causes enormous financial and emotional stress 
on patients and caregivers. Against this backdrop, the governments and industries have 
increased their support for drug discovery and development. The current FDA-approved 
therapies for moderate to severe AD provide only temporary and incomplete symptomatic 
relief and only represent a palliative tool to slow down the clinical course of the disease. 
The cause for the incredible high attrition rate for AD drug discovery has been attributed 
to several factors, including the fact that the AD pathogenesis is not yet fully understood. 
Nevertheless, what is increasingly recognized is that AD is a multifactorial syndrome, 
characterized by massive deposits of amyloid-β (Aβ) peptide, neurofibrillary tangles 
(NTF) of the hyper-phosphorylated τ protein (P-τ), inflammatory mediators, and reactive 
oxygen species (ROS), which may lead to neuronal death. 
Glycogen synthase kinase-3β (GSK-3β), is serine/threonine kinase largely expressed in 
the central nervous system (CNS), it proved to play a significant role in regulating tau 
phosphorylation under both physiological and pathological conditions. In particular, GSK-
3β dysregulation is believed to contribute to the etiology of chronic conditions such as 
cancer, and AD. GSK-3β, the major kinase responsible for τ hyper-phosphorylation, it is  
implicated in the formation of Aβ plaques and NFTs Further, GSK-3β modulates 
inflammatory response, axonal transport and microtubule dynamics impairment, 
apoptosis, cell cycle deregulation, and adult hyppocampal neurogenesis impairment.  
However, most the available GSK-3β inhibitors bind to the ATP-binding site which is 
highly conserved in all the kinome; therefore, such agents indicated low selectivity being 
able to block the actions of other kinases leading to severe adverse effects. Nowdays, only 
few non-ATP competitive GSK-3β inhibitors could reach the clinical investigations, in 
light of these considerations, the discovery of non-ATP competitive GSK-3β inhibitors is 
highly desiderable. 
This thesis deals with the design and synthesis of new non-ATP competitive GSK-3β 
inhibitors; The present study allowed identifying a new GSK-3β inhibitor in micromolar 
range, the Study of the mechanisms of action for this synthesised compound revealed that 
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it behaves as non-ATP competitive GSK-3β inhibitor, this compound have become an 
interesting lead-compound, and in order to estimate its toxicity and the bioavailability, it 
was evaluated in vivo using zebrafish model.  This new lead compound was subjected to a 
structure-activity relationships campaign and  further optimization in order to increase its 
inhibitory potency and the lipophilicity for better pharmacokinetic properties.  
In this thesis, we also describe the design of new “Multi-Target-Directed Ligand” able to 
tackle the multifactorial nature of AD, since AD is a complex multifactorial disease 
whose insurgence is due to a dys-regulation of different pathways, and various 
biochemical targets have been indicated to have a fundamental role in their development. 
Based on their complex nature, MTDLs has been emerged as a promising therapeutical 
approach able hit several targets responsible for the onset and/or progression of the 
pathology.  
Therefore, having developed a new GSK-3β inhibitor we used this scaffold to develop 
GSK-3 β- HDAC inhibitors agents as MTDLs for AD. Astudy by Sharma et al reported 
that sub-effective dose combination of lithium chloride (GSK-3β inhibitor) and Valproic 
acid (HDAC inhibitor) produced a synergistic neuroprotection against streptozotocin-
induced cognitive deficits in rats.  Based on this we designed and synthesized new 
MTDLs able to simultaneously inhibit GSK-3β and HDAC. The synthesized compounds 
have been evaluated for their ability to inhibit GSK-3β by using a luminescence assay, 
and HDAC by using fluorimetric assay, one of the synthesized compounds turned out to 
be the best of the series in terms of inhibition of both targets. For this reason, it has been 
selected for further biological evaluations, in particular, to test its HDAC inhibitory 
potential in cell, promising results was observed after performing Western blotting 
analyses in neuroblastoma (SH-SY5Y) cell lines.  
A second project related to develop new MTDLs was carried out during research stage at 
Barcelona University in Diego Muñoz-Torrero López-Ibarra’s group; In 2014 Muñoz’s 
group developed novel family of rhein−huprine hybrids as MTDLs for AD, and these 
compounds endowed ablitly to inhibit AChE and BchE enzymes and Aβ aggregation, with 
the aim of increasing the potency of the activity for rhein−huprine hybrids family, and 
enhance the ablitly to  hit several key targets for AD,  we synthesised new modified series 
of rhein−huprine hybrids. The  biological screening for the activity of the synthesized 
compounds performed in vitro and in Escherichia coli cells, they have been shown that 
these hybrids exhibit good level of inhibitory activities against human 
acetylcholinesterase, butyrylcholinesterase, and dual  Aβ42 and tau antiaggregating 
7 
 
activity, and brain permeability, and potent activity as antioxidant, the new synthesized 
compounds indicated a promising disease-modifying anti-Alzheimer drug candidates. 
Cancer is a very complex pathology characterized by a very complex etiology and several 
biochemical targets have been recognized to play a fundamental role in its development. 
In particular, in cancer therapy, DNA topoisomerase inhibitors are amongst the most 
widely used and effective, anticancer drugs target either type I or type II enzymes, have 
been raised as potential anticancer targets 
The principal aim of this research is design and synthesis of new topoisomerase inhibitors 
as potential new anticancer agents. Scope of this project is the modification of the 
tryptanthrin scaffold, a natural product that show anticancer properties by inhibit 
Topoisomerases I and II, to develop more potent and selective agents. Such modifications 
are achieved by linking several different positively charged chains with the aim of 
increasing the affinity towards topoisomerases and the cytotoxic activity, the synthesized 
compounds are currently under biological evaluation towards topoisomerases I and II. 
In conclusion, all these studies may represent a promising starting point for the 
development of new interesting molecules useful for the treatment of cancer and AD 
diseases. 
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Chapter 1. Introduction to Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the most common and well-known cause of dementia 
affecting the increasingly elderly population. AD is characterized by behavioral, 
psychological and cognitive degeneration and memory loss, influences the lives of 
patients and their families.  
The countries and regions of the world which are most affected by AD are Western 
Europe, USA and China. According to the World Health Organization, more than 37 
million people worldwide have dementia and AD affects 18 million of them (Mount 
2006), it is expected to raise to 81.1 million in 2040 (Ferri 2005). The expansion of 
dementia elevates with age, increasing from 1% in the 60-64 to between 24 and 33% in 
those 85 years or older (Blennow. 2006, Ferri 2005). 
AD was firstly described by Alois Alzheimer in 1907 during the 37th Conference of 
South-West German Psychiatrists in Tubingen when he gave a lecture on his 55 year old 
patient Mrs. Auguste Deter (Alzheimer 1907). He described the observation of the 
neuropathological lesions, neurofibrillary tangles in the brain of  the patient, and her case 
has showed memory impairment, aphasia, psychosocial incompetence and disorientation, 
which developed gradually over the remaining years of her life, including experiencing 
hallucinations and worsening cognitive function. The disease is known today as AD based 
on describing the work done by Alois Alzheimer in the 8th edition of the book Psychiatrie 
(Emil Kraepelin 1910). The case of Auguste Deter was interesting due to her younger age, 
as previous patients with such cognitive decline were in 70 years old. After her death, 
Alzheimer examined tissue sections in her brain using a silver staining technique, from 
these microscopic analyses, he noticed and reported the presence of fibrillary bundles and 
small miliary foci, nowadays recognized as neurofibrillary tangles (NFT) and senile 
plaques (SP) (Lage 2006, Alzheimer 1907). 
AD was considered a disease different from dementia in the late 1960’s, after the 
demonstration of some studies (Blessed 1968) that there is relationship between the 
characteristic hallmarks, SP and NFT, and cognitive decline (Lage 2006). Other 
researchers suggested that AD was separated from normal aging (Kay 1964) and 
identified mutations implicated in hereditary forms of the disease (Tanzi.1996). AD is 
classified into two types: Familial AD (FAD) and Sporadic AD (SAD), epidemiological 
studies suggest that more than 80% of AD cases are familial caused by mutations in genes 
and having an early age of onset before 65 years (van der Flier et al. 2011, Miyoshi 2009). 
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At the opposite, sporadic version has not commonly acknowledged, and causes and risks 
which are related to the disease are not well understood.  
The type of FAD is inherited in an autosomal dominant fashion; it is identified by genetic 
mutations in the amyloid precursor protein (APP) or presenilin-1 and -2 (PS1 and PS2) 
genes (Levy 1995; Bayer TA 1999), a family of multi-pass transmembrane proteins 
constituting the catalytic subunits of the α-secretase intramembrane protease complex. In 
AD the mutations occurring on PS1 leadto extra amounts of toxic forms of Aβ peptide, 
which may aggregate into SP and, probably, damage neuronal messaging leading to 
neuronal death (Zhang. 2001).  
The other type of AD is SAD, in which few members of a family have the disease, it is 
described as multifactorial disease where various risk factors add up to promote the 
dysfunction that leads to the symptoms of AD (Grundke 2010). The most relevant genetic 
factor is the inheritance of the ε4 allele of the apolipoprotein E (ApoE), which enhances 
the proteolytic breakdown of Aβ peptide within and between cells. At least one allele is 
present in 40-80% of SAD cases (Mahley RW 2006), its presence increases the risk of AD 
by three times in heterozygosis, and by 15 times in homozygosis (Blennow K 2006). 
Other risk factors linked to SAD include head trauma and vascular- related diseases such 
as high blood pressure, heart diseases, stroke, and diabetes or high cholesterol levels. In 
addition, environmental agents such as diet, aluminium and viruses have also been 
reported as factors involved in the etiology of AD (Grant WB 2002). Since Alois 
Alzheimer reported the description AD disease (Alzheimer 1907), various theories has 
been described the cause of AD. In the 1960’s, it was reported the relationships between 
SP and NFT and cognitive decline, attracting the attention of the scientists to intensive 
research on the causes behind these neuropathological lesions (Lage 2006). The discovery 
of metal aluminum observed in NFT in AD patients’ brains (Perl 1980, Terry, Pena 1965) 
led to theories that excess of this metal may resulted in AD. Nowadays, this theory is 
generally outcast due to circumstantial evidences. Currently, theories about AD 
pathogenesis include the identification of abnormal or large amounts of molecules, such 
as Aβ peptide within AD patients’ brains. Other studies have indicated that the variations 
in the brain’s homeostatic environment could lead to AD (Crouch, 2007), along with 
viruses and bacteria (Kamer.2008, Itzhaki 2004) that are able to cross the blood-brain-
barrier, as well as the possibility that the immune system loses the ability to proceed 
efficiently (Giunta 2008, Miklossy 2008).  
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1.1 Theories on the Causes of Alzheimer's Disease 
 
The following sections discuss some of the foremost theories thought to cause the brain to 
degenerate and develop AD. 
 
The cholinergic hypothesis: 
AD brains are characterized by low levels of acetylcholine (ACh), which is a main 
neurotransmitter in the brain (Martorana 2010, Contestabile 2010), from this observation 
it is derived the so-called “cholinergic hypothesis” of AD which states that damaging of 
the cholinergic pathway in the basal forebrain leading to decrease the cholinergic neurons 
(Bartus, 2000, Terry 2003), memory disruption and cognitive symptoms (Bartus, 2000). 
This theory justifies the use of drugs such as donepezil, rivastigmine, and galantamine, 
together with N-methyl-D-aspartate receptors (NMDA’s) antagonist memantine for the 
treatment of AD. Unfortunately, these compounds are Cholinesterases (ChE) inhibitors 
and are only palliative drugs, therefore, acting on the symptoms of the disease and are not 
able to slow the decline associated with the disease, these drugs act by blocking the 
activity of Acetylcholinesterase (AChE) leading to maintain ACh concentration in the 
synaptic cleft and its activity.  
 
The cholinergic hypothesis and cholinesterases: 
ChE belongs to family of serine hydrolases; it is implicated in many important 
physiological processes, e.g. digestion (Whitcomb 2007), blood coagulation (Flemmig 
2012) and neurotransmission (Pohanka 2011), which are linked to various diseases such 
as pancreatitis, thrombosis, and AD.  
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Figure 1: Structure of AChE (Cheung 2012). 
 
 
The cholinesterases consist of AChE and butyrylcholinesterase (BChE), AChE is 
considered the main enzyme in the cholinesterase family, in humans, AChE is encoded by 
a single gene, which localized on the long arm of chromosome 7 at position 7q22 
(Getman 1992). Crystallization of AChE has identified the residues involving the 
substrate binding pocket as well as the catalytic domain, which is responsible for the 
hydrolase activity. AChE acts as modulator of neurotransmission at cholinergic synapses 
by hydrolyzing ACh in both central and peripheral nervous system. Keeping the balance 
of ACh activity is crucial, since it was demonstrated that the lack of ACh decreases 
receptor stimulation which can be seen for example as the cognitive deficit occurring in 
AD (Garcia 2005). 
 
 
Figure 2: Reaction cascade of acetylcholinesterase hydrolysing acetylcholine. 
 
BChE is a glycoprotein of 340 kDa (Asojo 2011), it has long half-life due to its high 
amount of glycosylation (Nachon 2002), and it is localized on the long arm of 
chromosome 3 at position 3q26.1-q26.2 (Gaughan 1991). BChE is more active in the 
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peripheral tissue than in the brain (Liston 2004), it exists in serum, glial cells, and neurons 
(Darvesh 1998; Darvesh 2003). BChE is involved in many physiological processes, 
mainly in the hydrolysis of several choline and non-choline esters, such as ACh (Mesulam 
2002), succinylcholine (Kaufman 2011), cocaine (Xue 2011) and aspirin (Masson 1998), 
thus, it has an important role in neurotransmission, anaesthesia and drug abuse. 
The cholinergic hypothesis arose from the fact that there is a significant loss of 
cholinergic neurons in the brain of AD patients as well as a decreased activity of choline 
acetyltransferase which catalyzes the production of acetylcholine, leading to decrease 
neurotransmission and cognitive dysfunction (Whitehouse 1982; Francis 1999; Gauthier, 
2002), furthermore, a reduction of the nicotinic and muscarinic receptors has also been 
reported (Francis 2010).  
A strategy of AD therapy is based on the inhibition of AChE and BChE which can 
contribute to elevate the amount of free ACh, resulting in interact with neuronal receptors 
(Lane 2006). ChEs inhibitors, by restoring the levels of ACh, play an important role in 
enhancing the cognitive functions (Liston 2004). AChE has usually been the main drug 
target even if recently the research has been also focused in the discovery of BChE 
inhibitors (Darvesh 2007, Decker 2008, Carolan 2010, Nawaz 2011).  
 
Amyloid hypothesis: 
β-Amyloid (Aβ) peptide derived from APP, the gene encoding for this protein is located 
on chromosome 21. The amyloid hypothesis suggests that there is a primary imbalance 
between Aβ production and its subsequent clearance, with enhancing Aβ production in 
familial disease and reduced Aβ clearance in sporadic disease. Aβ oligomers may block 
hippocampus activity and damage the synaptic action, resulting in inflammation and 
oxidative stress caused by the aggregation and depositing of Aβ. These pathways together 
can impair neuronal and synaptic activity causing neurotransmitter deficits and cognitive 
symptoms. Aβ senile plaques are composed by Aβ insoluble peptides which derived from 
APP, it consists of 39-43 amino acid residues proteolytically derived from the sequential 
enzymatic action of β- and γ-secretases of transmembrane APP (Coulson EJ 2000). 
App is expressed in cells throughout the body, its amount is influenced by the 
physiological state of the cells, there are several isoforms of APP, and most of abundant 
form in brain is constituted APP695. APP could be processed following two different 
pathways: amyloidogenic and non-amyloidogenic pathway.  
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• Non-amyloidogenic pathway: It includes the enzyme α-secretase, while 
amyloidogenic contains two other secretases, β- and γ-secretase, APP cleavage by α-
secretase releases a large soluble fragment (α-APP) and the retention of an 83 amino acids 
fragment.  
• Amyloidogenic pathway: β-secretase (BACE) cleaves APP producing an extracellular 
soluble fragment called β-APP and an intracellular COOH-terminal fragment called C99 
that further processed by γ-secretase to generate peptides of different length such as Aβ1-
40 and the pathogenic Aβ1-42, the length of Aβ peptides varies at C-terminal according to 
the cleavage pattern of APP, being the Aβ1- 40 the most prevalent form followed by Aβ1-42, 
an hydrophobic form that aggregates faster (Perl DP 2010). Within plaques, Aβ peptides 
can assume different conformations and polymerize into structurally distinct forms such 
as fibrillar, protofibers and polymorphic oligomers (Selkoe DJ 1994).  
 
 
 
Figure3: The amyloid cascade hypothesis, (VerdileG. 2006). 
 
In normal brain, most of the Aβ peptides consist of 40 amino acids and only about 10% of 
Aβ1-42 peptide, in the brains of AD patients the production of Aβ1-42 peptide is increased, 
and this form is more hydrophobic and more neurotoxic than the Aβ1-40 peptide (Selkoe 
2001, Findeis 2007), it can be found as monomers, oligomers, protofibrils, fibrils and in 
the latter stages form of the SP. The presenilin proteins (PS1 and PS2) are essential in the 
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enzymatic cleavage of the APP, in subsequent it releases β-APP, the mutations in the 
presenilin genes leading to familial AD, through raising APP cleavage, which results in 
enhancing the production of β- amyloid (Mudher 2002). 
Studies indicated the role of apolipoprotein E type 4 (APOE ε 4) in enhancing the risk of 
late onset AD (Mattson 2004), experiments carried out on transgenic gene knockout 
animal models, characterized by mutations on APP and PS1 and PS2, illustrated the 
molecular mechanisms underlying plaque pathology (Mattson 2004, Mudher 2002, Oddo 
2003). There is suggestion that amyloid cascade theory contribute to genetically inherit or 
predisposed people, whereby a ready mutation is present (Mudher 2002). 
Other factors could contribute to Aβ formation such as sortilin (SORL1), a neuronal 
sorting receptor, which monitoring APP processing. Levels of SORL1 have been shown 
to be reduced in the brains of SAD patients (Rogaeva 2007) and in the brains of 
individuals with mild cognitive impairment (Sager 2007). SORL1 acts by directing APP 
into the recycling pathway from enzymatic cleaving by BACE1 and the presenilin 
proteins. Therefore, BACE1 and the presenilin proteins can not work on APP, can lead to 
decrease Aβ production; whereas the low levels of SORL1 lead to a direct transit of APP 
to BACE, resulting in increasing Aβ production. 
 
 
 
Figure 4: Role of APP cleavage processing in AD and microglial activation (Heppner FL 2015). 
 
Clusterin is chaperone protein implicates in the production of Aβ, recent genome-wide 
association studies in patients with AD, demonstrated that this protein is correlated with 
the severity and progression of the disease (Thambisetty 2010). 
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Lipid/cholesterol metabolism is also involved in AD pathogenesis, by influencing the 
activity of enzymes which contribute in the metabolism of APP and in the production of 
Aβ. Studies including AD patients treated with Statins, well-known cholesterol lowering 
drugs, showed decreasing in the risk of the development of dementia (Jick 2000), but it 
did not show any improvement in recover cognitive impairment has been observed (Jones 
2008). APOE ε4 is involved in the transporting of cholesterolis which are linked to the 
production of tau, Aβ and dysfunction of cholinergic neurotransmission (Reiman 2009, 
Holtzman 2000). 
 
β-Secretase (BACE1): 
β-Secretase (BACE-1) is a transmembrane human aspartic protease, known as β-site 
amyloid precursor protein cleaving enzyme, which exists in high levels in the brain, 
mostly in neurons, peripheral tissues and in pancreas (L.Katz 1999). BACE-1 enzymatic 
functions are displayed only in the brain (S.D.Hanton 2001), where it is implicated in the 
early stage of formation of Aβ plaques characterized as the major symptoms of AD. In 
AD neurotoxic Aβ1-40 and Aβ1-42 are generated from the APP, which is cleaved by 
BACE-1, initiating an amyloidogenic pathway. APP can be cleaved by BACE-1 at the M-
D bond including in the sequence KMDAE, producing two fragments: an Aβ N-terminus 
soluble fragment, called APPsβ, and a C-terminus fragment, called CTF99, (S.L.Cole 
2008), the last one is then heterogeneously cleaved by γ-secretase, giving neurotoxic 
peptides Aβ1-40 and Aβ1-42. 
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Figure 5: APP is cleaved by BACE1 and secreted as Aβ, which is thought to be associated with 
amyloid fibres aggregation and deposition, leading to AD (John 2003). 
 
In the metabolism of APP there is another alternative and non-amyloidogenic pathway, it 
is start by zinc metallo proteinase α-secretase; this pathway dominates in most cell types. 
It has been revealed that BACE-1 inhibition decreases Aβ peptide levels in mouse brain, 
and up-regulates the α-secretase non amyloidogenic pathway (S. Sankaranarayanan 2008). 
Since BACE-1 is important for certain hippocampal memory processes (D. De Pietri 
2004), its partial blocking may not impact normal learning and memory processes. 
Therefore, BACE-1 inhibitors have been suggested to have therapeutic advantages in AD. 
 
Tau phosphorylation theory: 
Neuropathologically, AD is defined as the presence of intraneuronal neurofibrillary 
lesions consisting of tau proteins (Forman MS 2004). Tau proteins are mainly found in the 
axons of neurons, it belongs to the family of microtubule-associated proteins (Tucker RP 
1990). Tau protein has six isoforms ranging from 352–441 amino acids in length, formed 
from MAPT gene which localizes on chromosome 17 (Lace 2007, Brown 1992), these 
isoforms differ in the numbers of binding domains; recent studies suggested that all tau 
forms are present in AD (Iqbal 2009, Lace 2007, Andrea 1992). 
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Figure 6: (A) Tau facilitates microtubule stabilisation within cells and is particularly abundant in 
neurons. (B) In ADthe loss of tau function leads to microtubule instability and reduced axonal 
transport, which could contribute to neuropathology (Brunden KR 2009). 
 
In AD, tau protein in abnormally phosphorylated, that resulting from the imbalance 
between kinases and phosphatase activities. This phosphorylation occurs at serine and 
threonine by protein kinases cyclin-dependent kinase-5 (CDK-5), glycogen synthase 
kinase-3 (GSK-3) and mitogen-activated protein kinase (MAPK). Other kinases including 
Akt, Fyn, protein kinase A (PKA), calcium-calmodulin protein kinase-2 (CaMKII) and 
microtubule affinity-regulating kinase (MARK), are also involved in the tau 
phosphorylation process. 
Hyperphosphorylation of Tau; leads to the production of NFTs which are the second 
major hallmarks of AD. NFTs consist of paired helical filaments PHF-τ, the main 
component of the NFTs is the protein tau, and microtubule associated protein (MAP) 
(Grundke 1986) under normal conditions, tau, which is a soluble protein, undergoes 
phosphorylation and dephosphorylation, forming insoluble aggregates; dysregulation of 
this process leads to increase the levels of abnormally hyperphoshorylated tau (P-tau 181, 
P-tau 199, P-tau 231, P-tau 396, P-tau 404), which in turn aggregates into PHF-τ and 
induces neurotoxicity through the formation of NFT and the disassembly of microtubules 
(Blennow 2007). 
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Inflammation: 
Inflammation is a defensive mechanism of the body against multiple threats such as 
infections and injury. It is a complex event that involves both soluble factors and 
specialized cells (Brown KL 2007). Similar inflammatory processes occur both in the 
brain and peripheral tissues; in the brain astrocytes and microglia, the activation undergos 
under pro- inflammatory conditions, by increasing the production of inflammatory 
cytokines in CNS, which becomes deleterious leading to progressive tissue damage in 
degenerative diseases. 
 
 
 
Figure 7: The neuroinflammatory process (Morales I 2014). 
 
Both astrocytes and microglia suffer from gradual activation triggered by damage or 
injury leading to secretion of pro-infammatory elements such as cytokines, cytotoxic 
elements or ROS. The constant exposure to factors causing injuries induces a neuro 
inflammatory process that eventually triggers neuronal death (Morales I, 2014). 
In chronic disorders such as AD, inflammation plays a critical role; indeed, increased 
neuronal inflammatory mediators such as cytokines and microglia have been observed in 
AD brains (Wyss-Coray 2002), it has been reported that insoluble fibrillar Aβ surrounding 
microglia, reactive astrocytes and dystrophic neurites contributes to the neuronal process 
of degeneration by initiating a series of cellular events which are able to elicit an immune 
20 
 
response; furthermore, it was suggested that chronic inflammation is a risk factor which 
plays the major role in AD brain injury (Guo 2000, Mayeux 1995). 
Cyclooxygenase (COX), key mediator of the inflammatory cascade, is targeted by non-
steroidal antiinflammatory drugs (NSAIDs); some studies showed that anti-inflammatory 
drugs (more specifically with NSAIDs) did not decrease the risk or delay of AD in 
patients treated with these drugs (Van Gool 2001), while in other animal models it was 
observed that NSAIDs lead to decrement of Aβ deposits without inhibition of COX 
(Weggen 2001).  
 
 
 
Figure 8: Neuroinflammation in AD condition (Meraz 2013). 
 
Multiple inflammatory mediators are observed in postmortem AD brains (Finch 2007, 
McGeer 2007). Aβ deposition in parenchyma and blood vessels has been described to 
trigger microglial migration and mediate acute and chronic inflammatory response against 
the aggregates, thus inducing the production of nitric oxide (NO), ROS, pro-inflammatory 
cytokines such as tumour necrotic factor α (TNFα) or inter leukins-1β and -6 (IL-1β, IL-6) 
and prostaglandin E2 (PGE2), which eventually may promote neuronal death (Kitazawa 
M2004, Graeber 2010). Microglia makes up 12% of brain cells and they are normally in a 
‘resting’ state controlling the brain (Zilka, 2006), it was suggested that it may has 
essential role in synaptic disruption and early event in memory impairment and 
participation in disease etiology of AD (Cagnin 2001). 
Other studies showed that microglia cluster exists around Aβ peptide aggregation sites, 
which suggested the role of Aβ peptide deposits in this microglia activation (Tuppo 2005). 
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Microglia produces pro-inflammatory molecules such as interleukin-1β, interleukin-6 and 
(TNFα), which recruits lymphocytes to inflamed parts by modifying vascular cell 
adhesion (Ghoshal 2007). 
 
Oxidation and Mitochondrial dysfunction: 
Redox reactions are necessary for the generation of ATP and free radical intermediates; 
they are produced via the establishment of proton gradient in oxidative phosphorylation. 
Multiple damaging mechanisms coexist in AD pathology, affecting each other at multiple 
levels (Bernhardi R 2012). Oxidative stress (OS) involves in the impairment of many 
biological macromolecules, it is considered being a hallmark of neurodegenerative 
diseases. OS resulting from the imbalance in prooxidant/antioxidant homeostasis leads to 
the production of toxic reactive oxygen species (ROS), such as hydrogen peroxide, nitric 
oxide, superoxide and the highly reactive hydroxyl radicals. Constant evidence reported 
that ROS and reactive nitrogen species (RNS) mediated injury, are observed in AD 
(Praticò D 2008). Studies in animal models indicated that oxidative damage precedes the 
pathological modifying correlated with AD (Nunomura 2001). 
 
 
Figure 9: Imbalance in pro-oxidant/antioxidant in normal and pathological condition (Sayre, 
L.M.2008). 
 
ROS can directly oxidize and destroy DNA, lipids and proteins and enhance stress-
responses, resulting in apoptosis through mitochondrial process (Altman 2010, Casadesus 
2007). Based on these observations, the “oxidative stress hypothesis of AD” stated that 
oxidative stress is a key event in both the onset and progression of this disease. OS is a 
wide spread cellular process that currently lacks specific biochemical targets for 
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atreatment, such as a receptor or a single major metabolic pathway (Galasko DR 2012). In 
AD, there are established connections between OS and other key AD events, which 
amplify its complexity.  
 
 
 
Figure 10: Prevailing connections between OS and other key players in AD (Mattson MP 2004). 
 
Mitochondrial abnormalities, initially caused by gradual oxidative disturbances are 
enormous contributor of ROS to the cell (Bonda DJ 2010). In elderly people these 
pathways become less effective, and mitochondrial dysfunction is suggested to be 
associated to AD (Gibson 1998, Onyango 2010, Swerdlow 2009, Hyde 2008). The 
increase of ROS and other oxidized molecules, such as lipids and glucose, may lead to the 
impairment of the memory, long term potentiation (LTP), and AD pathogenesis (Cheng 
2010). The primary role of OS in AD onset and progression has been overwhelmingly 
confirmed, offering the chance to develop specific disease-modifying antioxidant 
approaches to confronting the disease.  
 
Biometal hypothesis: 
Several studies in AD and other neurodegenerative disorders have described increase the 
levels of oxidative stress reflected by dysregulated content of metals, such as iron, copper 
and zinc in the brain of patients. Recent discoveries have strongly pointed to brain 
oxidative stress as one of the earliest changes in AD pathogenesis that might play a central 
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role in the disease progression (Guglielmotto M 2010, Lee HP 2010). Redox-active 
metals, especially Fe2+, Cu2+ and Zn2+, are capable of stimulating free radical formation 
via Fenton reaction increasing protein and DNA oxidation and enhancing lipid 
peroxidation.  
 
 
 
 
Figure 11: The highly hydroxyl radicals lead to OS-induced lipid peroxidation, mitochondrial 
dysfunction and increase in intracellular free-calcium concentration, causing neuronal death (Khalil 
M 2011).  
 
Metals are required in the body especially in the brain; they are components of some 
enzymes that play crucial role in proceeding biological functions such as redox reactions 
(Crouch 2007). The imbalance in metals can lead to oxidative stress and neurodegeneration 
(Crouch 2007), which could involve in the initial cause of AD. 
Metals, such as iron, zinc, and copper have been identified in AD brains to be in 
dyshomeostasis (Crouch 2007, Adlard 2008). Aggregation of Aβ peptide can lead to 
reducing copper and zinc resulting in the production of ROS which in role can react with a 
multitude of different molecules damaging cellular functions, forming toxic species, and 
neuronal cell death (Curtain 2001). 
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1.2 Therapeutical Approaches to AD 
 
The above-mentioned complexity of AD pathology has encouraged the development of 
multiple therapeutic approaches targeting several pathological events that occure in this 
multifaceted pathology.  
 
 
 
 
 
Figure 12: Schematic representation of the main cellular targets that are currently under 
development to prevent and/or delay the progression of AD (Aso E 2013). 
 
In the recent years, the appearance of several hypothises explaining AD pathogenenesis, 
allowed the scientist to develop different therapeutic strategy to try to prevent or block the 
development of AD. To date, only five drugs have been approved by the U.S. Food and 
Drug Administration (FDA- USA) for the treatment of AD. The first class successfully 
used for AD treatment is the inhibitors of Acetylcholinesterase (AChEIs); tacrine was the 
first AChEI approved drug in 1993, but recently it has been withdrawn because of its 
hepatotoxicity. Other AChEIs are available in the market for thetreatment of AD such as 
donepezil, rivastigmine, and galantamine. More recently, the role of an overactivation of 
glutamate receptors in neuronal death has been definitely cleared out, and the NMDA 
antagonist Memantine has been approved in the US in the late 2003, Figure (13). 
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Figure 13: Chemical structures of approved drugs for AD treatment 
 
 
1.2.1 Cholinomimetic Therapy: 
The “cholinergic hypothesis” was the first theory postulated to describe the onset of AD. 
These findings led to the development of drugs specifically were designed to treat the 
distinctive hallmarks of this neurologic disorder by increasing the reduced levels of the 
neurotransmitter ACh in AD through the use of AChEIs (BartusRT 2000, Bartus RT 
1982). 
Tacrine or tetrahydroaminoacridine (THA), is the first drug for AD treatment, it has been 
approved by the FDA in 1993 marketed as Cognex®, it is competitive AChEI with high 
lipid solubility (Nielsen JA 1989), which able to interact with muscarinic receptors (Adem 
A 1993) and MAO A and B (Adem A 1989). Tacrine suffers from several disadvantages, 
such as poor oral bioavailability and considerable side effects, which led to be withdrawn 
from the market. In particular, its hepatotoxic effects seem to be related to toxic quinone-
type metabolites produced by the hepatic oxidative metabolism (Qizilbash N 1998). 
Donepezil (Aricept®) which is reversible AChEI was approved by FDA in 1997. In many 
clinical trials of donepezil beneficial effects were observed on standard measures of 
cognitive function, activities of daily living, behavioral and neuropsychiatric symptoms, 
such as hallucinations, distractibility, aberrant motor behavior and apathy in patients with 
mild to moderate or severe AD. Rivastigmine (Exelon®) is another selective, reversible 
AChE and BChE inhibitor; it was approved by FDA in 2000. Rivastigmine transdermal 
patch proved to be efficient, in terms of improving cognitive and global function, 
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generally it presents good tolerability in patients with mild to moderate dementia of the 
Alzheimer’s type in large well designed trial. 
Galantamine (Reminyl®) selectively and reversibly inhibits AChE, itwas approved by 
FDA in 2001 for the treatment of mild to moderate AD. It has dual mechanism of action 
able to attenuate the symptoms of cognitive decline in AD. It is, indeed, reversible 
selective competitive AChEI (Greenblatt HM 1999) able to modulate simultaneously 
nicotinic receptors (nAChERs) (Dajas 2003 ). The main mechanism of action of this 
molecule is the ability to increase the content of ACh, enhancing the cholinergic 
neurotransmission and, therefore, improving cognition in AD patients. Moreover, 
galantamine has also demonstrated to interact directly with n AChER as low-affinity 
agonist allosterically binding to a distinct binding site from that of classical nicotinic 
agonists, such as ACh, choline or carbachol, (Akk G 2005). 
One of the recent approaches for the modulation of cholinergic receptors is based on 
targeting M1 muscarinic receptor in AD brain, since it was reported that M1 muscarinic 
receptor activation could mediate many of cognition promoting effects. Unfortunately, 
M1 agonists lack of M1 selectivity with resultanting intolerable effects, which limited 
their use in AD treatment.  
Studies also focused on M2 muscarinic receptor subtypes in AD treatment, since this 
receptor subtype has important role in learning, memory and neuronal plasticity. 
Developed drugs such as SCH 57790, SCH 57790, and BIBN-99, are emerging as 
selective M2 antagonists able to raise the extracellular levels of ACh and cognitive 
function. Unfortunately, these drugs showed poor pharmacokinetic profile, and limiting 
the potential use in AD treatment. 
Other drugs such as SIB1553A, and ABT418 were developed to target nAChR since AD 
patients are defined by a remarkable decrease in the number of nAChR; different studies 
illustrated strong connections between AD and such receptors, but unfortuantly the use of 
these drugs in the treatment of AD are limited because of the fast desensitization of 
nAChR to the effect of these agonists. 
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Figure 14: Chemical structure of M2 mAChR antagonists 
 
 
Studies revealed that clinical use of AChE inhibitors are temporary stabilization of 
cognitive deficits, other recent studies have reported apparent retardation of the 
progression of neurodegenerative process, and interfere with the accumulation and 
precipitation of Aβ in patients treated with AChEIs. This led the scientists to reconsider 
this enzyme as a target mediates two important effects in the neurotoxic cascade, that is, 
Aβ fibrils formation and ACh breakdown. Therefore, it seems that cholinergic hypothesis 
will continue to drive drug discovery with the aim to design and synthesize new 
multipotent AChEIs combining the ability to increase the cholinergic response with 
inhibition of the Aβ-aggregation deposition. 
 
1.2.2 Anti-amyloid Strategies: 
In the recent years the amyloid cascade hypothesis allowed the scientists to understand the 
mechanism of neuronal death, the attention of researchers was mainly focused on the 
modulation of Aβ-production by using α-secretase stimulators, BACE1 inhibitors,           
γ-secretase inhibitors and modulators, aggregation blockers, catabolism inducers with the 
aim to decrease Aβ in the brain, which may lead to ameliorate the symptoms of Aβ-
induced neurotoxicity. 
 
• Secretase inhibition: 
γ-Secretase is implicated in the cleavage of APP leading to the production and formation 
of β-amyloid plaques. Inhibition of BACE1 has emerged as attractive target to design safe 
anti-amyloid agents, the exploration of BACE-1 as a target derived from a study reported 
that transgenic mice lacking BACE gene does not produce Aβ (Luo, Y., 2001). 
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Several peptidomimetics and non-peptidomimetics compounds have been synthesized as 
BACE1-inhibitors, such as OM99-2, which represents the first generation of BACE1 
peptidomimetic inhibitors, with an IC50 of 0.002 μM. However, it is well known that 
peptidomimetic inhibitors suffer from difficulties typical of polypeptides, such as poor 
blood–brain barrier crossing and poor oral bioavailability. In order to enhance the potency 
and to increase blood-brain barrier crossing ability, further developing has been developed 
by using X-Ray structure-based modification in order to obtain new low molecular weight 
peptidomimetics BACE1 inhibitor, such as compound I in figure 15. 
 
 
 
Figure 15: Chemical structure of peptide mimetic BACE1 inhibitors OM99-2 and I 
 
The lead compound II has been developed by Elan/Pharmacia showed an IC50= 0.03 μM; 
further development carried out on compound II by the truncation of the N-terminus and 
C-terminus led to the compound III, with an IC50 of 0.3 μM. Further structural 
modification of III led to the discovery of IV as potent and cell-permeable BACE1 
inhibitor, with an IC50 of 0.12 μM; the corresponding diacide V is more potent (IC50 = 
0.02 μM), but it showed no inhibition of Aβ in HEK cell due to the poor cell permeability. 
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Figure: 16 
 
Further, the developments led to the compound VI with an IC50 of 4.8 and compound VII 
characterized by an IC50 of 1.2 nM, in order to obtain better pharmacokinetic profile, the 
compounds which are characterized by hydroxyethylamino residue, were deeply 
investigated leading to VIII and XI, which displayed an IC50 of 5 nM and 20 nM, 
respectively. 
 
 
 
 
Figure 17: Chemical structures of VI-VII and hydroxyehtyl amino-based BACE1 inhibitors VIII-
IX. 
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Aminoethyl-substituted tetraline have been discovered in 2001 as BACE1 inhibitors, the 
compound X in the figure (18) was the most potent inhibitor in this series with an IC50 of 
0.35 μM, Furthermore, the compound XI displayed high BACE1 inhibitor activity in 
micromolar range. 
 
 
 
 
Figure 18: Most potent BACE inhibitors based on the aminoethyl-substituted tetraline scaffold X, 
and Vertex’s inhibitor XI 
 
γ-secretase is responsible for the final cleavage of the APP to produce the Aβ peptide and, 
therefore, it is implicated in the pathogenesis of AD. Thus, this protease is consider a 
promising target for the development of AD therapeutics in spite of the interferences of   
γ-secretase inhibitors with Notch signaling that may lead to several side effects. However, 
compounds that inhibit γ-secretase with little effect on Notch could be useful in AD 
therapy. For instance, DAPT has advanced into late-phase clinical trials for the treatment 
of AD: it inhibits Aβ production with an IC50 of 115 nM, the most potent γ-secretase 
inhibitor was LY-411575 with an IC50 of 119 pM. But unfortunately, this compound 
showed the ability to interfere with maturation of B- and T-lymphocytes in mice due the 
inhibition of Notch signaling. 
 
 
 
 
 
Figure19: Chemical structures of γ-secretase inhibitors 
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Interesting studies reported that some NSAIDs, such as ibuprofen, indomethacin, are able 
to decrease the release of Aβ1-42 and enhancing the release of less amyloidogenic Aβ 
without interfering with the Notch. The effect of NSAIDs on amyloidogenic-pathway is 
not mediated by interaction with COX, but they interact directly with the γ-secretase 
complex; currently R-flurbiprofen (Tarenflurbil®) is in Phase III clinical trials for AD 
treatment. 
 
 
 
 
 
Figure 20: Modulation of γ-secretase cleavage by NSAIDs (Citron, 2004). 
 
 
• β-sheet breakers: 
Amyloid plaques are important hallmarks of AD, which could be considered as potential 
target candidates in AD treatment. Agents able to interfere with the formation of Aβ-
aggregates may have neuroprotective effects through promoting the disaggregation of Aβ-
fibrils. It was reported that the developed compound XII in the figure (21) is able to bind 
to Aβ and to form a complex stabilized by hydrophobic interaction, and it enhances the 
changes in the β-sheet structure. Unfortunatly, the use of these peptides in AD treatment is 
limited because of the poor drug-like profile, due to their pharmacokinetic characteristics. 
 
 
 
Figure 21: Structure of XII pentapeptide compound 
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• Aβ immune therapy: 
This strategy in AD therapy has received considerable attention for its ability to decrease 
the APP levels. Several theories have been proposed to clarify the mechanism of how the 
reduction of the APP levels can be achieved by using Aβ antibodies. The first one says 
that antibodies link to Aβ in the brain and trigger microglia to Aβ phagocytose via Fc-
receptors; the second one supposes that the antibodies can act as chaperone and block the 
Aβ aggregation, and may sequester Aβ in the plasma promoting fast efflux of Aβ from the 
brain. 
 
• τ-hyperphosphorylation directed strategies: 
The presence of NFTs is important hallmark of AD and dementia. It has been suggested 
that reducing tau phosphorylation via inhibition of kinases is major therapeutic strategy 
based on the presence of hyperphosphorylated tau protein in the brain. Studies reported 
the important involvement of the inhibition of both glycogen synthase kinase-3β (GSK-
3β) and cyclin-dependent protein kinase 5 (cdk5) in blocking AD neurofibrillary 
degeneration. Furthermore, the activation of phosphatases could result in the restoration of 
correct tau functionality; an example of this approach was verified during the use of 
Memantine, it can make restoration of protein Phosphatases PP2A activity, leading to the 
inhibition of tau hyperphosphorylation. 
Several small molecules have been developed as tau-aggregation inhibitors such as 
rhodanine and its derivatives, which were developed by Waldmann group. Also 
Phenothiazine derivatives showed inhibitory activity toward tau-aggregation such as 
Thionin which displaied IC50 of 12 μM, moreover, Porphyrinsuch as Hemin, are 
organometallic example of tau-aggregation inhibitor. 
 
 
 
 
 
Figure 22: Structure of the hit compound Rhodanine 
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1.2.3 Antioxidant therapy: 
Oxidative stress is suggested to have causative role in the pathogenesis of AD. ROS and 
other radical species are implicated in the cellular damage leading to neuronal death. 
Potential antioxidants which could be used to contrast oxidative stress include 
mitoquinone, vitamin E, and natural polyphenols, such asextracts from Ginkgo biloba, 
green tea, wine, blueberries, and curcumin. These agents protect cells from free radicals 
because they are able to accept radical or free electron. Fortunately; none of them is 
reported to show any serious toxic effects. 
Among antioxidant agent, Lipoic acid chelates redox-active transition metals and shows 
relevant antioxidant activities by inhibiting the formation of hydroxyl radicals and 
scavenges ROS. And melatonin is the most promising radical scavenger; it is a hormone 
able to react with hydroxyradical forming non-toxic derivatives that are easily 
metabolized. Furthermore, melatonin reacts with peroxynitrile and ROS, displaying other 
interesting activities such as the inhibition of amyloid fibril formation and anti-apoptotic 
effects. 
 
 
 
 
Figure 23: antioxidants examples used in AD 
 
1.2.4 Targeting NMDAR-mediated neurotoxicity: 
NMDAR plays an important role in neuronal death in AD; the use of NMDAR antagonist 
is emerged as useful therapeutic approach to treat AD. For instance, Memantine, which 
derived from the antiinfluenza drug amantadine, is the only NMDAR antagonist approved 
for the treatment of moderate to severe form of AD. It binds near the Mg2+ binding site 
within the ion receptor channel. 
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1.2.5 Cholesterol-reducing approach:  
The mechanism of how cholesterol can influence Aβ production in AD is not yet well 
understood, several studies have been reported that cholesterol modulated the Aβ 
production, and indicated that the high levels of cholesterol caninduce the BACE-mediate 
APP proteolysis (the amyloidogenic pathway). Drugs able to decrease the cholesterol 
concentration, such statins, showed the ability to reduce the level of Aβ in mice and 
guinea pigs. A promising approach could be the use of inhibitors of acyl-coenzyme, 
cholesterol acyltransferase; this enzyme catalyzes the formation of cholesteryl-esters from 
cholesterol, its inhibition result in reducing Aβ formation. 
 
1.2.6 Metal-chelating approach: 
High concentrations of metal ions, such as Cu2+, Fe2+, and Zn2+, have been found within 
Aβ deposits in AD brains, there are studies indicate that metals are able to enhance Aβ 
aggregation in AD. It was reported that metal-chelators, such as 
diethylenetriaminepentaacetic acid (DTPA), triethylenetetraamine (TETA), and 
desferrioxamine (DFO), may solubilize Aβ in AD brains and reduce the production of 
hydrogen peroxide derived from the interaction of Cu2+ and Fe3+ with Aβ1-42. 
 
 
 
Figure 24: Chemical structure of some metal-chelators used in AD treatment 
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However, it should be considered that, despite the metal chelator could represent 
therapeutic benefits in decreasing metal-mediated brain injury; their protracted use could 
present serious side effects by interfering with the normal function of physiological metal 
enzymes.  
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Chapter 2. Glycogen synthase kinase 3 (GSK-3) functions and 
structure  
 
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase involves in the 
regulation of glycogen synthase (Embi 1980, Hemmings 1981, Woodgett 1990, Woodgett 
1982). It was primarily found in skeletal muscles, then it was discovered that it is 
ubiquitously distributed in all tissue; in particular, it is present in high levels in the brain 
(Leroy 1999). GSK-3 is one of the first kinases discovered and studied for its important 
role in various biological process such as gene transcription regulation, cell survival and 
cell division cycle, stem cell renewal and differentiation, insulin action, apoptosis, Wnt 
and hedgehog signaling pathway, and DNA damage responses (Meijer 2004). 
Dysregulation in GSK-3 activity is involved in the development of several human 
diseases, such as diabetes mellitus, AD, bipolar disease, and many types of cancers (Doble 
2003). Given to its implication in the pathophysiology of various human diseases; in the 
last 25 years GSK-3 attracted the attention of the researchers as an important target for 
developing therapies to treat, through its inhibition, different diseases such 
neurodegenerative disorders (Meijer 2004, Doble 2003). 
 
2.1 Crystal structure of GSK-3 
 
In mammals there are two conserved GSK-3 isoforms, GSK-3α (51 kDa) and GSK-3β (47 
kDa), (Hansen 1997, Woodgett 1990). The two isomers share 98% similarities within 
their catalytic domains and the difference between them is due to the extra Glycine-rich in 
the N-terminal region of GSK-3α. 
GSK-3α and GSK-3β have high similarity in the structure, but they are functionally 
different, furthermore they have some diverse substrate specificities, a study demonstrated 
that mice carrying a selective deletion of exon 2 of GSK3-β undergo embroyonic death 
due to extensive hepatocyte apoptosis despite the presence of GSK-3α (Hoeflich 2000).  
GSK-3β activity is central for TNF alpha enhance NF-kappa B activation in hepatocytes 
while GSK-3α knockout mice are able to stay alive, with the abilitily to promote glucose 
and insulin sensitivity and decrease fat mass. Other studies indicated that GSK-3α knock-
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out mice induced defects in metabolic and neuronal developmental (MacAulay 2007, 
Kaidanovich 2009).  
The crystal structure of GSK-3β was solved in 2001 figure (25) (Bax 2001, Dajani 2001, 
Haar 2001) GSK-3β structure consists of a small N-terminal domain, a large C-terminal 
domain, ATP binding site and the activation loop (Dehmelt L2004). The N-terminal lob 
(25 to 134 residues) comprises of seven antiparallel β-strands which intermittent by the α-
C helix and this domain, the entrance of this domain localize ATP binding site which is 
enclosed by the glycine-rich loop (residues 60 to 70) and the hinge (residues134 to 139). 
The C-terminal lob (residues 135 to 380) involves the activation domain, which is 
essential for the kinase activity (Baas P.W 2005, Lucas F.R 1997).The activation loop 
begins with the DFG motif (Asp 200 to Gly 202), terminates with the APE motif (Ala 224 
to Glu 226) and sets up one edge of the substrate-binding groove. The other edge is 
founded by the loop that connects β strand five with the α-C helix. The last 55 residues 
after the kinase domain (residues 330 to 384) compose a cluster of loops and helices that 
gathers against the C-terminal domain (Alessi D.R 1996). 
 
 
 
 
Figure 25: The different regions of GSK-3β (Haar 2001). 
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2.2 Regulation of GSK-3 activity 
 
The crystal structure of GSK-3β has provided the researchers with important information 
illustrating the regulation of GSK-3β (Dajani 2001, Haar 2001). GSK-3β kinase activity is 
mainly regulated at varied levels, first by post translational phosphorylation, second by 
interaction with other proteins, third through its intracellular distribution and finally GSK-
3β action requires priming phosphorylation to its substrates.  
 
• Post translation phosphorylation of Serine and Tyrosine: 
Phosphorylation of serine and tyrosine is an important physiological process that regulates 
the activity of GSK-3: the inhibition of GSK-3 is caused by the phosphorylation of an N-
terminal serine 9 in the GSK-3β and serine-21 in the GSK-3α (Frame S. 2001) forming an 
intramolecular association which acts as a pseudo-substrate that prevents the access of 
substrates to the catalytic domains of GSK-3 resulting in its inhibition (Dajani R. 2001). 
This inhibition of GSK-3 through serine-phosphorylation is catalyzed by various protein 
kinases such as protein kinase-A (cyclic AMP-dependent protein kinase), protein kinase B 
(Akt), and protein kinase C. 
 
 
 
 
Figure 26: Sites of Phosphorylation of GSK-3beta which regulate its Activity  
(James R Woodget 2001). 
 
The activity of GSK-3 is also regulated by the phosphorylation of tyrosine-216 in GSK-3β 
and tyrosine-279 in GSK-3α (Takahashi 2004) and several nonreceptor tyrosine kinases 
such as src (Kotova 2006). It is reported that the inhibition of tyrosine phosphorylation 
blocks the access of primed substrates which is essential for GSK-3 activity (Dajani 
2001). 
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• protein-protein interactions: 
GSK-3 is central to many signaling pathways and its activity can be regulated by 
interactions with many other proteins. The canonical Wnt signaling pathway is an 
example of regulating GSK3 activity through complex formation. GSK-3 is regulated 
through protein-protein interaction by binding to the scaffolding protein Axin, which 
associates with other proteins including adenomatous polyposis coli (APC), Casein 
kinase1 (CK-1), and β-catenin. Under basal conditions, CK-1 phosphorylates β-catenin 
Ser45 resultingin a primary site for GSK-3 phosphorylation (Culbert 2001, Hagen 2002). 
Phosphorylation of β-catenin leads to its degradation through the ubiquity in proteosome 
pathway (Amit 2002, Liu 2002).  
 
• Intracellular distribution: 
GSK-3 is a cytoplasmic protein, but it has been discovered also in the nucleus and 
mitochondria where it is more active compared to its cytoplasmatic forms (Bijur 2003). 
GSK-3 activity is increased during apoptosis and considerable part of GSK-3 is subjected 
to intracellular distribution (King 2001, Meares 2007). For instance, it has been shown 
that nuclear levels of GSK3 are decreased by the activation of the PKB/Akt (Bijur 2001), 
as well as binding of FRAT1 to GSK-3 assists nuclear release (Franca 2002). 
A study has been revealed (Azoulay 2011) that extra glycine-rich stretch in N-terminal of 
GSK-3 leads to block the nuclear translocation (Azoulay2011). Notably, the N-terminal of 
GSK-3β contains a potential nuclear localization signal, and cancellation of the nine 
aminoacids on N-terminal of GSK-3β leads to decrease the aggregation in the nucleus 
(Meares 2007). 
 
2.3 GSK-3 substrates 
 
In mammalian cells GSK-3 is ubiquitously expressed, and it is essential to several 
signaling pathways. Requisition of GSK-3 to various signaling modules and pathways let 
the specificity of the stimulus giving the effect. GSK-3 activity is regulated by inhibiting 
the phosphorylation at their serine 9/21 or via Wnt pathway, and based on the upstream 
signal the cellular consequences are changeable. GSK-3 phosphorylates over than 100 
putative substrates, only few of them have been confirmed as physiological substrate of 
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GSK-3. Since the discussion in details about GSK-3 regulation of its substrates is outside 
the field of this summarized introduction, we will highlight only some of these targets. 
GSK-3 acts as a negative regulator of glycogen synthesis and glycogen synthase is the 
first discovered substrate of GSK-3. It has been proved that GSK-3 is able to 
phosphorylate three serine residues of glycogen synthase, which results in decreasing of 
its activity (Embi 1980, Rylatt 1980). GSK-3 activity inhibition via insulin stimulation 
results in reducing the phosphorylation, enhancing glycogen synthase activation and 
increasing glucose uptake due to the increasing in the expression of glucose transporter1 
(GLUT1). This important role in glucose metabolism emerged as a promising path to treat 
insulin resistance in Type II Diabetes via small molecules able to act as pharmacological 
inhibitors of GSK-3 (Buller 2008). 
GSK-3 is involved in synaptic plasticity through the phosphorylation of MAP (Sanchez 
2000). It was also reported that GSK-3 is implicated in the phosphorylation of tau in more 
than ten sites (Hanger 1998); therefore, GSK-3 might be responsible for tau 
hyperphosphorylation causing its aggregation and precipitation to form NFT in AD brains 
(Lucas 2001, Spittaels 2000).  
Other studies revealed that GSK-3 is a negative regulator in Wnt signaling. Wnt contains 
a series of 19 different secreted proteins, which have important role in early embryonic 
development (Miller JR. 2002, Dann CE 2001). During embryonic development, Wnt 
family enhances cell growth, differentiation, migration, and cell fate. In the lack of Wnt 
signals, it results a complete activation of GSK-3 which binds and phosphorylates β-
catenin (Lagna G 1999, Winston. JT1999). Before the interaction with GSK-3, 
cytoplasmic β-catenin is primed phosphorylated by CK-1 at Ser45, then GSK-3 
phosphorylates β-catenin, at residues Thr41, Ser37 and Ser33 (Luo. J 2009, Lagna G 
1999, Winston JT 1999).  
Other recent studies explained the role of GSK-3 in self-renewal and differentiation of 
stem cells, various experiments have been performed in the human and mouse embryonic 
(HESC and MESC respectively), demonstrated that GSK-3 inhibition results in enhancing 
pluripotency and deficiency of differentiation through activation of Wnt signaling 
pathway (Sato N 2004). A study by Sato showed that leukemia inhibitory factor 
(LIF)/Stat-3 has function in retaining pluripotent status in mouse embryonic stem cells 
(MESC) but does not have the same influence on HESCs (Sato N 2004, Smith AG 2001). 
LIF/Stat-3 signaling pathway functions through activating both JAK/STAT and MAPK 
42 
 
signaling pathways which can subsequently result in the activation of PI3K-Akt cascade 
and block the activity of GSK-3 (Paling NR 2004). 
GSK-3 participation in regulating the gene transcription and expression is of fundamental 
importance. GSK-3 does not link DNA itself, but it phosphorylates and activates a wide 
range of transcription factors, and extending its regulatory action in gene expression. 
GSK-3 is involved in the phosphorylation of several transcription factors, including AP-1, 
CREB, β catenin, Hif1, NFAT, STAT, driving the gene transcription involved in cell 
survival, cell growth, toxin response, stress, and inflammation (Beurel 2008, Grimes 
2001). It is clear that GSK-3 reacts to numerous various stimuli, which in turn has 
important role in genes transcription engaged in cell growth, survival, toxin response, 
stress, and inflammation.  
 
2.4 Involvement of GSK-3 in human diseases 
 
GSK-3β is one of the principal regulators of several cellular processes. The dysregulation 
of GSK-3β activity is correlated with various human diseases. To date, GSK-3 was 
implicated in the pathophysiology of various diseases, including type2 diabetes, bipolar 
disorder, schizophrenia, AD, PD, developmental disorders, and cancer. For example, 
GSK-3 has central role in the Wnt and Hedgehog pathways, which promotes cell fate 
determination and morphology changes (Hart 1998, Jia2002). These pathways are both 
implicated in different types of human cancer (Polakis, 2000, Taipale 2001). Furthermore, 
there are plenty of studies aim to understand the role of the overexpression of GSK-3 
activity in AD, and the involvement of GSK-3 in tau hyperphosphorylation which is 
important pathological hallmarks in the development AD (Aghdam 2007). 
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Figure 27: Role of GSK-3 in multiple cellular pathways (Eldar 2010). 
 
2.4.1 GSK-3 and diabetes Type 2:  
GSK-3 is engaged in Type 2 diabetes disorder which correlated with insulin resistance in 
peripheral tissues and chronic inhibition of muscle glycogen synthase leading to hyper 
insulinemia (Wagman 2004, Lee 2007). It has also been demonstrated that overexpression 
of GSK-3 in the diabetic patient muscle is implicated in insulin signaling (Conde. S 
2003), and designing small molecules able to inhibit GSK-3 might be beneficial to treat 
non-insulin dependent diabetes mellitus through their ability to mimic insulin function in 
enhancing glycogen synthase activation, converting glucose to glycogen and raising the 
glucose uptake in various cell cultures. 
 
2.4.2 GSK-3 and Cancer: 
Different types of cancers, especially colorectal cancers, have impairment in elements of 
the Wnt pathway that result in the abnormal activation of Wnt signaling and accumulation 
of β–catenin whose overexpression contributed totumorigenesis. GSK-3 inhibition is 
expected to mimic Wnt signaling and stabilize three cell-cycle regulators, namely cyclin 
D1, cyclin E and c-Myc. 
GSK-3 is a negative regulator of Wnt signaling pathway, it phosphorylates and targets β-
catenin for ubiquitination and degradation, it also contributes in the phosphorylation and 
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activation of the Wnt co-receptor LRP6. Axin and APC are substrates of GSK-3 in this 
pathway as their phosphorylation induces the interactions within the β-catenin destructing 
multi-protein complex. By maintenance β-catenin levels in the cytosol, GSK-3 blocks the 
nuclear translocation and the activation of target genes such as c-myc and cyclin D1, 
which would finally result in raising cell proliferation. Moreover, GSK-3 has central role 
in the dynamics of the mitotic spindle. GSK-3 inhibitors prohibit chromosome movements 
and result in the stabilization of microtubules and a pro- metaphase- like arrest. Therefore, 
GSK-3 inhibitors emerged as potential therapeutic treatment thanks to the potential role of 
aberrant GSK3 in malignancy development. 
 
2.4.3 GSK3 and inflammation: 
Studies indicated that inflammation is a frequent component in mood disorders, 
neurodegenerative diseases, diabetes, and various cancers (Beurel 2010, Jope 2007). 
Whether inflammation occurs to protect or harm the host that is still controversial, the 
capacity to stimulate an inflammatory response is critical for keeping the general wellness 
of the organism, GSK-3 has important role in the inflammatory signals (Jope 2007, Martin 
2005). GSK-3 is involved in the production of pro-inflammatory cytokines inclusive 
interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor (TNF) (Beurel 
2008,Yuskaitis 2009). On the contrary, GSK-3 blocks the production of anti-inflammatory 
cytokine IL-10. Consequently, inhibition of GSK-3 was discovered to have anti-
inflammatory effects, some studies indicated that GSK-3 inhibitors are able to protect 
against endotoxin shock in mice (Martin 2005), other studies demonstrated that treating 
various systemic inflammation mice models with GSK-3 inhibitors able to produce anti-
inflammatory effect, that confirm the role of GSK-3 in the inflammation. 
 
2.4.4 GSK3 and Nervous system disorders: 
Latest data using pharmacological and genetic approaches have led to propose a central 
role for GSK-3 in the array of neural developmental activities including neural progenitor 
homeostasis, neuronal migration, neurite growth/specification, and synapse development. 
Furthermore, various studies suggested that dysregulation of GSK-3 activity contributed 
to the pathogenesis of nervous system disorders such as Prion diseases, Parkinson’s 
disease, Huntington's disease (HD), AD, and others. In this introdution it will be briefly 
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described the role of GSK-3 in the development of some of these diseases and it will be 
provide more details to describe the contribution of GSK3 in AD. 
 
2.4.4.1 Prion diseases: Dysregulation of the prion protein (PrP) has essential role in 
neurodegeneration. It was reported that the activation of GSK-3 is critical in prion 
peptide-enhancing neuronal cell death and neurodegeneration (Perez, M. 2003). 
 
2.4.4.2 Parkinson’s disease (PD): PD is age-related disorder, characterized by 
degeneration of dopaminergic neurons. Recently, it was proved that GSK-3 inhibition can 
protect dopaminergic neurons against several degenerations (Smith, P.D 2003); therefore, 
GSK-3 inhibitors might be a therapeutic advantage in the treatment of PD. 
 
2.4.4.3 Huntington's disease (HD): HD is an inherited neurodegenerative disease 
characterized by the extension of Huntington protein by polyglutamine. The resulting 
protein is toxic, makes intracellular accumulation and reducing in β-catenin level. Studies 
performed in cells and invertebrate animal models showed that using GSK-3 inhibitors 
results in reducing the overexpression of GSK-3, suggested that these agentsmay be new 
therapeutic appropriateness for HD treatment (Carmichael, J 2002). 
 
2.4.4.4 Ischemic stroke: It was revealed that activation of GSK-3 contributes to the 
development of excite toxicity phenomenon in Ischemic insults, which results in the death 
of particular neurons and causing stroke. This was further supported by a study reported 
that treatment with Lithium in rat model of stroke decreases the neurological impairments 
and reduces the brain-infarct size that supported the suggestion of deisgning  selective 
GSK-3 inhibitors might be useful in the therapy of stroke (Yan 2007). 
 
2.4.4.5 Human immunodeficiency virus type 1 (HIV-1): HIV-1 pervades the CNS and 
induces cognitive deficits (Cherner 2002). There is much benefit in the potential 
therapeutic use of GSK-3 inhibitors in HIV patients because of their neuroprotective and 
anti-inflammatory actions. A study in eight patients with HIV-1 correlated neurocognitive 
deficits is reported that lithium treatment for 12 weeks enhanced cognitive performance in 
all patients and cognitive deficits which reduced in six patients (Letendre 2006). 
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2.4.4.6 GSK3 signaling in Alzheimer’s disease pathogenesis: There are epidemiological 
analyses that supported important relationships between overexpression of GSK-3 and 
increase of its activity and neuropathological developments in AD (Leroy 2002, Mateo 
2006). Immunohistochemical data demonstrated that GSK-3 co-centralizes to neuronal in 
clusions generated by neuritic plaques, NFT, and dysfunctional neurons. These feed backs 
suggest that GSK-3 may be implicated in the processes resulting into neuropathological 
changes (Baum 1996, Pei 1999). 
 
• GSK-3 mediated tau hyperphosphorylation: 
Tau is a neuronal microtubule-associated protein, plentifully expressed in the brain whose 
pharmacological function is regulated through phosphorylation process by several protein 
kinases at tyrosine, threonine, or serine residues. Tau kinases are classified in proline- 
(PDPK) and nonproline- (NPDPK) directed protein kinases (Morishima 1995). 
 
 
 
 
 
Figure 28: GSK3 hypothesis of Alzheimer's disease (Hooper C 2008) 
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In AD, tau protein is hyperphosphorylated and could be found in aggregated form and can 
be congregate into paired helical filaments (PHF) which result in the aberrant structure 
known as NFTs. Tau protein links to C-terminal end of tubulin protein through three or 
four repeat sequences which is critical for microtubule aggregation (Cho 2004).  
GSK-3β is known as tau kinase for its important role in tau hyperphosphorylation (Hoshi, 
1996; Ishiguro, 1993). GSK-3β inhibitors may have a beneficial effect in AD since they 
may decrease tau hyperphosphorylation. For instance, transgenic mice having 
overexpressed GSK-3β and tau were treated with Lithium an inhibition of tau 
hyperphosphorylation and NTF formation was observed (Engel 2004). 
 
• GSK-3 mediated Aβ production: 
Aβ formation and aggregation have essential role in the development of AD; Aβ is 
generated from sequential cleavage of APP via two different cleavages, the first one by 
BACE-1 and second one by γ-secretase. Alteration in the expression or in the activity in 
anyone of these two enzymes results in modification in APP processing pathway and 
enhances the production of Aβ.  
Various studies reported the role of GSK-3 in Aβ production and aggregation. One of the 
studies revealed that GSK-3 may contribute to the phosphorylation of Thr668 site in APP 
(Aplin 1996, Sun 2002), and promotes the association of APP with BACE-1 (Lee 2007). 
Other researchers demonstrated that GSK-3 could behave as a γ-secretase modulator; a 
research by Phiel reported that lithium, well known GSK-3 inhibitor, induced the 
inhibition of γ-secretase and the reduction of Aβ production without affecting other signal 
transduction pathways such as Notch cleavage (Wolfe 2008). Furthermore Qing and 
colleagues proved that the use of GSK-3 inhibitor valproate resulted in preventing γ-
secretase activity and inhibited the formation of Aβ (Qing 2008). 
Moreover, GSK-3 may regulate several members of γ-secretase complex (presenilin-1/2, 
APH-1, PEN-2, nicastrin, TMP21), for example, phosphorylation of presenilin-1 by 
GSK3 regulates the interaction with APP protein, and mutations in this process links to 
FAD (De Strooper 2003). However, more experiments and studies should be carried out 
in order to shed light in the role of GSK-3 in γ-secretase complex and Aβ production, 
surprisingly, one of recent studies including GSK-3α and GSK-3β knockout animals, 
showed that neither GSK-3α nor GSK-3β isoforms are involved in APP processing by 
48 
 
acting on γ-secretase activity. Furthermore, the authors reported that there are no changes 
in the levels of APP gene or Aβ production (Jaworski 2011). 
 
• GSK-3 and neuronal cell death: 
AD is characterized by cell death and the neurons are loosed via apoptotic mechanism 
through two different apoptotic pathways, the intrinsic one that involves intracellular 
impairments, and the extrinsic one promoted by cell death receptors. GSK-3 is involved in 
promoting the apoptotic intrinsic pathway in AD (Meijer 2003). 
Studies demonstrated that GSK-3 has major role in neuronal cell death, through its role in 
forming overexpression of shaggy (Drosophila homolog of GSK-3) and increasing Tau 
hyperphosphorylation, which leads to enhance the neurodegeneration (Jackson 2002), 
studies performed by using kinase with dead mutant shaggy resulted in enhancing 
neuronal death (Jackson 2002), conferming the important role of GSK-3 in neuronal cell 
death. 
 
• GSK-3 and memory: 
The damage in Long term potentiation (LTP) is associated with memory failure in AD 
progresses and results from the inhibition of Wnt and PI3, which are both also negative 
regulators for GSK-3 (Sanna 2002). A study on mice with aberrant GSK-3 showed 
inhibition in LTP induction and reduce in spatial learning, while the treatment of mice 
with GSK-3β inhibitor results in enhancing the learning and inhibits long term depression 
(LTD). That demonstrates the crucial role of GSK-3 inhibitors in improving the memory 
formation in AD (Hamilton 2007, Reiman 2007). 
 
2.5 Targeting GSK3 in drug disovery  
 
The contribution of GSK-3 in the important biological functions and in the pathogenesis 
of various diseases, made it an important target in drug discovery since agents able to 
inhibit this enzyme could have therapeutic potential for the treatment of various disorders 
including cancer, diabetes, bipolar disorder, AD, PD, schizophrenia. 
To date, more than 30 molecules have been described as GSK-3 inhibitors with wide 
various chemical types, including cations and compounds isolated from natural sources 
and synthetic compounds. The crystal structure of GSK-3β was obtained, and this was a 
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key to clarify the binding sites within the enzyme and to classify the inhibitors based on 
their mechanism of action. The inhibitors could be divided in ATP-competitive, non ATP-
competitive and substrate- competitive inhibitors. Recently, Palomo et al. figure (29) 
explained the map of the GSK-3 surface by using the geometry-based algorithm fpocket, 
and hpocket programs. They declared that it is characterized with seven conserved 
binding sites; three of them are ATP substrate, and peptides axin/FRATide-binding sites. 
The other four sites are non ATP binding: one of them is localized on the C-terminal 
domain of GSK-3, the second one is located on hinge region, and the other two sites are 
situated on the N-terminal domain of GSK-3. 
 
 
 
Figure 29: The binding sites available on the surface of GSK-3 (Palomo2011) 
 
The selectivity and safety are important challenges in the design and synthesis of GSK-3 
inhibitors to produce effective drug useful to treat the human diseases. The common 
properties for all GSK-3 inhibitors include: low molecular weights, flat planar structures, 
most of them are hydrophobic and contain cyclic ring moieties. Additionally, since GSK-
3 is essential for life, smooth or moderate inhibitors are requested to avoid the toxicity, 
since high values for IC50 can prevent the cells from acting normally. Another important 
challenge for GSK-3 inhibitors to turn into in an efficient drug for AD treatment is the 
ability to cross the blood brain barrier in order to regulate the exacerbated GSK-3 brain 
levels. To date only a few GSK-3 inhibitors reached the clinical trials in human subjects. 
Most of them are ATP-competitive inhibitors targeting cancer and diabetes disorders, and 
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only two compounds are non ATP - competitive inhibitors including lithium chloride and 
Tideglusib. 
Lithium is the first natural identified cation as GSK-3 inhibitor, it has been used for long 
time as a clinical treatment of bipolar disorder, it acts as GSK-3 inhibitor directly by 
competing with magnesium cation and indirectly by increasing the auto regulation and the 
phosphorylation on the serine site, a study by Davies et al. demonstrated the selectivity of 
the lithium as GSK-3 inhibitor, the study included 24 different kinases and displayed an 
inhibition of GSK-3 more than the other kinases.  
Clinical studies have been widely developed to investigate the therapeutic effect of 
lithium on AD, some studies reported that treating transgenic mice with Lithium, resulted 
in APP inhibition, and decreasing in Aβ and tau phosphorylation, some other 
investigations revealed toxic side effects in old patients, so the clinical studies on Lithium 
were stopped, and currently it is used just as reference compound for bipolar disorders. 
 
2.5.1 ATP-competitive GSK-3 inhibitors:  
Many compounds has been identified as ATP-competitive GSK-3 inhibitors, most of them 
show low specificity and high toxicity since the human body has more than 500 proten 
kinases which have high similarity of homology in the catalytic domain; for this reason 
most of the tested compounds failed in the preclinical studies. 
Some of GSK-3 ATP-competitive inhibitors were isolated from natural resources, in 
particular from Marine organisms, such as Indirubins, they showed selectivity toward 
GSK-3 over CDKS, 6-bromoindirubin 3-oxime was studied at 1.5 µM concentration in 
transgenic mice, proved neuroprotection properties and axon formation in addition to 
decrease of tau phosphorylation.  On the contrary, studies carried out on rat brain with the 
same compound, showed no effect in reducing tau phosphorylation because of its poor 
bioavailability which due to its limited water solubility (Selenica 2007, Leclercetal 2001). 
Hymenialdisine (HD) is potent protein kinase inhibitor targeting GSK-3β, CDKs, MEK, 
CK-1, and Chk1 functions in competition with ATP (Wanetal 2004), it induced the 
reduction in tau phosphorylation and the neuroprotective effect already at 10nM 
concentrations and currently it is evaluated in preclinical studies. 
Purine group, including compounds CT98014, CT98023, CT99021, represents one of the 
first synthetic ATP competitive GSK-3β inhibitors with high selectivity toward this 
isoform and IC50 in nanomolar range concentrations (Alabed2011). AR-A014418 is 
another ATP-competitive GSK-3β inhibitor showed decrease in tau phosphorylation and 
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NFT formation in transgenic mouse model (Bhat 2003). SB-216763 is a synthetic ATP-
competitive GSK-3β inhibitor that showed advantages in AD therapy; for instance, it 
decreased Aβ aggregation and tau phsphorylation in mice (Hu 2009, Selenica 2007). 
 
 
 
 
Figure 30: Structures of ATP-competitive GSK-3 inhibitors 
 
 
2.5.2 Non-ATP competitive GSK-3β inhibitors: 
Kinase selectivity is one of the major challenges in design and synthesis of protein kinases 
inhibitors (Eglen 2009), ATP -competitive GSK-3β inhibitors are emerged as distinct real 
potential drugs with more selectivity than ATP-competitive GSK-3β inhibitors, since they 
should bind to unique regions within the kinase producing more subtle modulation of 
kinase activity than only blocking ATP entrance, they act as covalent inhibitors, substrate 
competitive inhibitors or allosteric modulators. Non ATP-competitive GSK-3β inhibitors 
are promising potential drugs which could provide important benefits in therapeutic for 
various disorders with a safer use in the clinic. 
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Figure 31: Structures of ATP non-competitive GSK-3 inhibitors (Martinez A 2013) 
 
In 2002, Martinez et al. have reported cyclic thiadiazolidinones (TDZD) as first group of 
synthetic non ATP–competitive GSK-3β inhibitors, through its interaction with the 
oxyanion binding site of GSK-3β, several derivatives were synthesized and evaluated for 
inhibiting GSK-3β, and one of these synthesized compound currently known as 
Tideglusib, showed high selectivity toward GSK-3β over a panel of several protein 
kinases including Protein Kinase A, Protein kinase C, casein kinase II (CK-2), and cyclin-
dependent kinase 1 (CDK1/cyclin B). Tideglusib was investigated for treatment of AD 
and progressive supranuclear palsy (PSP). It demonstrated positive results after several 
studies in different animal models, it showed enhanced in cognitive performance, 
reducing in tau phosphorylation and decreasing in Aβ production, furthermore, it showed 
the ability to cross the BBB, currently, Tideglusib is under clinical studies to investigate 
the safety and efficacy characteristics in human patients. 
Emodin was reported by Gebhardt as non-ATP competitive GSK-3β inhibitor and its 
analogue, carrying an ethylenediamine chain, showed an insulin sensitizing influence 
mediated by an increase in hepatocellular glycogen and in the biosynthesis of fatty acids. 
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Other compound is 5-imino-1, 2, 4- thiadiazoles (ITDZs), it was demonstrated by Polomo 
et al. as a first class able to block reversible GSK-3β acting as substrate competitive 
inhibitor. 
Chloromethylthienyl ketones and Halomethyl phenyl ketones were reported by Condeas 
irreversible non ATP-competitive inhibitors toward GSK-3β: these two classes showed 
cell permeability and reduced tau phosphorylation and are highly selective (Perez 2009).  
Other ATP non-competitive GSK-3 inhibitors from natural resources were reported, such 
as Manzamine, which was isolated from an Indopacific sponge, and Palinurin and 
Tricantin isolated from Mediterranean sponges. These compounds showed reducing in tau 
phosphyrlation, but no clinical studies were developed on these compounds.  
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2.6 Drug Design 
 
As largely discussed in the introduction, GSK-3β enzyme is involved in the development 
of AD. Some GSK-3β inhibitors are currently evaluated in clinical trials for the treatment 
of AD and other pathologies, such as diabetes and cancer. Most of these inhibitors 
interacting with the ATP-binding site which is, as already reported, highly conserved in 
all the different kinases. The human kinome is known to be about 500 kinases and all 
these enzyme share high homology in the catalytic domain. Therefore, agents that bind to 
this site are characterized by low selectivity, which may lead to toxic side effects. One of 
the main challenges in these years in GSK-3β inhibitors research is to develope non-ATP 
competitive GSK-3β inhibitors, binding in other sites such as substrate-binding or 
allosteric binding sites.  
The aim of the present work is the development of new non-ATP competitive GSK-3β 
inhibitors. In medicinal chemistry different strategies can be followed to discover 
biologically active compounds (hit) which may represent a starting point for a new drug 
discovery program. One of the most promising strategies is based on the screening of 
collections of small molecules towards a given biological target. Following this strategy, 
we screened our in-house collections towards GSK3β with the aim of discover a potential 
new hit compound. The compounds were assayed at 10 μM concentrations, and those 
which showed a degree of inhibition at least 40% were considered for further IC50 
determination. Among all the compounds, only compound 1 met the criteria for further 
development and it was subjected to IC50 determination (IC50 = 1.56 ± 0.05 μM) (Figure 
32).  
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Figure 32: Schematic representation of the screen strategy leading to compound 1 
 
Compound 1 is structurally characterized by a napthalendiimmidic scaffold and an o-
methoxybenzyl moiety linked by a two-methylene spacer. Compound 1 is characterized 
by a diimide moiety, which is characteristic of phthalimide-based compounds, such as 
SB-216763, which are known to behave as ATP-competitive inhibitors. SAR studies 
performed on these inhibitors reported that the -NH engage a critical interaction with the 
carbonylic oxygen of Asp133 located in the ATP binding site and that the replacement of 
the H atom with an alkyl moiety induces a loss of the activity. Therefore, based on these 
considerations and on the structure of tideglusib, we hypothesize that compound 1 may be 
able to inhibit GSK-3β by interacting with different sites out of ATP binding site. 
Based on these results, we started a campaign of SAR evaluations and hit to lead 
optimization with the goal of discovering potent and selective GSK-3β inhibitor (Figure 
33 and Figure 34). 
We started synthesizing compounds 2-4 characterized by alkyl chain of different length in 
order to evaluate the importance of the distance between the two aromatic moieties for a 
good interaction with the enzyme. Then, we focused our attention on the evaluation of the 
methoxy group in orto position of the aromatic ring (5-8) together with the elimination of 
the chain (9), in one of the aromatic ring (10 and 18) and other of carbonyl group (11). 
Then we evaluated the effects of the replacement of the methoxybenzylamine group with 
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a dimethylamino (12-13), morpholino (14), piperazine (15), hydroxyl (16) and benzyl (17) 
groups, methoxyphenyl-methanamine (18) (Figure 33). 
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Figure 33: Structure-Activity Relationships of compound 1. 
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Lastly, the most interesting structure obtained through this study compound (18) was 
further modified in order to increase the lipophilicity to improve its pharmacokinetic 
properties (19-23) (Figure 34).   
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Figure 34: Drug design leading to 19-23. 
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2.7 Methods 
 
2.7.1 Synthesis: 
1-4 were obtained by reacting 1, 8-Naphthalic anhydride with the corresponding diamines 
(n=1-4) leading to 41-44 following the procedure reported in literature (Braña 2002); then 
41-44 were condensate with 2-methoxybenzaldehyde and then reduced by sodium 
borohydride giving the products 1-4 (Scheme 1). 
The compounds 5-8 were obtained following the procedure reported in Scheme 2, by 
reacting 1, 8-Naphthalic anhydride with the corresponding amine (51-54). The 
compounds 51-54 were obtained reacting the Boc diamine 45-46 with the corresponding 
aldehyde to give 47-50 which were followed by treatment withHCland then worked up to 
give 51-54 which, finally,reacted with 1, 8-Naphthalic anhydride to give the final 
compounds 5-8. 
The compounds 9-10 were obtained by dissolving the corresponding anhydride in 
ammonium hydroxide, in particular, 1,8-naphthalic anhydride or phthalic anhydride, 
respectively,and leaving the reaction under reflux for 6 hours (Scheme 3). 
Compound 11 was synthesized by dissolving benzoic acid and Dimethylethylenediamine 
in dichloromethane in the presence of EDCI, HOBt and triethylamine, the reaction stirred 
at room temperature for 12h (Scheme 4). 
Compounds 12-13 were obtained by the condensation of dimethylethylenedi amine with 
the corresponding anhydride, 1,8-naphthalic anhydride or phthalic anhydride, 
respectively, dissolved in ethanol (Scheme 5). 
The compounds 61 and 62 were synthesized following the procedure described in 
(scheme 6), starting from 2-cloroetilammina hydrochloride which was treated with Boc2O 
to have the compound 56, then 56 was treated with 57 and 58  under reflux to give  59 and 
60 followed with deprotection to give the corresponding compounds 61 and 62, 
The synthesis of the final compounds 14-17 was carried out following the procedure 
described in (Scheme 7), phthalic anhydride was suspended in water then glacial acetic 
acid and the reported side chains were added to the suspension, 61 for the compound 15, 
62 for the compound 15, ethanolamine and benzylamine for 16 and 17. Then the mixture 
was stirred under reflux for 4 hours. The amines and phthalic anhydride are used in ratio 
(1:1). The work-up was different for the reactions based on the nature of the side chains. 
Compounds 16-17 were obtained by adding water, and then filtering the precipitated solid 
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in water, followed by crystallization. To note that compounds 14-15 were purifieddirectly 
by flash chromatography. 
Compound 18 was obtained by dissolving phtalic anhydride with diamine 65 in ethanol 
and stirred under reflux for 3 hours (Scheme 8). Compound 65 was obtained by reacting 
the compound 62 with the reagent EtOCOCF3 in methanol to give the compound 63, 
which furthered with metalation reaction by reacting with formic acid 85% and form 
aldhyde 40% to give the copound 64, and after removing the protection group we obtained 
65 (Scheme 8). 
The synthesis of the final compounds 19-23 was carried out following the procedure 
described in (scheme10) by react the compound 68 with the corresponding amine. The 
synthesis of the compound 68 is described in (scheme 9), it was obtained by reacting the 
compound 65 with Nitrophtalic amide to give the compound 66, which was subjected to 
reduction reaction using Fe under acidic condition and using ultra sonic for 2 hours, to 
give the compound to give 67 which was reduced to into isothiocyanate group using 
Tiocarbonyl dipyridine, to give the compound 68. 
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2.7.2 Biology: 
To determine the potential interest of compounds 1-23, their inhibitory potency against 
GSK-3β was evaluated  by luminescence assay. 
For the characterization of the mechanism of action of the lead compound 13, the 
application of the ESI-QTOF methodology developed by Andrisano and coworkers was 
applied (Annalisa D’Urzo 2016).  
To estimate the toxicity and the bioavailability in vivo for the lead compound 13, we used 
zebrafish model. 
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2.8 Results and Discussion 
 
2.8.1 The evaluation of GSK-3β inhibition: 
Target compounds have been evaluated for their ability to inhibit GSK-3β by using a 
luminescence assay. The method of Baki (A. Baki, 2007) was followed to analyze the 
inhibition of GSK-3β. Assays were performed in 50 mM HEPES, 1 mM EDTA, 1 mM 
EGTA, and 15 mM magnesium acetate pH 7.5 assay buffer using white 96-well plates. In 
a typical assay, 10 μL of test compound (dissolved in DMSO at 1 mM concentration and 
diluted in advance in assay buffer to the desired concentration) and 10 μL (20 ng) of 
enzyme were added to each well followed by 20 μL of assay buffer containing 25 μM 
substrate and 1 μM ATP. The final DMSO concentration in the reaction mixture did not 
exceed 1%. After 30 min incubation at 30 °C, the enzymatic reaction was stopped with 40 
μL of Kinase-Glo reagent. After 10 min, luminescence in the entire visible range was 
recorded using a Victor™ X3 Perkin Elmer multimode reader. The activity is proportional 
to the difference of the total and consumed ATP. The inhibitory activities were calculated 
on the basis of maximal kinase and luciferase activities measured in the absence of 
inhibitor and in the presence of reference compound inhibitor SB-415826 (M.P. Coghlan, 
2000) at total inhibition concentration, respectively. The linear regression parameters were 
determined and the IC50 extrapolated (Graph Pad Prism 4.0, GraphPad Software Inc.). 
 
2.8.2 Results and Discussion for the compounds (1-13): 
As could be observed in table 1, increasing the length of the spacer between the 
naphthalendiimide and the methoxybenzyl moiety led to a decrease in the inhibition 
activity (1 vs 2-4) as well as the elimination of the methoxy substituent (5) or its 
replacement with group characterized by different chemical-physical properties, such as 
methyl (6) or nitro group (7). Elimination of the chain in compound (9) led to a decrease 
in the activity, as well as the concomitant elimination of both the chain and an aromatic 
ring (10). 
The elimination of one of carbonyl group (11) led to reduce the activity toward the 
enzyme. Replacement of the methoxybenzylamino group with dimethylamino amino 
group in the naphthalimide group in compound (12) led to a drop of the activity. 
The phthalimide with dimethylamino amino group in compound (13) do not induces a 
similar reduction of the activity. 
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Table 1: Inhibitory activity towards GSK-3β for compounds 1-13. 
 
The compounds (1-4) and the compound 9 showed good levels of activity tward GSK-3β, 
but since the structures are characterized by a naphthalimide moiety, and it was reported 
in the letreture it is ablitly to interact with DNA (Czerwinska I 2014) that may lead to 
additional deleterious interaction which could result to serious side effects. 
The compound 13 characterized by an IC50 (9.51 ± 0.13), it exhibited good level of 
activity tward GSK-3β, so that we decided to investigate its mechanism of action. 
 
2.8.3 Mechanism of action for the compound 13: 
The application of the ESI-QTOF methodology developed by Andrisano and coworkers 
(Annalisa D’Urzo 2016) was applied for the characterization of the mechanism of action 
of compound 13. The Lineweaver-Burk plot was first obtained for Tideglusib as reference 
compound, and then following the same procedure the mechanism of 13 was investigated. 
The analysis of Lineweaver-Burk reciprocal plots for this compound reported in Figure 
(35) reveals a non ATP-competitive mechanism of action. Reciprocal plot obtained by 
Compound % inhibition IC50 (μM) 
1  1.56 ± 0.05 
2  2.10 ± 0.14 
3  2.38 ± 0.54 
4  3.01 ± 0.74 
5 69.15 at 10 μM  
6 33.64 at 10 μM  
7 31.62 at 10 μM  
8 46.75 at 10 μM  
9  9.50 ± 1.43 
10  20.22 ± 0.40 
11  45.00 ± 10.90 
12  21.72 ± 2.68 
13  9.51 ± 0.13 
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monitoring enzymatic velocity of 13 (0-10μM) at increasing ATP concentration (15-125 
μM) shows a decreasing vmax value while the KM value resulted not affected by inhibitor 
concentration (Figure. 35 A). Conversely, the graph obtained by plotting the inverse of 
velocity, expressed as P-GSM intensity, versus reciprocal GSM concentrations showed a 
change in vmax only at higher inhibitor concentrations, while the x-intercept value 
(1/KM) increases proportionally with the concentration of compound 13. The detailed 
analysis of these plots compared to that obtained for tideglusib (data not shown) reveals 
that 13 is a non ATP- competitive inhibitor. Moreover, it was also possible to determine 
the Ki value for this novel compound and promising compound by plotting the slope 
values versus the concentration of compound 13, A Ki value of 3.49 μM was determined. 
 
 
 
. Figure 35: Kinetic study of compound 13 mechanism on GSK-3β inhibition. Overlaid 
Lineweaver–Burk reciprocal plots of GSK-3β initial velocity at increasing ATP (A) or substrate (B) 
concentration (0.015–0.125 mM) in the absence and in the presence of compound 13 are shown.  
 
2.8.4 In vivo Evaluation for the compound 13 by using zebrafish model: 
The compound 13 was tested for their in vivo activity on wild-type zebrafish embryos. In 
litreture it is reported that Wnt pathways is activated with sequential alteration of the 
normal embryogenic development. The final effect of the treatment of zebrafish embryo 
with GSK3-β inhibitors in 5 hours post fertilization (hpf), determines the appearance of 
eyeless phenotype with crocked tail after 48 hpf (Funke, A 1958, Hormann, R. E. 2004, 
Kimmel, C. B 1995). 
We exposed the embryos to these compounds at early stages of development. The 
embryos were collected and maintained in E2 into 40-well plates, 10 embryos per well 
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and maintained in E2 medium at 28 °C. Compounds were added 5 hpf (50% epiboly) with 
three concentrations 25 μM, 40 μM and 50 μM, the embryos allowed to grow in chemical 
compound solution up to 2 days. The phenotypes were compared using the Axio 
Scope.A1 microscope system at 44−48 hpf, compound 13 causes the eyeless phenotype 
and crooked tail at 40 μM figure (36). 
 
 
 
Figura 36: Effects on wild-type zebrafish embryos by compounds 13. The embryos were 
collected and maintained in E2 medium at 28 °C, compounds were added 5 hpf, and the 
phenotypes were compared at 44−48 hpf. This compound causes the eyeless phenotype and 
crooked tail at 40 μM. 
 
2.8.5 Results and Discussion for the compounds (14-23): 
The compound 13 considered as a lead compound for developing new non-ATP 
competitive GSK-3β inhibitors, and it was subjected for further mondifications in order in 
order to obtain a novel agent chractrized with better activity and to increase the 
lipophilicity for better pharmacokinetic properties. 
Modifining compound 13 led to the compounds (14-18), the compounds (14-17)  
characterized by a different substitution pattern in the phthalimide series, using different 
basic functions (14,15) and even without any basic function (16,17), resulted in reducing 
theactivity levels of GSK-3β inhibition as it is observed in table 2. 
Interestingly compound 18 is difined by o-methoxyethylendiamino chain and a 
phthalimide, and its value of IC50 7.5± 0.18.  
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Table 2: Inhibitory activity towards GSK-3β for the compounds 14-18 
Compound % inhibition IC50 (μM) 
14 < 40% at 100 μM  
15 < 40% at 100 μM  
16 45.51% at 100 μM  
17 < 40% at 100 μM  
18  7.5± 0.18 
 
Compound 18 subjected for further modifications through adding a chain linked to the 
benzyle ring, ethyleamine 19, morpholin 20, methyl pyrazine 21, benzyle 22, and N- 
butylamine 23, the synthsised compounds 19- 23 are currently under the evaluation for 
their activity as GSK-3β inhibitions. 
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2.9 Conclusion 
 
In this work it has been developed a hit compound 13 exhibited good level of activity 
tward GSK-3β, characterized by micromolar range, studying the the mechanisms of action 
indicated that it acts as non-ATP competitive GSK-3β inhibitors. Applying the 
compounds on zebrafish model caused eyeless phenotype at 25 μM and a crooked tail at 
50 μM. In order to obtain more potent derivatives compound 13 was subjected for further 
optimization which led to have an interesting deritive 18 charchtrized with lower IC50 
value. More modifications were applied on the compound 18 by adding a chain with 
different sustituent linked to the benzyle ring by the aim to enhance the potency and 
increase the lipophilicity for better pharmacokinetic properties, and the synthesized 
compound currently are under the biological evaluation against GSK-3β. 
 
 
  
72 
 
2.10 Experimental Section 
 
Chemistry: 
Melting points were measured in glass capillary tubes on a Buchi SMP-20 apparatus and 
are uncorrected. ESI-MS spectra were recorded on Perkin-Elmer 297 and WatersZQ 4000. 
1H NMR and 13C NMR were recorded on Varian VRX 200 and 300 instruments. 
Chemical shift are reported in parts per millions (ppm), and are relative to peak of 
tetramethylsilane (TMS).Spin multiplicities are given as s (singlet), br s (broad singlet), d 
(doublet), t (triplet), q (quartet) or m (multiplet) Although IR spectral data are not 
included (because of the lack of unusual features), they were obtained for all compounds 
reported, and they were consistent with the assigned structures. Chromatographic 
separations were performed on silica gel columns by flash (Kieselgel 40, 0.040-0.063 
mm, Merck) or gravity (Kieselgel 60, 0.063-0.200 mm, Merck) column chromatography. 
Reactions were followed by thin layer chromatography (TLC) on Merck (0.25 mm) glass-
packed precoated silica gel plates (60 F254) and then visualized in an iodine chamber or 
with a UV lamp.The term “dried” refers to the use of anhydrous sodium sulfate. 
 
General procedure for the synthesis of 41-44: compounds 41-44 have been synthesized 
following the procedure reported in literature (Andrea Milelli 2012). 
General procedure for the synthesis of derivatives 1-4: amixture of 41-44 and 2- 
methoxy benzaldehyde (inaratio1:1.2) in toluene was refluxed in a Dean Stark apparatus 
for 3h. Following solvent removal ,the residue was taken u p  in EtOH, NaBH4 
(ina1:2.5molarratio) was added, and the stirring was continued at room temperature for 
12h. The mixture was made acidic with 6 NHCl and the solvent removed. Then, the 
residue was dissolved in water and the resulting solution was washed with ether, made 
basic with K2CO3 and extracted with DCM (3x30ml). Removal of the dried solvent gave 
the desired products 1-4 which were purified by flash chromatography. 1-4 were finally 
converted into the para-toluen sulfonate salt. 
2- (2- (2-Methoxybenzylamino) ethyl)-1H- benzo [de] isoquinoline -1,3 (2H)- dione 
(1): Compound 1 was synthesized from compound 41; eluting solvent petroleum ether 
/CHCl3/MeOH/aqueous 33% ammonia (6:3.5:0.5/0.1); yellow oil ; 24%yield; 
1
H-NMR 
(400 MHz, CDCl3) δ 1.92 (s, H1), 2.97 (t, J= 6.6 Hz, 2H), 3.77 (s, 3H), 3.84 (s, 2H), 4.32 
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(t, J=8.0 Hz, 2H), 6.76-6.88 (m, 2H), 7.12-7.24 (m, 2H), 7.62-7.70 (m, 2H), 8.08- 8.13 (m, 
2H), 4.48-8.52 (m, 2H); MS (ESI+) m/z = 361 (M+H)+. 
2- (3- (2-Methoxybenzylamino) propyl)- 1H- benzo [de] isoquinoline- 1,3 (2H)- dione 
(2): Compound 2 was synthesized from 42; eluting solvent petroleum ether /CHCl3/ 
MeOH /aqueous 33%ammonia (6:3.5:0.5/0.1); yellow oil; 24%yield; 
1
H-NMR (400 MHz 
,CDCl3) δ 1.91-2.05 (m, 2H), 2.36 (s, 1H), 2.73 (t, J =7.0 Hz, 2H), 3.81 (s,3H), 3.84 (s, 
2H), 4.25 (t, J =7.0 Hz, 2H), 6.82-6.90 (m, 2H), 7.15-7.25 (m, 2H), 7.65-7.74 (m, 2H), 
8.13-8.17 (m, 2H), 8.52-8.55 (m, 2H); MS (ESI+)m/z = 375 (M+H)+. 
2-(4- (2- Methoxybenzylamino) butyl) -1H- benzo [de] isoquinoline- 1,3 (2H)-dione 
(3): Compound 3 was synthesized from 43; eluting solvent petroleum ether/ CHCl3/ 
MeOH/ aqueous 33% ammonia (6:3.5:0.5/0.1); yellow oil; 29% yield; 
1
H-NMR (400 
MHz, CDCl3) δ 1.60-1.82 (m, 4H), 2.45 (s, 1H), 2.67 (t, J =7.0 Hz, 2H), 3.79 (s, 3H), 3.83 
(s, 2H), 4.17 (t, J =7.4 Hz, 2H), 6.81-6.92 (m, 2H), 7.16-7.25 (m, 2H), 7.69 (t, J =8.0 Hz,  
2H), 8.12-8.17 (m, 2H), 8.51-8.55 (m, 2H); MS (ESI
+
) m/z = 389 (M+H)+. 
2- (5- (2-Methoxybenzylamino) pentyl)- 1H- benzo[de] isoquinoline-1,3 (2H)-dione 
(4): Compound 4 was synthesized from 44; eluting solvent petroleum ether /CHCl3/ 
MeOH/ aqueous 33% ammonia (6:3.5:0.5/0.1); yellow oil; 34%yield; 
1
H-NMR (400 MHz, 
CDCl3) δ 1.27-1.80 (m, 7H), 2.65 (t, J=7.4 Hz, 2H), 3.81 (s, 2H) ,3.84 (s, 3H), 4.17 (t, 
J=7.8 Hz, 2H), 6.84-6.94 (m, 2H), 7.19-7.30 (m, 2H), 7.72 (t, J=8.2 Hz, 2H), 8.15-8.19 
(m, 2H), 8.53-8.57 (m, 2H); 
13
CNMR (101,CDCl3) δ 24.76,27.91, 29.18, 40.19, 48.57, 
48.76, 55.15, 110.11, 120.32, 122.57, 126.58,127.18 ,127.98, 128.35, 130.02, 131.02, 
131.45,133.72, 157.55, 164.02; MS(ESI
+
) m/z = 403 (M+H)+. 
General procedure for the synthesis of compounds 45- 46: To a solution of 
Ethylendiamin and other solution of n-methylethylenediamine in DCM (1eq) we added 
Boc (1eq), the resulting mixture was stirred for 12 h in room temperature, concentrated 
under reduced pressure. The crude residue was used for the synthesis of 47, 48, 49, 50 
without any further purification. 
General procedure for the synthesis of compounds 47-50: A mixture of 45-46 with the 
corresponding aldyhide (inaratio1:1.2) into luene was reflux Edina Dean –Stark apparatus 
for 3h. Following solvent removal, the residue was taken u p  in EtOH, NaBH4 
(ina1:2.5molarratio) was added, and the stirring was continued at room temperature 
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for12h. Following solvent removal; then dissolving in DCM. The organic layer was 
washed with saturated solution of sodium chloride, The combined organic extracts were 
dried (MgSO4) and concentrated under reduced pressure, The crude residue was then 
subjected to flash silica gel column chromatography with DCM / MeOH / aq NH3 33% 
(9:1:0.1). 
Tert- butyl (2- (benzylamino) ethyl) carbamate (47): 77% yield; 1H-NMR (400 MHz, 
CDCl3) δ 1.42 (s, 9H), 2.67 (t, 2H), 3.24 (t, 2H), 3.77 (s, 2H), 7.12-7.26 (m, 4H ). 
Tert-butyl (2-((2-methylbenzyl) amino) ethyl) carbamate (48): 65% yield, 1H-NMR 
(400 MHz, CDCl3) δ 1.22 (s, 9H), 2.21 (s, 3H), 2.70 (t, 2H), 3.27 (t, 2H), 3.84 (s, 2H), 
7.10-7.27 (m, 4H). 
Tert-butyl (2-((2-nitrobenzyl) amino) ethyl) carbamate (49): 71% yield;1H-NMR (400 
MHz, CDCl3) δ 1.19 (s, 9H), 2.75 (t, 2H), 3.33 (t, 2H), 3.72 (s, 2H), 6.99-7.17 (m, 4H). 
Tert-butyl (2-((2-methoxybenzyl) (methyl) amino) ethyl) carbamate (50): 41%yield; 
1H-NMR (400 MHz, CDCl3) δ 1.28 (s, 9H), 2.27 (s, 3H), 2.52 (t, 2H), 3.27 (t, 2H), 3.75 
(s, 2H), 3.89 (s, 3H), 7.02-7.20 (m, 4H). 
General procedure for the synthesis of compounds 51-54: The solution of 47-50 in 
MeOH was acidified with 6 NHCl and the solvent removed. Then, the residue was 
dissolved in water and the resulting solution was washed with ether, made basic with 
K2CO3 and extracted with DCM (3x30mL). The combined organic extracts were dried 
(MgSO4) and concentrated under reduced pressure, the crude residue was then subjected 
to flash silica gel column chromatography with DCM / MeOH / aq NH3 33% (9:1:0.1). 
General procedure for the synthesis of compounds  5-8: To a solution of 1 eq of the 
compound (20-23) in toluin, we added 1 q of 1,8 naftalinamide, then the resulting mixture 
was stirred under reflux for 5 hours, concentrated under reduced pressure, the crude 
residue was then subjected to flash silica gel column chromatography with DCM / MeOH 
/ aq NH3-33% (9:1:0.1). 
2-(2-(Benzylamino) ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (5): 55%  yield’ 
1H-NMR (400 MHz, CDCl3) δ 1.32 (s, 9H), 2.97 (t, 2H), 3.66 (t, 2H), 3.79 (s, 2H), 7.09-
7.26 (m, 4H), 7.98-8.11 (m, 4H). MS (ESI+) m/z = 331 (M+H)+. 
2-(2-((3-Methylbenzyl)amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione(6): 49%  
yield, 1H-NMR (400 MHz, CDCl3); δ 1.29 (s, 9H), 2.25 (s, 3H), 2.98 (t, 2H), 3.45 (t, 2H), 
3.79 (s, 2H), 7.03-7.21 (m, 6H), 8.02-8.33 (m, 4H); MS (ESI+) m/z = 345 (M+H)+. 
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2-(2-((3-Nitrobenzyl)amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (7): 60% 
yield; 1H-NMR (400 MHz, CDCl3) δ 1.19 (s, 9H), 2.88 (t, 2H), 3.57 (t, 2H), 3.99 ( s, 2H), 
6.91-7.15 (m, 6H), 8.11-8.27 (m, 4H); MS (ESI+) m/z = 367 (M+H)+. 
2-(2-((3-Methoxybenzyl) (methyl)amino) ethyl)- 1H- benzo [de] isoquinoline-1, 
3(2H)- dione (8): 47% yield, 1H-NMR (400 MHz, CDCl3) δ 1.19 (s, 9H), 2.25 (s, 3H), 
2.72 (t, 2H), 3.44 (t, 3H), 3.89 (s, 3H), 3.99 ( s, 3H), 6.99-7.15 ( m, 6H), 7.99-8.15 (m, 
4H); MS (ESI+) m/z = 375 (M+H)+. 
Tert- butyl (2-chloroethyl) carbamate (56): to a solution of 2-cloroetilammina 
hydrochloride (18 mmol, 1 eq) in 4 ml of water we added triethylamine dropwise (23 
mmol, 1.3 eq) ,the resulting mixture was stirred at room temperature for 30 minutes. Then 
we added a dissolved Boc2O (20 mmol, 1.1 eq) in 20 ml of THF, resulting mixture was 
stirred at room temperature for 12 h. Then it was extracted with EtOAc, concentrated 
under reduced pressure. The crude residue was used for the synthesis of 60 without further 
purification. 
General procedure for the synthesis of (9-10): Compounds 9-10 have been synthesized 
following the procedure reported in literature (Braña MF, 2002).  
 N-(2-(dimethylamino) ethyl) benzamide (11): To a solution of benzoic acid in 
dichloromethane, we added EDCI, HOBt and triethylamine; the resulting mixture was 
stirred for 30 minutes. Then we added Dimethylethylenediamine, the resulting mixture 
was stirred at RT for 12h, concentrated under reduced pressure. The crude residue was 
then subjected to flash silica gel column chromatography with DCM/MeOH, (9: 1), 
yellow oil, 47% yield;1H-NMR (400 MHz, CDCl3) δ 2.45b (s, 6H), 2.77 (t, 2H), 3.65 (m, 
2H), 7.30-7.44 (m, 4H), 7.66 (s, 1H), 7.81-7.83 (m, 1H); MS (ESI+) m/z = 178 (M+H)+. 
General procedure for the synthesis of compounds 12-13: The corresponding 
anhydride was dissolved in ethanol and we added Dimethylethylenediamine and DMAP, 
the resulting mixture was stirred at reflux for 4 h then concentrated under reduced 
pressure, the crude residue was then subjected to flash silica gel column chromatography 
with DCM/MeOH, (9: 1). 
2-(2-(Dimethylamino) ethyl)- 1H- benzo [de] isoquinoline-1,3 (2H)- dione (12):  61% 
yield; yellow oil; 1H-NMR (400 MHz, CDCl3) δ 2.01 (s, 6H), 2.72 (t, 2H), 3.54 (t, 2H) 
7.31 (d, 2H), 7.89 (d, 2H), 8.11 (d, 2H); MS (ESI+) m/z = 269 (M+H)+. 
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2-(2-(Dimethylamino) ethyl) isoindoline-1, 3-dione (13): 72% yield; Yellow oil; 1H-
NMR (400 MHz, CDCl3) δ 2.28 (s, 6H), 2.58 (t, 2H), 3.79 (t, 2H), 7.67-7.70 (m, 2H), 
7.78-7.83 (m, 2H). MS (ESI+) m/z = 219 (M+H)+. 
Tert-butyl (2-(piperazin-1-yl)ethyl)carbamate (58): Compound 55 (9 mmol, 1 eq) was 
dissolved in DMF, we added triethylamine (1.2 ml, 1 eq) and piperazine (36mmol, 4 eq). 
The resulting mixture was stirred under reflux for 12h, concentrated under reduced 
pressure. The crude residue was then subjected to flash silica gel column chromatography 
with DCM / MeOH / aq NH3 33% in the ratio (9.5: 0.5: 0.05); 43% yield; yellow oil;  1H-
NMR (400 MHz, CDCl3) δ 1.36 (s, 9H), 2.33-2.40 (m, 6H), 3.13-3.14 (m, 2H), 3.30-3.36 
(m, 2H), 3.51-3.54 (m, 2H), 5.03 (s, 1H). 
Tert- butyl (2-morpholinoethyl) carbamate (59):  Compound 55 (6 mmol, 1 eq) was 
dissolved in DMF, we added DIPEA (1.19 ml, 6 mmol, 1 eq) and morpholine (0:55 ml, 6 
mmol, 1 eq). The resulting mixture was stirred under reflux for 12h, concentrated under 
reduced pressure. The crude residue was then subjected to flash silica gel column 
chromatography with DCM / MeOH / aq NH3 33% (9.5: 0.5: 0:02); ); yellow oil 55% 
yield, 1H-NMR (400 MHz, CDCl3) δ 1.31 (s, 9H), 2.31-2.45 (m, 6H), 3.21 (t, 2H), 3.61-
3.68 (m, 4H).  
2-(Piperazin-1-yl) ethan-1-amine (60): We dissolved compound 58 (3.21 mmol) in 
dioxane, the solution was cooled to 0°C, and then we added 20 ml of HCl 3N. The 
resulting stirred overnight at room tempreture. Then the solution was basified with 
potassium carbonate, extracted with DCM (3 x 30 ml). The organic layer was washed 
with saturated solution of sodium chloride, the combined organic extracts were dried 
(MgSO4) and concentrated under reduced pressure; 1H-NMR (400 MHz, CDCl3) δ 2.81 
(t, 2H), 2.95 (t, 2H), 3.10 (m, 4H), 3.53-3.65 (m, 2H). 
2-Morpholinoethan-1-amine (61): We dissolved compound 59 (3.21 mmol) in dioxane, 
the solution was cooled to 0 ° C; we added 20 ml of HCl 3N. The resulting stirred 
overnight at room tempreture. Then the solution was basified with potassium carbonate, 
extracted with DCM (3 x 30 ml). The organic layer was washed with saturated solution of 
sodium chloride, The combined organic extracts were dried (MgSO4) and concentrated 
under reduced pressure; 80% yield, yellow oil; 1H-NMR (400 MHz, CDCl3) δ 2.29-2.36 
(m, 4H), 2.97 (t, 2H), 3.15 (m, 2H), 3.52-3.63 (m, 4H). 
General procedure for the synthesis of compounds 14-17: To a suspension of Phthalic 
anhydride (6 mmol, 1 eq) in water (20 ml) we added 5 ml of acetic acid and the 
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corresponding amine (6 mmol, 1 eq); the resulting mixture stirred under reflux for 4 
hours. The purification procedure differs based on the nature of the side chain. 
Work-up for the compounds 14-15: The resulting solution was basified (PH=9) with 
sodium bicarbonate and extracted with DCM (3 x 20 ml). The combined organic extracts 
were dried (MgSO4) and concentrated under reduced pressure. The crude residue was 
then subjected to flash silica gel column chromatography with, DCM / MeOH / aq NH3 
33% (9: 1: 0:02). 
2-(2-Morpholinoethyl) isoindoline-1,3-dione (14): 65% yield; yellow oil; 1H-NMR (400 
MHz, CDCl3) δ 2.49-2.51 (m, 4H), 2.60-2.64 (m, 2H), 3.61-3.63, (m, 4H), 3.79-3.82 (t, 
2H), 7.69-7.72 (m, 2H), 7.82-7.84 (m, 2H); ESI-MS (m/z): 261 (M+H)+. 
2-(2-(Piperazin-1-yl)ethyl)isoindoline-1,3-dione (15): 43% yield; yellow oil; 1H-NMR 
(400 MHz, CDCl3) δ 1.91 (s, 1H), 2.12-2.24 (m, 4H), 2.61-2.72 (m, 4H), 2.89-2.95 (m, 
2H), 3.76 (t, 2H), 7.63-7.77 (m, 2H), 7.86-7.91 (m, 2H); ESI-MS (m/z): 260 (M+H)+. 
Work-up for the compounds 16-17: After the resulting solution cooled to room 
temperature we added, the precipitated solid was filtered and crystallized in ethanol. 
2-(2-Hydroxyethyl) isoindoline-1, 3-dione (16): 66% yield; yellow oil; 1H-NMR (400 
MHz, CDCl3) δ 2.57 (s, 1H), 3.84-3.90 (m, 4H), 7.69-7.73 (m, 2H), 7.80-7.84 (m, 2H). 
ESI-MS (m/z): 192 [M +H]. + 
2-Phenethylisoindoline-1, 3-dione (17): 71% yield; yellow oil; 1H-NMR (400 MHz, 
CDCl3) δ 4.84 (s, 2H), 7.25-7.30 (m, 3H), 7.42-7.44 (m, 2H), 7.76-7.78 (m, 2H), 7.80-7-
83 (m, 2H). ESI-MS (m/z): 238 (M+H)+. 
N1-(2-methoxybenzyl) ethane-1, 2-diamine (62): A mixture of the appropriate diamine 
and aldehyde (in a 5:1molar ratio) in toluene was refluxed in a Deane Stark apparatus for5 
h. Following solvent removal, the residue was taken up in EtOH, NaBH4 (1:2.5 molar 
ratio) was added at 0 ° C, and the stirring was continued at room temperature for 4 h. The 
solvent was then removed and the residue was dissolved in dichloromethane and washed 
with brine. Removal of the dried solvent gave a residue that was purified by flash 
chromatography using as eluent a mixture of Dichloromethane /methanol/33% aqueous 
ammonia (9:1:0.1), providing the desired products.  
2-(2-((2-Methoxybenzyl) amino) ethyl) isoindoline-1, 3-dione (18): Phtalic anhydride 
was dissolved in ethanol and we added the compound (62) and DMAP, the resulting 
mixture was stirred at reflux for 4 h then concentrated under reduced pressure. The crude 
residue was then subjected to flash silica gel column chromatography with DCM/MeOH, 
(9: 1); 1H-NMR (400 MHz, CDCl3) δ 7.9 (s, 1H), 7.25 (d, 1H), 6.76-6.83 (m, 3H), 3.77 (s, 
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2H), 3.70 (s, 3H), 3.59-3.63 (m, 2H), 2.74 (t, 2H); 
13
CNMR (101, CDCl3) δ 170, 169.1, 
157.2, 132,5, 127.9, 123.8, 122.4, 119.7, 112.6, 57.2, 51.9, 48.9, 45.3. 
Hoxybenzyl) amino)ethyl) acetamide (63): We dissolved 63 in Methanol, then we 
cooled the flask till -78 under the  Nitrogen, we added the ETOOCF3 dropwise, and we 
left the reaction stierring at 0 ° C for 1 hour, then the result mixture was extracted with 
DCM . The organic layer was washed with saturated solution of sodium chloride, the 
combined organic extracts were dried (MgSO4) and concentrated under reduced 
pressure.The crude residue was then subjected to flash silica gel column chromatography 
with DCM / MeOH / aq NH3 33% (9: 1: 0:01). 
2,2,2- Trifluoro-N-(2-((2-methoxybenzyl) (methyl) amino)ethyl) acetamide (64): We 
dissolved 64 in Formic acid, then we added form aldhyde dropwise, the resultion mixture 
was stirred under reflux for 12 hours. The resulting solution was cooled to room 
tempreture then basified (PH=8) with sodium bicarbonate and extracted with DCM. The 
combined organic extracts were dried (MgSO4) and concentrated under reduced pressure. 
The crude residue was then subjected to flash silica gel column chromatography with, 
DCM / MeOH / aq NH3 33% (9.9: 0.1:0:1). 
N1- (2-methoxybenzyl)- N1-methylethane-1,2- diamine (65): We dissolved 65 in 
Ethanol then we added 2 eq of NHOH disoolved in water dropwise, the resulting mixture 
was stirred overnight in room tempreture, then the result mixture was extracted with 
DCM. The organic layer was washed with water. The combined organic extracts were 
dried (MgSO4) and concentrated under reduced pressure. The crude residue was then 
subjected to flash silica gel column chromatography with, DCM / MeOH / aq NH3 33% 
(9.5:0.5:0:1). 
2-(2-((2-Methoxybenzyl)(methyl)amino) ethyl)-5-nitroisoindoline-1,3-dione (66): We 
dissolved 66 in Ethanol, then we left the reaction stirring in room tempreture for 15 
minutes, then we added 1 eq of 4 Nitro phtalic anhydride, the result mixture stirred under 
reflux for 5 hours, then concentrated under reduced pressure. The crude residue was then 
subjected to flash silica gel column chromatography with, DCM / MeOH / aq NH3 33% 
(9.5:0.5:0:1). 
5-Amino-2-(2-((2-methoxybenzyl) (methyl) amino) ethyl) isoindoline -1, 3-dione (67): 
We dissolved 67 in Ethanol, and then we added SnCl2, the reaction stirred under reflux 
for 1 hour. Then concentrated under reduced pressure, and washed withwater then 
extracted with DCM, the combined organic extracts were dried (MgSO4) and 
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concentrated under reduced pressure. The crude residue was then subjected to flash silica 
gel column chromatography with, DCM / MeOH / aq NH3 33% (9.5: 0.5: 0:1). 
2-(2-((2-Methoxybenzyl)(methyl)amino)ethyl)-5-thiocyanatoisoindoline-1,3-dione 
(68): In a flask, provided with an inert atmosphere, we placed compound 68 dissolved in 
DCM anhydrous. The resulting solution was treated drop wise with a solution of 
Tiocarbonyl dipyridine in DCM anhydrous, The resulting mixture was left stirring 
overnight in room temperature, then it was  concentrated under reduced pressure. The 
crude residue was then subjected to flash silica gel column chromatography with, DCM / 
MeOH / aq NH3 33% (9.5: 0.5: 0:1). 
Generalprocedureforthesynthesisof (19-23): We dissolved the amine in DMF then we 
added TE3N, and we left the result mixture stirring in room temperature for 5 minutes, 
before adding the compound 68 (dissolved in DMF), The resulting mixture was left 
stirring for 3 hours in room temperature, then it was  concentrated under reduced pressur. 
The crude residue was then subjected to flash silica gel column chromatography with, 
DCM / MeOH / aq NH3 33% (9.5: 0.5: 0:1). 
1-Ethyl-3-(2-(2-((2-methoxybenzyl)(methyl)amino)ethyl)-1,3-dioxoisoindolin-5-yl) 
thiourea (19): 1H-NMR (400 MHz, CDCl3) δ 8.01 (s, 2H), 7. 82 (d, 1H), 7.47 (d, 2H), 
6.83-6.79 (m, 3H), 5.28 (s, 2H), 3.87-3.8 (m, 7H), 3.76 (d, 2H), 2.83 (t, 3H), 2.39 (s, 3H); 
13
CNMR (101, CDCl3) δ 168.25, 167.9, 164.65, 157.82, 145.10, 142.14, 134.53, 132.90, 
131.28, 129.19, 123.88, 120.46, 120.29, 110.6, 107.36, 55.40, 55.059, 54.50, 53.43, 46.89, 
41.65, 35.26; MS (ESI+) m/z = 426.53 (M+H)+. 
N-(2-(2-((2-methoxybenzyl)(methyl)amino)ethyl)-1,3-dioxoisoindolin-5-yl) 
morpholine - 4- carbothioamide (20): 1H-NMR (400 MHz, CDCl3) δ 7.69 (t, 2H), 7.53 
(d, 1H), 7.26-7.19 (m, 2H), 6.84 (t, 3H), 3.91-3.755 (m, 15H), 2.84 (s, 1H), 2.41 (s, 3H);
 
13
CNMR (101, CDCl3) δ 182.1, 167.83, 167.77, 157.83, 145.69, 133.164, 131.18, 128.1, 
127.24, 123.6, 120.41, 117.57, 110.55, 77.31, 77, 76.68, 66.19, 55.38, 55.29, 54.86, 54.27, 
49.43, 48.66, 41.6, 35.32; MS (ESI+) m/z = 468.6  (M+H)+. 
N-(2-(2-((2-methoxybenzyl)(methyl)amino)ethyl)-1,3-dioxoisoindolin-5-yl)-4 methyl 
piperazine -1- carbothioamide (21): 1H-NMR (400 MHz, CDCl3) δ 8.25 (d, 2H), 7.98 (t, 
1H), 7.3 (d, 1H), 6.9 (m, 3H), 3.75 (m, 11H), 2.64 (t, 2H), 2.3- 2.17 (m, 10H); 
13
CNMR 
(101, CDCl3) δ 181.1, 167.98, 167.7, 158.7, 140.6, 132.7, 130, 129.8, 128.9, 128.6, 127.8, 
126.5, 122.5, 120.7, 112.8, 59.7, 56.9, 56.6, 56.1, 51.9, 51.6, 49.3, 46.7, 43.8; MS (ESI+) 
m/z = 481.6 (M+H)+. 
80 
 
1-Benzyl-3-(2-(2-((2-methoxybenzyl)(methyl)amino)ethyl)-1,3-dioxoisoindolin-5-yl) 
thiourea (22): 1H-NMR (400 MHz, CDCl3) δ 7.86 (s, 3H), 7.74 (d, 2H), 7.62 (d, 6H), 
7.31-7.26 (m, 3H), 4.79 (d, 2H), 3.79-3.66 (m, 7H), 2.92-2.77 (m, 2H), 2.33 (s, 3H);
 
13
CNMR (101, CDCl3) δ 180.64, 180.62, 167.78, 167.61, 157.69, 157.7, 144.02, 133.30, 
130.88, 128.75, 127.87, 127.76, 124.13, 120.32, 110.47, 77.31, 77, 76.68, 55.32, 55.11, 
54.45, 48.78, 41.81, 35.48; MS (ESI+) m/z = 488.6 (M+H)+. 
1,1-Diethyl-3-(2-(2-((2-methoxybenzyl)(methyl)amino)ethyl)-1,3-dioxoisoindolin-5-yl) 
thiourea (23): 1H-NMR (400 MHz, CDCl3) δ 8.19 (t, 2H), 7.9 (d, 1H), 7.29 (t, 1H), 6.79-
6.9 (m, 3H), 3.71-3. 59 (m, 11H), 2.61 (t, 2H), 2.27 (s, 3H), 1.2 (t, 6H);
 13
CNMR (101, 
CDCl3) δ 180.6, 168.6, 168.4, 158.56, 140.76, 132.58, 130.9, 129.78, 128.63, 127.98, 
127.52, 122.84, 120.21, 113.1, 58.9, 56.83, 55.87, 49.72, 35.7, 13.3, 13.12; MS (ESI+) 
m/z = 454.6 (M+H)+. 
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Chapter 3. Multi Target Directed Ligand approach in AD  
 
The only used drugs for the treatment of Alzheimer’s disease (AD), with the exception of 
memantine, are cholinesterase (ChE) inhibitors, which derived from the classical drug 
design strategy based on the “one-molecule-one-target” paradigm. This strategy enforced 
many effective drugs able to hit a single target of a given disease, but such drugs that 
modulate a single target may not be clinically effective when dealing with multifactorial 
diseases, such asAD. Molecules developed through this strategy are usually highly 
selective for a given target but it should be noted that a highly selective ligand for a given 
target does not always result in a clinically efficacious drug. This may happen because (1) 
the ligand does not recognize the target in vivo, (2) the ligand does not reach the site of 
action, or (3) the interaction with the respective target does not have enough impact on the 
diseased system to restore it effectively. 
Among several drug discovery methods, a very promising modern strategy consists of 
designing multi-target-directed ligands (MTDLs) able to modulate simultaneously 
multiple targets. This methodology has been specifically developed for the treatment of 
disorders with complex pathological mechanisms (multifactorial) such as AD. 
Several strategiescan be used to develop drugs able to modulate simultaneously different 
targets (Morphy, R 2005).The first approach is called multiple-medication therapy 
(MMT),which consists of the administration ofa cocktail of two or three different drugs, 
characterized bydifferent mechanisms of action and in two or more individual dosage 
forms. This approach has some disadvantages including patient compliance issues. In 
another strategy called multiple-compoundmedication (MCM) (single-pill drug 
combination), two or more drugs are comprisedin a single dosage form, which implies the 
incorporation of several drugs into the same formulation in order to simplify dosing 
regimens and enhance patient compliance. Finally, a third strategy is now emerging on the 
basis of theassumption that a single compound may be able to hit multiple targets 
simultaneously. These compounds are called Multi-Target-Directed Ligands (MTDL). 
This approachhas been widely used as design strategy by a lot of scientists as evidenced 
by the increased number ofpublications in the field in recent years. MTDLs may have 
some advantages or disadvantages compared to the two other approaches (Schmitt, B, 
2004). For instance, MTDLs can show a less complex ADMET profile in contrast to 
MMT/MCM, in which the different drugs can suffer of several troubles trelated to their 
bioavailability, pharmacokinetic properties, and metabolism. Not last, by this approach 
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the risk of possible problems arising from drug-drug interactions would be avoided and 
the therapeutic regimen greatly simplified in relation to MMT (Kola, I 2004). 
There is, therefore, a strong indication that the development of compounds able to hit 
multiple targets might disclose new avenues for the treatment of, for instance, major 
neurodegenerative diseases, for which an effective cure is an urgent need and a principal 
goal (Cavalli. A 2008, Morphy. R 2005). 
 
 
 
 
Figure 37: Pathways leading to the discovery of new medications (a) Target driven drug discovery 
approach; ( b) MTDLs approach to drug discovery (Cavalli, A. 2008). 
 
The methods for generating novel MTDLs are based on the combination of distinct 
pharmacophores of different drugs in the same structure by cleavable or non cleavable 
metabolically stable linker groups (termed as conjugates) or the pharmacophores can be 
overlapped (fused or merged) by taking advantage of structure commonalities to afford 
hybrid molecules. Important in the design of new MTDLs is that each pharmacophore of 
these new drugs should retain the ability to interact with its specific site (s) on the target 
and, consequently, to generate specific pharmacological responses that, taken together 
could enable the modulation of multiple targets. 
The multifactorial nature of AD and the lack of therapeutic effectiveness of the current 
FDA-approved drugs, which are based on the single-target paradigm, has inexorably 
fueled the rational design and development of novel MTDLs able to directly interact with 
multiple targets associated with AD by the molecular hybridization of different 
pharmacophoric subunits from known bioactive molecules. The mainchallenges in 
designing and synthesizing multitarget anti-Alzheimer agents are the choice of the targets 
to be hit and the potency of the compounds at the different targets, since a multitarget 
action will be only effective when balanced activities are achieved at the different targets. 
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One of the most widely adopted approaches in the field of anti-AD MTDLs has been to 
modify the molecular structure of an AChEI in order to provide it with additional 
biological properties useful for treating AD.Well known drugs such as tacrine, donepezil, 
rivastigmine, berberine, have been used as structural scaffold for the design and 
development of new compounds as MTDLs for the treatment of AD. 
 
 
 
 
Figure 38: Structure of some developed MTDLs for AD disease 
 
In spite of the fact that MTDLs are not true network medicines yet, they may be 
considered as lead drugs possessing a great value as a real alternative to the current 
unsuccessful pharmacological therapies for effectively fighting against AD and other 
complex diseases. The researchers exploit the strategy of MTDL in designing “dual 
binding site” AChEIs able to simultaneously interact with AChE catalytic (CAS) and 
peripheral sites (PAS) which may lead to advantages in reducing Aβ aggregation 
(Recanatini,M 2004). Indeed, Inestrosa et al discovered that AChE is endowed with 
interesting noncholinergic activities: it exerts Aβ pro-aggregating action by promoting the 
formation of Aβ fibrils through the PAS of the enzyme (Alvarez,A 1995) and therefore, 
AChEIs able to bind at PAS can block the proaggregating action of the enzyme 
(DeFerrari,G.V 2001, Inestrosa,N.C 1996). Pang and coworkers developed dimers of 
tacrine with the aim of enhancing its affinity towards AChE (Pang,Y.P 1996). 
Interestingly, the leadcompound, XV, also acts as NMDAR antagonist (Li, W 2007), as 
inhibitor of the nitric oxide synthase and is able to reduce in vitro Aβ formation by 
inhibition of BACE-1 (Fu,H 2008). This compound resulted 500-fold more potent than 
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tacrine in inhibiting hAChE (Pang,Y.P 1996). The structure-activity relationships around 
this class of compounds are summarized in Figure 39. 
 
 
 
Figure 39: structure-activity relationships studies on bis-tacrine derivatives as MTDLs (Muñoz-
Torrero,D 2008). 
 
In 2003, Sharpless and coworkers developed new dual-binding AChEIs (Lewis,W.G 
2002), using tacrine as catalytic-site inhibitorand phenylphenanthridium and other 
molecules as PAS-inhibitors;these compounds contain alkyl-azide and alkyl-acetylene 
side chainswith varying length to allow to undergo a Huisgen 1,3-dipolar cycloaddition 
leading to the formation of a 1,2,3-triazole ringwithin the enzyme AChE (click chemistry 
in situ). The compound XVI (figure 40) is one of the most potent AChE inhibitors, having 
KD values between 77 fM (Torpedo californicaAChE) and 410 fM (mouse AChE), 
clearly lower than those of tacrine and propidium (18 and 1100 nM on mouseAChE, 
respectively). It is important to point out that the XVI anti isomer was not obtained using 
this approach and was chemically synthesized and found to beless active by two-orders of 
magnitude thanits syn isomer. X-Ray structure of the complexes of both syn and anti 
isomers of XVI with mouse AChE confirmed that XVI is a dual-binding inhibitor and the 
triazole ring is not just a passive linker but itestablishes hydrogen-bonding and stacking 
interactions with amino acids located in the AChE mid gorge (Manetsch,R. 2004, 
Krasiński, A 2005). 
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Figure 40: Chemical structure of  XVI (Lewis,W.G 2002, Manetsch,R 2004, Krasiński, A 2005). 
 
Ladostigil (TV3326),one of the most promising MTDLs, described as ChEI and 
neuroprotective against oxidative stress, is structurally constituted by a carbamate moiety 
derived from rivastigmine, introduced into theposition 6 of a unitof rasagiline. This 
modification resulted in drop of approximately 5-fold of in vitro MAO B inhibitory 
activity compared to that of rasagiline. In vitro ladostigil was found to selectively inhibit 
100-fold more potently BuChE than AChE (Youdim,M.B 2006), which could be 
advantageous as, in contrast to AChE,the centrallevels of BuChE are not reduced as AD 
progresses,so that BuChE inhibition may contribute to the maintenance of ACh levels in 
the synaptic cleft (Giacobini E. 2001).  
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Figure 41: Drug design leading to Ladostigil 
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It was reported that cortical ChE activity of rats was inhibited by 20-80% after oral 
administration of 9-200 mg/kg of ladostigil. Furthermore, ladostigil increased dose-
dependently brain ACh levels in scopolamine-induced spatial memory deficits in rats 
(Weinstock M 2000). Moreover, the ability of ladostigil to inhibit both MAO isoforms 
provides it with effective antidepressant capacity. In an in vivo experiment using ratsit 
was observed that a single dose of 120 mg/kg of ladostigil was necessary to inhibit brain 
MAO isoforms activity by at least 50%. Ladostigil does not inhibit MAO A and MAO B 
in vitro at concentrations below 250 μM and 1 mM, respectively, but it does in the brain 
in vivo probably due to the formation of an active metabolite. One of these is produced by 
the hydrolysis of the carbamate moiety by ChE to yield the 6-OH derivative, a molecule 
able to inhibit MAO A and MAO B with IC50 values of 0.46 μM and 0.35 μM, 
respectively. On July 2014, Avraham Pharmaceuticals Ltd (www.avphar.com) announced 
successful interim results in a Phase IIb clinical trial for the evaluation of the safety and 
efficacy of ladostigil in patients diagnosed with MCI. These findings suggest that 
ladostigil may have a therapeutic value for the treatment of extrapyramidal symptoms in 
AD and dementia with Lewy bodies (DLB). 
PBT2 is another example of MTDL, it is a second-generation 8-hydroxyquinoline 
derivativeof clioquinol developed to resolve the toxicity problems, as well as to improve 
its solubility and ability to cross the BBB (Crouch PJ 2012). It was observed that PBT2 
selectively chelates copper and zinc while forming soluble complexes able to pass through 
cellular membranes, leading to bioavailable delivery of these two metals into the cells 
(Adlard PA 2008, Crouch PJ 2011,Adlard PA 2011). PBT2 also showed significant 
therapeutic effects on both AD mouse model (Adlard PA 2008) and phase II clinical trials 
(Lannfelt L 2008; Faux NG 2010). This compound also exhibited neuroprotective activity 
as a copper-zinc ionophore able to enhance the inhibition of the phosphorylation of the 
GSK-3α and βisoforms and subsequently lower Aβ levels (Crouch PJ 2011).  
ASS234 is another MTDL designed and conceived for use in AD therapy. Structurally, 
ASS234 is based on the hybridization of the benzylpiperidine moiety 
fromdonepezil,responsible for the ChE inhibition, and the indolyl propargylamine of 
FA65, apotent MAO inhibitor and derivative of PF9601N. Previous studiesreported 
ASS234 as a potent dual inhibitor of both ChEand MAO isoforms (Bolea I 2011). More 
recently, new findings with this brain-permeable molecule have revealed neuroprotective 
properties of ASS234 against Aβ1-42-induced toxicityin SH-SY5Y cells. By potently 
reducing Aβ self-aggregation in vitro, ASS234 was able to prevent the formation of 
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fibrillary and oligomeric species. This activity might be due to the direct interaction of 
ASS234 with the amyloid peptides during the oligomerization process, by stabilizing the 
less extended forms of Aβ, hence preventing further assembly towards toxic species. 
Moreover, ASS234 was also able to block the AChE-dependent aggregation of both Aβ1-
40 and Aβ1-42, revealing its capacity to bind to the PAS (Bolea I 2013).  
 
 
 
 
Figure 42: The multiple targets and activities reported for ASS234 for use in AD pathology (Bolea 
I 2013). 
 
Besides the anti-amyloid properties of ASS234, this multi-target molecule was also 
reported to have significant antioxidant activity, by capturing free radical species in 
vitro(ORAC-FL) as well as by increasing the expression of the antioxidant enzymes 
catalase and superoxide dismutase-1 (SOD-1) in Aβ1-42-treated SH-SY5Y cells. It was 
reported that ASS234 is able to inhibit MAO and ChE activities after subcutaneous 
administration in rats (Stasiak A 2014). To date, the differentpropertiesthat have been 
reported for ASS234 provide strong evidence to consider this molecule a promising 
compound for use in AD therapy, which has promptednew studies currently under 
investigation.  
Avery promising MTDL is memoquin, which has been developed in the Melchiorre’s 
group. It was generatedthroughincorporation of the benzoquinone fragment of coenzyme 
Q10 into the flexible chain of caproctamine. The design of this compound was based on 
the finding that coenzyme Q10 has been reported to have two different beneficial actions 
against AD: ROS scavengerand inhibitorof the deposition of Aβ in the brain. The 
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antioxidant activity of memoquin was confirmed by its in vitro ability to neutralize 
radicals and to act as a substrate for the NADPH quinone oxidoreductase 1 (NQO1), an 
enzyme responsible for the in vivo transformation of memoquin into the more antioxidant 
hydroquinone form (Melchiorre,C. 2007). 
 
 
 
 
 
Figure 43: Drug design for memoquin 
 
Memoquin displayeda nanomolar inhibitory potency against human AChE, and was able 
to inhibit the AChE-induced Aβ aggregation and to inhibit the self-assembly of Aβ. 
Moreover, the antiamyloidogenic profile of memoquin was also evaluated by testing its 
ability to act as an inhibitor of BACE-1. The compound was found to have an IC50 value 
of 108 nM against this enzyme. In addition, memoquin has been testedin vivo in an 
ADtransgenic mouse model: it showed the ability to ameliorate the cholinergic and 
cognitive impairment, and to reduce Aβ deposition and τ hyperphosphorylation at three 
different stages of neurodegeneration (2, 6, and 15 months of age). Further studies on 
memoquin showed other promising properties, such as good oral bioavailability, efficacy 
in crossing the blood-brain barrier, and a favorable safety profile in preclinical non-
regulatory acute and chronic toxicology studies (Cavalli, A 2007, Bolognesi, M.L 2009). 
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3.1 Multi-target-directed ligands developed in Diego Muñoz-Torrero 
group 
As previously mentioned, the design of inhibitors able to simultaneously reach both sites 
of AChE, dual binding site AChE inhibitors (AChEIs), emerged some years ago as a 
promising source of multitarget anti-Alzheimer compounds, inasmuch as they should be 
endowed at least with potent anticholinesterase and Aβ antiaggregating effects. 
In the recent years Drs. Pelayo Camps and Diego Muñoz-Torrero have developed new 
agents with strong affinity and inhibitory potency towards  AChE and able to inhibit Aβ 
aggregation. They developed aseries of dual binding site AChE inhibitors named  
huprine−tacrine hybrids  (Galdeano, C 2012), which consist of a unit of racemic or 
enantiopure hupine Y, 14, as the active site interacting unit, and a moiety of tacrine or 6 
chlorotacrine, as the peripheral site interacting unit, and oligomethylene  linkers of 
different lengths, or, for compounds XII  and XIV,a linker incorporating a protonatable 
methylamino group in order to enable cation−piinteractions with midgorge  aromatic 
residues (Figure 44). 
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Figure 44: Design of huprine-tacrine hybrids XII, XIV  
 
The dual site binding huprine−tacrine hybrids within AChEwas furtherconfirmed by with 
kinetic and molecular modelling studies (Galdeano, C 2012). The inhibition of the 
catalytic activity of hAChE was potent with IC50values in the range0.31−11.5 nM, and the 
experiments to assess thein vitroneutralization of the pathological chaperoning effect of 
AChE toward the Aβ aggregation showeda23−67% of inhibition at 100 µM concentration 
of inhibitor. Moreover, these compounds also demonstrated a potent inhibitory activity 
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towards hBChE (IC50= 24.6−139 nM), a significant inhibitory activity of the self-induced 
Aβ aggregation (28−61% of inhibition at 10 µM concentration of inhibitor) and BACE-1 
(IC50= 4.9−7.3 µM). 
In 2008, Drs. Camps and Muñoz-Torrero, developed  novel series of donepezil−tacrine 
hybrids designed to simultaneously interact with the active, peripheral and midgorge 
binding sites of AChE. These compounds contained a unit of tacrineor 6-chlorotacrine, to 
occupy the same position as tacrine at the AChE active site, and the 5,6-dimethoxy-2-[4-
piperidinyl)methyl]-1-indanone moiety of donepezilor the corresponding indane moiety,  
(Figure 45), (Galdeano, C 2012, Scarpellini, M 2006, Camps, P 2008). 
All donepezil−tacrine hybrids (XV, XVI, XVII, XVIII) turned out to behighly potent 
inhibitors of hAChE (IC50= 0.27−5.13 nM) and hBChE (IC50= 7.25−88.7 nM). Moreover, 
six out of the eight hybrids of the series, particularly those bearing anindane moiety, 
exhibited a significant AChE-induced Aβ aggregation inhibitory activity (38−66% of 
inhibition at 100 µM concentration of inhibitor) (Camps, P 2008). 
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Figure 45: Design of donepezil−tacrine hybrids XV, XVI,XVII, and XVIII 
 
In 2009,  Drs. Camps and Muñoz-Torrero established a collaboration with Dr. Rodolfo 
Lavilla of the Universitat de Barcelonain Spain,to develop two series of dual binding site 
AChE inhibitors which consisted of a unit of 6-chlorotacrine, as the active site interacting 
unit and a Povarov-type multi component reaction-derived pyrano[3,2-c] quinoline 
scaffold, reminiscent of the peripheral site inhibitor propidium, to block the peripheral site 
(Figure 46) (Formosa X 2006, Galdeano C 2012, Galdeano C 2009).  
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The novel compounds were endowed  with the AChE inhibitory activity of the parent 6-
chlorotacrine (IC50 = 7.03−50.0 nM), while exhibiting a significant in vitro inhibitory 
activity toward the AChE-induced (23−46% inhibition at 100 µM concentration of 
inhibitor) and self-induced Aβ aggregation (12−49% inhibition at 50 µM concentration of 
inhibitor) and toward BACE-1 (14−78% inhibition at 2.5 µM concentration of inhibitor), 
which makes them promising anti-Alzheimer lead compounds (Galdeano, C 2009). 
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Figure 46: Structure of propidium, and pyrano[3,2-c] quinoline−6-chlorotacrine hybrids 
 
In 2014 the group of Muñoz-Torrero developed anovel family of multitarget hybrid 
compounds (Figure 47), which consisted of a unit of the natural productrhein attached, 
through different linkers, to a unit of huprine Y, 4. The linkages between the huprine and 
rhein moieties involvedan N−C bond fromthe exocyclic amino group of huprine Y and an 
amide bond from the carboxylic acid ofrhein. Chains from 5 to 11 methylene groups were 
considered for the linkers to afford suitable distances between huprine and rhein moieties 
to achieve a dual site binding to AChE and to explore the effect of the length of the linker 
in a target with a large binding site such as BACE-1.  
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Figure 47: Design of the novel nonamethylene-linked rhein−huprine XIX 
 
The lead rhein−huprine hybrid, the nonamethylene-linked compound XIX (Figure 48) 
exhibits potent inhibitory activities against human hAChE (IC50 = 2.39 nM) and hBChE 
(IC50 = 513 nM), and strikingly against human BACE-1 (IC50 = 80 nM), and it showed 
43% of Aβ antiaggregating activity at 10 µM concentrationin vitro and ability to cross the 
blood-brain barrier. In in vivo studies in Escherichia coli cells,thisrhein−huprine hybrid 
showed 47% of Aβ antiaggregating activity and 34% of tau antiaggregating activity at 10 
µM concentration (Muñoz-Torrero,D, 2014).  
 
 
 
Figure 48: The biologicalprofile of the novel rhein−huprine hybrid XIX (Muñoz-Torrero,D, 2014) 
 
Ex vivo studies with this compound in brain slices of C57bl6 mice have revealed that they 
efficiently protect against the Aβ-induced synaptic dysfunction, preventing the loss of 
synaptic proteins and/or have a positive effect on the induction of long-term potentiation. 
In vivoexperiments with transgenic APP/PS1 mice have shown that intraperitoneal 
administration of this compound for 4 weeks leads tolower hippocampallevels of total 
soluble Aβ and increased levels ofits precursorAPP both in initial and advanced stages of 
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this AD model, thus suggesting a reduction of APP processingby BACE-1 inhibition. 
Therefore, the novel nonamethylene-linked rhein−huprine hybrid has emerged as very 
promising disease-modifying anti-Alzheimer drug candidate (Muñoz-Torrero,D, 2014). 
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3.2 Drug design 
 
The aspartic protease BACE-1 (β-secretase) is recognized as one of the most promising 
targets in the treatment of AD. The accumulation of β-amyloid peptide (Aβ) in the brain is 
a major factor in the pathogenesis of AD. Aβ is formed by initial cleavage of β amyloid 
precursor protein (APP) by BACE-1; therefore its inhibition represents one of the 
therapeutic approaches to control progression of AD, by preventing the abnormal 
generation of Aβ. For this reason, in the last decade, many research efforts have focused 
on the identification of new BACE-1 inhibitors as anti-Alzheimer drug candidates. 
As previously mentioned, the compound XIX, which was designed and synthesized by the 
group of Muñoz-Torrero in 2014 as a MTDL, showed a potent BACE-1 inhibitory 
activity, (IC50 = 80 nM) among other activities of interest. Due to its interesting profile, 
we investigated new scaffold modifications on the huprine moiety of this compound in 
order tofurther expand the structure-activity relationships in this structural class and to 
obtain novel useful chemical entities as potent BACE-1 inhibitors. 
In particular, we wanted to synthesize novel huprine-rhein hybrids which might be 
endowed with better cell membrane permeabilities, including brain permeability, while 
retaining BACE-1 inhibitory activity. Indeed, Lercher group (Andreas Lerchner 2010) 
designed a series of macrocyclic BACE-1 inhibitors with different basicity in order to 
increase the potency of the compounds and to enhance the brain permeation . This group 
reported that there was a strong correlation between pKa values of their basic amino group 
and permeability properties.  
In this context, we designed novel analogues of the compound XIX by replacing its 
huprine Y moiety by other huprines in order to obtain different pKa values of the pyridine 
nitrogen atom of the huprine moiety with the aim of retaining or increasing the potency 
towards BACE-1 and improving brain permeability. In this project, we envisaged the 
synthesis of one analogue, 28, with lower basicity, and one analogue, 29, with higher 
basicity than the parent XIX (Figure 49). 
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Figure 49: Design of the novel rhein−huprine hybrids with different basicity  
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3.3 Methods 
 
3.3.1 Synthesis: 
The synthetic route to the target compounds is depicted in Scheme 1. It started with an 
initial acidic hydrolysis of the diacetal protected form of malonaldehyde (1,1,3,3-
tetramethoxypropane) in the presence of aqueous HCl followed by reaction with two 
equivalents of dimethyl acetonedicarboxylate, in the presence of NaOH in MeOH, to give 
tetraester 70. Acidic hydrolysis followed by decarboxylation of tetraester 70 with HCl and 
AcOH, afforded diketone 71. Addition of MeLi to diketone 71 gave oxaadamantanol72, 
which was transformed into the corresponding mesylate 73, by treatment with MsCl in the 
presence of Et3N. Silica gel-induced fragmentation of mesylate 73 gave the enone 74. 
The synthesis of the rhein−huprine hybrid 28 is depicted in Scheme2. It started with a 
Friedländer condensation of enone 74 with 2-aminothiophene-3-carbonitrile, in the 
presence of AlCl3, followed by a tedious silica gel column chromatography purification, 
which gave the novel thienohuprine 75. 
The subsequentalkylation of racemic huprine 75 with 9-bromononanenitrile in the 
presence of NaOH in DMSO at r. t. overnight gave cyanoalkylhuprine 76, after silica gel 
column chromatography purification  
Cyanoalkylhuprine 76 was reduced with LiAlH4 in Et2O at r. t. overnight to afford the 
corresponding aminoalkylhuprine 77, which was used for the next step without any 
further purification. 
A suspension of rhein in EtOAc and DMF was treated with EDC·HCl, Et3N and HOBT, 
it was allowed to stir for 1 h and then it was treated with theaminoalkylhuprine 77, the 
novel rhein−huprine hybrid 28 after silica gel column chromatography purification of the 
crude product. 
The synthesis of the novelrhein−huprine hybrid 29 is depicted in Scheme 3.It was carried 
out following the same methodology used for the synthesis of hybrid 28,  i.e. by an initial 
Friedländer condensation of enone 74 with 2-amino-5-methoxybenzonitrileto afford the 
novel methoxyhuprine 78, followed by alkylation with9-bromononanenitrile, LiAlH4 
reduction of the resulting nitrile 79, and final amide coupling of the primary amine 80 
with rhein. 
 
 
 
98 
 
Scheme 1: 
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Conditions: (i) HCl, H2O, (ii) NaOH, MeOH, (iii) HCl, AcOH, H2O, (iv) MeLi, THF, (v) MsCl, 
Et3N, CH2Cl2, (vi) SiO2, CH2Cl2 
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Scheme 2: 
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Conditions: (i) AlCl3, 1,2-dichloroethane, (ii) KOH, DMSO, 9-bromononanenitrile, (iii) 
LiAlH4, Et2O, (iv) EDC, Et3N, HOBT, EtOAc, DMF. 
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Scheme 3: 
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Conditions: (i) AlCl3, 1,2-dichloroethane, (ii) KOH, DMSO, 9-bromononanenitrile, (iii) 
LiAlH4, Et2O, (iv) EDC, Et3N, HOBT, EtOAc, DMF. 
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3.3.2 Biology:  
To determine the potential interest of compounds 28-29 for the treatment of AD, their 
inhibitory potencyagainst recombinant human AChE and BChE was evaluated by 
studying the hydrolysis of acetylthiocholine(ATCh) following the method of Ellman et al 
(Ellman, G. L 1961). The inhibitory potency was expressed as IC50 values, 
whichrepresent the concentration of inhibitor required to decrease enzyme activity by 
50%.  
The evaluation of the inhibition of Aβ42 and tau aggregation in intact Escherichia coli 
cells was carried out through a methodology that is based on the in vivo staining with 
thioflavin S of inclusion bodies (IBs) of aggregated proteins inintact E. coli cells that 
overexpress a given amyloidogenic protein, in the presence and absence of the inhibitors 
and monitoring of the corresponding changes in the fluorescence of thioflavin S 
(Pouplana, S. 2014). 
The novel racemic rhein−huprine hybrids were tested in vitro against human recombinant 
BACE-1 using a FRET assay (Ballatore, C. 2010), and their antioxidant activity was 
evaluated by total polyphenols, ABTS+ and DPPH assays.  
The brain penetration of the synthesized hybrids was assessed using the parallel artificial 
membrane permeation assay for blood−brain barrier described by Di et al (Di, L. 2003).  
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3.4 Results and discussion 
 
 3.4.1 Activity toward cholinesterases: 
Human recombinant AChE (Sigma, Milan, Italy) inhibitory activity was evaluated 
spectrophotometrically by the method of Ellman et al. Initial rate assays were performed 
at 37 °C with a Jasco V-530 double beam spectrophotometer. Stock solutions of the tested 
compounds (1 mM) were prepared in MeOH and diluted in MeOH. The assay solution 
consisted of a 0.1 M potassium phosphate buffer, pH 8.0, with the addition of 340 μM5,5′-
dithiobis (2-nitrobenzoic acid) (DTNB, used to produce the yellow anion of 5-thio-2-
nitrobenzoic acid), 0.02 unit/mL hAChE, and 550 μM substrate (acetylthiocholine iodide). 
Assay solutions with and without inhibitor were preincubated at 37 °C for 20 min, 
followed by the addition of substrate. Blank solutions containing all components except 
hAChE were prepared in parallel to account for the nonenzymatic hydrolysis of the 
substrate. Five increasing concentrations of the inhibitor were used, able to give an 
inhibition of the enzymatic activity in the range of 20−80%. The results were plotted by 
placing the percentage of inhibition in function of the decimal log of the final inhibitor 
concentration. Linear regression and IC50 values were calculated using Microcal Origin 
3.5 software (Microcal Software, Inc.).  
Human serum BChE inhibitory activities were also evaluated spectrophotometrically by 
the method of Ellman et al. The reactions took place in a final volume of 300 μL of 0.1 M 
phosphate-buffered solution pH 8.0, containing hBChE (0.02 u/mL) and 333 μM DTNB 
solution. Inhibition curves were performed in duplicates using at least 10 increasing 
concentrations of inhibitor and preincubated for 20 min at 37 °C. One duplicate sample 
without inhibitor was always present to yield 100% of BChE activity. Then substrate 
butyrylthiocholine iodide (300 μM, Sigma-Aldrich) was added and the reaction was 
developed for 5 min at 37 °C. The color production was measured at 414 nm using a 
labsystems Multiskan spectrophotometer. Data from concentration− inhibition 
experiments of the inhibitors were calculated by nonlinear regression analysis, using the 
GraphPad Prism program package (GraphPad Software; San Diego, USA), which gave 
estimates of the IC50 values. Results are expressed as mean ± SEM of at least four 
experiments performed in duplicate. 
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The table 3 shows thatmonomeric thienohuprine75 and methoxyhuprine 78 turned out to 
be moderate inhibitors toward hAChE and hBChE,exhibiting IC50values in the 
micromolar range. The novel rhein–huprine hybrid29 exhibited higher inhibitory activity 
toward hAChE than for hBChE exhibiting IC50values in the micromolar range, while the 
compound 28 was found essentially inactive against hAChE, but exhibited moderate 
inhibitory activity toward hBChE comparing with Rac-HUPY and the compound XIX. 
 
Table 3: hAChE and hBChE inhibitory activities of the novel huprines and rhein–huprine 
hybrids. 
Compound IC50hAChE (µM) ± SEM IC50hBChE (µM) ± SEM 
Rac-HUPY 0.00126 ± 0.00004 0.181 ± 0.015 
75 2.61 ± 0.17 0.531 ± 0.047 
78 5.16 ±0 .44 2.90 ± 0.02 
28 >>10a 40.8 ± 8.9 
29 1.40 ± 0.24 100 ± 9 
a%inhibitionat15µM=15.2 ± 2.5% 
 
3.4.2 Aβ42 aggregation inhibition assay in intact Escherichia colicells overexpressing 
Aβ 42 and tau  
 
• Cloning and overexpression of Aβ42 peptide: 
Escherichia coli competent cells BL21 (DE3) were transformed with the pET28a vector 
(Novagen, Inc., Madison, WI, USA) carrying the DNA sequence of Aβ42. Because of 
the addition of the initiation codon ATG in front of both genes, the overexpressed 
peptide contains an additional methionine residue at its N terminus. For overnight culture 
preparation, 10 mL of lysogeny broth (LB) medium containing 50 μg·mL−1 of 
kanamycin were inoculated with a colony of BL21 (DE3) bearing the plasmid to be 
expressed at 37 °C. After overnight growth, the OD600 was usually 2−2.5. For 
expression of Aβ42 peptide, 20 μL of overnight culture were transferred into Eppendorf 
tubes of 1.5 mL containing 980 μL of LB medium with 50 μg·mL−1 of kanamycin, 1 
mM of isopropyl 1-thio-β-D-galactopyranoside (IPTG) and 10 μM of each hybrid  or 
reference compound to be tested in DMSO. The samples were grown for 24 h at 37 
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°C and 1400 rpm using a Thermomixer (Eppendorf,Hamburg,Germany). In the negative 
control (without drug), the same amount of DMSO was added in the sample. 
  
• Cloning and overexpression of tau protein: 
E. coli BL21 (DE3) competent cells were transformed with pTARA containing the RNA-
polymerase gen of T7 phage (T7RP) under the control of the promoter pBAD. E. coli 
BL21 (DE3) with pTARA competent cells were transformed with pRKT42 vector 
encoding four repeats of tau protein in two inserts. For overnight culture preparation, 10 
mL of M9 mediumcontaining 0.5% of glucose, 50 μg·mL−1 of ampicillin, and 12.5 
μg·mL−1of chloramphenicol were inoculated with a colony of BL21 (DE3) bearing the 
plasmids to be expressed at 37 °C. For expression of tau protein, the required volume of 
overnight culture to obtain 1:500 dilution was added into fresh M9 minimal medium 
containing 0.5% of glucose, 50 μg·mL–1 of ampicillin, 12.5 μg·mL–1 of chloramphenicol, 
and 250 µM of Th-S. The bacterial culture was grown at 37 ºC and 250 rpm. When the 
cell density reached OD600 = 0.6, 980 µL of culture were transferred into eppendorf 
tubes of 1.5 mL with 10 µL of each compound to be tested in DMSO and 10 µL of 
arabinose at 25%. The final concentration of drug was fixed at 10 µM. The samples were 
grown overnight at 37 °C and 1400 rpm using a Thermomixer (Eppendorf, Hamburg, 
Germany). As negative control (maximal presence of tau) the same amount of DMSO 
without drug was added in the sample. In parallel, non-induced samples (in absence of 
arabinose) were also prepared and used as positive controls (absence of tau).  In addition, 
these samples were used to assess the potential intrinsic toxicity of the compounds and to 
confirm the correct bacterial growth. 
 
3.4.2.1 Activity toward Aβ42 aggregation: 
The Aβ42 antiaggregating activityhasbeen evaluated by using an assay based on the direct 
thioflavin S staining of IBs in intact E. coli cells that were genetically altered to 
overexpress Aβ42  protein. 
The table 4 shows thatthe novel rhein−huprine hybrids exhibited a moderately potent 
Aβ42 antiaggregating activity in E. coli cells, with percentages of inhibition at 10 Μm 
slightly lower than that of compound XIX (47% inhibition). 
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Table 4: Inhibitory activities of the novelrhein−huprinehybrids toward Aβ42in intact E. 
colicells. 
Compound Aβ42aggregation (% inhibition) 
Aβ42  Non Induced (C+) 100.0 ± 0.7 
Aβ42  Induced (C-) 0.0 ± 1.0 
75 -3.7 ± 0.9 
28 23.9 ± 1.1 
78 -5.4 ± 2.1 
29 40.0 ± 2.7 
        *Using 10 µM as a concentration of drug. 
 
3.4.2.2 Activity toward tau protein aggregation: 
The anthraquinone−derived rhein moiety of the novel hybrids allows these compounds to 
have the ability to inhibit tau-protein aggregation. Their expected tau antiaggregating 
activityhas been evaluated by using an assay based on the direct thioflavin S staining of 
IBs in intact  E. coli cells that were genetically altered to overexpress tau protein. 
The results showedthat the novel rhein−huprine hybrids significantly inhibit tau protein 
aggregation at 10 µM concentration of inhibitor with percentages of inhibition higher than 
that of the parent hybrid XIX (34% of inhibition), The most active compound is the 
methoxyhuprine-based hybrid 29, which exhibited 52% inhibition of tau aggregation at 
10µM, while the thienohuprine-basedhybrid 28 exhibited 41%inhibition and the novel 
monomeric huprines were either inactive or only weakly active. 
 
Table 5: Inhibitory activities of the novel rhein−huprinehybrids toward tau aggregation in 
intact E. colicells. 
Compound tau aggregation (% inhibition) 
tau Non Induced (C+) 100.0 ± 1.5 
tau Induced (C-) 0.0 ± 1.1 
75 2.6 ± 3.6 
28 40.7 ± 2.2 
78 12.8 ± 4.5 
29 52.4 ± 1.9 
         *Using 10 µM as a concentration of drug. 
 
106 
 
3.4.3 Activity toward BACE-1: 
β-Secretase (BACE-1, Sigma) inhibition studies were performed by employing a peptide 
mimicking APP sequence as substrate (Methoxycoumarin-Ser-Glu-Val-Asn-Leu-Asp-
Ala-Glu-Phe-Lys-dinitrophenyl, M-2420, Bachem, Germany). The following procedure 
was employed: 5 μL of test compounds (or DMSO, if preparing a control well) were pre-
incubated with 175 μL of enzyme (in 20 mM sodium acetate pH 4.5 containing CHAPS 
0.1% w/v) for 1 h at room temperature. The substrate (3 μM, final concentration) was then 
added and left to react for 15 min. The fluorescence signal was read at λem=405 nm 
(λexc=320 nm). The DMSO concentration in the final mixture was maintained below 5% 
(v/v) to guarantee no significant loss of enzyme activity, the fluorescence intensities with 
and without inhibitor werecompared and the percent inhibition due to the presence of the 
test compounds were calculated. The background signal was measured in control wells 
containing all the reagents, except BACE-1 and subtracted. The % inhibition due to the 
presence of increasing test compound concentration was calculated by the following 
expression: 100 – (IFi/IFo× 100) where IFi and IFo are the fluorescence intensities 
obtained for BACE-1 in the presence and in the absence of inhibitor, respectively. 
Unfortunately, it was not possible to determine IC50 values due to interferences in 
fluorescence emission of compounds at higher concentrations, the IC50 value for the novel 
thienohuprine-based hybrid 28 has been extrapolated taking into account some 
percentagesof inhibitionobtained in the rangefrom 4nM until 80nM. The maximum 
percentage of inhibition detected was of 34% at 80nM. 
 
Table 6: Inhibitory Activities of the novel Rhein−Huprine Hybrids and Reference 
Compounds toward BACE-1 
Compound Inhibition at<5μM 
28 0.49 μM ± 0.08 
29 n.d. 
            n.d.: not detectable 
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3.4.4 Antioxidant activity:  
The antioxidant activity of the tested compoundswas determined bythree different 
analytical methods: total polyphenols, the 1,1-diphenyl-2-picryl-hydrazyl (DPPH) and, 
2,20-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid (ABTS.+). 
 
• Sample pre treatment: 
Samples (1 mg) were weighed and homogenized with EtOH (1 mL). The homogenate was 
sonicated for 5 min and filtered through a 0.45 µm polytetrafluoroethylene (PTFE) filter 
from Waters (Milford, USA) into a vial. 
 
• Antioxidant capacity- ABTS.+ assay: 
The antioxidant capacity (AC) was first measured using an ABTS.+ radical decolorization 
assay.1 mMTrolox (standard antioxidant) was prepared in MeOH. Working standards were 
obtained by diluting 1 mMtrolox with MeOH. Solutions of known trolox concentration 
were used for calibration. An ABTS+ radical cation was prepared by passing 5 mM aqueous 
stock solution of ABTS (in MeOH) through manganese dioxide powder. Excess manganese 
dioxide was filtered through a 0.45 µm PTFE filter. Then, 245 µL of ABTS.+ solution were 
added to 5 µL of trolox or to samples and the solutions were stirred for 30 s. The 
homogenate was shaken vigorously and kept in darkness for 1 h. Absorption of the samples 
was measured on a UV/VIS ThermoMultiskan Spectrum spectrophotometer at 734 nm and 
MeOH blanks were run in each assay. Results were expressed as trolox equivalents 
(µmoltrolox / µmol tested compound). Analyses were carried out in triplicate. 
 
• Antioxidant capacity- DPPH assay: 
The antioxidant capacity (AC) was also determined through the evaluation of the free 
radical-scavenging effect on the DPPH radical. Solutions of known trolox concentration 
were used for calibration. Five µL of samples or trolox were mixed with 250 µL of 
methanolic DPPH (0.025 g L–1). The homogenate was shaken vigorously and kept in 
darkness for 30 min. Absorption of the samples was measured on the spectrophotometer at 
515 nm. Results were expressed as trolox equivalents (µmoltrolox / µmol tested 
compound). Analyses were carried out in triplicate. 
 
 
108 
 
• Analysis of total polyphenols: 
For the TP assay, each sample was analyzed three times; 20 µL of the samples were mixed 
with 188 µL of Milli-Q water in a thermo microtiter 96-well plate (nuncTM, Roskilde, 
Denmark), and 12 µL of F-C reagent and 30 µL of sodium carbonate (200 g/L) were added 
following a described procedure. The mixtures were incubated for 1 h at room temperature 
in the dark. After the reaction period, 50 µL of Milli-Q water was added and the absorbance 
was measured at 765 nm in a UV/Vis Thermo Multiskan Spectrum spectrophotometer 
(Vantaa, Finland). Results were expressed as mg of gallic acid equivalents (GAE)/g sample. 
The total polyphenolscontent was expressed in mg of gallic acid, the value is assigned by 
comparing the scavenging capacity of an antioxidant to that of gallicacid; high total 
polyphenols value indicates a high level of antioxidant activity. Table 7 shows that both 
monomeric huprines75 and 78 showed higher antioxidant activity than rhein,and to our 
surprise, higher than the corresponding hybrids. DPPH and ABTS.+ assaysare based on the 
trolox equivalent antioxidant capacity (TEAC), to assess the amount of radicals that can be 
scavenged by an antioxidant. The TEAC value is assigned by comparing the scavenging 
capacity of an antioxidant to that of trolox. A high TEAC value indicates a high level of 
antioxidant activity. Values listed in table 7 show an outstanding antioxidant activity for the 
novelrhein−huprine hybrids 28 and 29 when measured through the DPPH and ABTS+ 
assays,more potent than that of the known antioxidant gallic acid and of monomeric 
huprines 75 and 78 and rhein, which still display a significant antioxidant activity.  
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Table 7: Antioxidant activity by total polyphenols, ABTS.+ and DPPH assays. 
Compound 
Total Phenolics 
(mg gallic acid.g-1) 
ABTS.+ 
µmol Trolox.µmol-1 
DPPH 
µmol Trolox.µmol-1 
Rhein 29.50 ± 2.04 4.019 ± 0.180 5.756 ± 0.273 
Gallic acid 1004 ± 3.08 12.51 ± 0.409 9.723 ± 0.409 
75 151.6 ± 5.70 4.770 ± 0.408 3.941 ± 0.313 
28 99.93 ± 5.01 20.68 ± 2.521 12.41 ± 0.360 
78 90.12 ± 6.19 5.010 ± 0.206 2.635 ± 0.129 
29 10.69 ± 1.16 21.57 ± 1.242 12.40 ± 1.01 
Mean ± SD.Results for totalphenolicsassay in mg of gallic acid. µmol-1 compound.Results for 
ABTS.+ and DPPHassays expressed in µmol Trolox.µmol-1 compound 
 
3.4.5 In vitro BBB permeation assay: 
To evaluate the brain penetration of the different compounds, a parallel artificial 
membrane permeation assay for blood-brain barrier was used, following the method 
described by Di et al (2003). The in vitro permeability (Pe) of fourteen commercial drugs 
through lipid extract of porcine brain membrane together with the test compounds was 
determined. Commercial drugs and targetcompounds were tested using a mixture of 
PBS:EtOH 70:30. Assay validation was made by comparing the experimental 
permeability with the reported values of the commercial drugs by bibliography and lineal 
correlation between experimental and reported permeability of the fourteen commercial 
drugs using the parallel artificial membrane permeation assay was evaluated (Pe (exp) = 
1.6315 Pe (lit) − 1.3308; R2=0.9341). From this equation and taking into account the 
limits established by Di et al. for BBB permeation,  we established the  ranges of 
permeability as  compounds of high BBB permeation (CNS+): Pe (10-6 cms-1) > 5.196; 
compounds of low BBB permeation(CNS-): Pe (10-6 cm s-1) < 1.933 and  compounds of 
uncertain BBB permeation (CNS+/-): 5.196>Pe (10-6 cm s-1) > 1.933.   
Table 8 shows permeability results from the different commercial and target compounds 
(three different experiments in triplicate) and predictive penetration in the CNS. The novel 
monomeric huprines, the methoxyhuprine based hybrid 29 and the thienohuprine-based 
hybrid 28 were predicted to be able to cross the BBB, with their measured Pe values being 
far above the threshold for high BBB permeation (Table 8). 
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Table 8: Permeability (Pe10-6 cm s-1) in the PAMPA-BBB assay of 14 commercial drugs, 
the targetcompounds and predictive penetration in the CNS. 
Compound Bibliography value(a) 
Experimental value 
(n=3)  ± S.D. CNS Prediction 
Verapamil 16.0 28.6 ± 0.3  
Testosterone 17.0 26.4 ± 0.3  
Costicosterone 5.1 6.7 ± 0.1  
Clonidine 5.3 6.5 ± 0.05  
Ofloxacin 0.8 0.99 ± 0.06  
Lomefloxacin 0.0 0.8 ± 0.05  
Progesterone 9.3 16.8 ± 0.03  
Promazine 8.8 13.8 ± 0.3  
Imipramine 13.0 12.3 ± 0.1  
Hidrocortisone 1.9 1.4 ± 0.05  
Piroxicam 2.5 2.1 ± 0.03  
Desipramine 12.0 17.8 ± 0.1  
Cimetidine 0.0 0.7 ± 0.03  
Norfloxacine 0.1 0.9 ± 0.02  
75  18.6 ± 1.4 CNS+ 
*28  8.4 ± 0.8 CNS+ 
78  16.8 ± 1.3 CNS+ 
*29  10.4 ± 0.8 CNS+ 
Taken from Di et al. (2003); *Poor dissolution 
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3.5 Conclusion 
 
The new hybrids endowed with a very interesting multipotent pharmacological profile, as 
they should be able to block the neurodegenerative cascade associated to AD at different 
levels. Theses new rhein-huprine hybrids display lower hAChE and hBACE-1 inhibitory 
activities than the lead XIX, even though they retain or display increased potencies as 
Aβ42 and tau antiaggregating agents. Also, we have demonstrated that they are endowed 
with a potent antioxidant activity. PAMPA-BBB studies suggest that the novel rhein-
huprine hybrids should be able to readily penetrate into the CNS. 
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3.6 Experimental Section 
 
Chemistry: 
Tetramethyl 3,7- dihydroxy bicyclo [3.3.1] nona-2,6- diene- 2,4,6,8-t etracarboxylate 
(70): In a 2L round bottomed flask equipped with a magnetic stirrer, a solution of 1,1,3,3-
tetramethoxypropane (113 mL; 113 g; 0.69mol) and 2NHCl(345 mL; 0.69mol)  was 
prepared and stirred at r. t. for 1.5 h. Then, the solutionwas alkalinized dropwise with 
5NNaOH (240 mL; 1.2mol), and diluted with MeOH (337 mL). The resulting solution 
was treated with dimethyl 1,3-acetonedicarboxylate (199 mL; 236 g, 1.36mol) and MeOH 
(231 mL). The reactionmixture was stirred at r. t. for 72 h, treated with concentrated HCl 
(21 mL). The resulting precipitatewas separated by filtration in vacuum, washed with 
H2O (2 × 25 mL),and dried under reduced pressure to give the tetraester 70 (78.8 g, 30% 
yield)as a beige solid.  
Bicyclo[3.3.1]nonane-3,7-dione (71): In a 3 neck 2 L round bottomed flask equipped 
with a magnetic stirrer, a suspension of tetraester70 (78.8 g; 205mmol) in H2O (205 ml) 
was prepared and successively treated with concentrated HCl (205 mL) and AcOH 
(420mL). The reaction mixture was stirred under reflux for 24 h. The resulting mixture 
was allowed to cool to r. t.,then it was extracted with CH2Cl2 (5 × 212 mL) and the 
combined organic layers were washed with 5N NaOH (2 × 345 mL), dried with anhydrous 
Na2SO4, filtered, and evaporated under reduced pressure to give diketone87 (19.0 g, 61% 
yield)as ayellowishsolid. 
1 H NMR (200 MHz, CDCl3) δ 2.23 (s, 2H), 2.38 (d, J = 15.4 Hz, 4H), 2.62 (dd, J = 15.4 
Hz, J’=5.4 Hz, 4H),2.88 (s,2H); 13C NMR (50.4 MHz, CDCl3) δ 31.0, 32.3,47.5,208.9. 
3-Methyl-2-oxaadamantan-1-ol (72): In a 3 neck 1L round bottomedflask equipped with 
an inert atmosphere, magnetic stirrer, and pressure equalizing dropping funnel, MeLi (1.6 
Nsolution in Et2O; 93.5 mL; 150mmol) was cooled to 0 ºC in an ice bath and treated 
dropwise with a solution of diketone 71 (19.0 g; 125mmol) in anhydrous THF(250 mL). 
The reaction mixture was stirred at 0ºC for 35 min. Then, the mixture was treated 
dropwise with saturated aqueous NH4Cl(250 mL) and extracted with Et2O (3 × 200 mL). 
The combined organic layers were dried with anhydrous Na2SO4, filtered, and evaporated 
under reduced pressure to afford 72 (18.8 g, 90% yield) as a yellow solid.The 1H and 13C 
NMR data coincided with those previously reported (Camps, P.; El Achab, R.; Font-
Bardia, M.; Görbig, D.; Morral, J.; Muñoz-Torrero, D.; Solans, X.; Simon, M. Easy 
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synthesis of 7-alkylbicyclo[3.3.1]non-6-en-3-ones by silica gel-promoted fragmentation of 
3-alkyl-2-oxaadamant-1-yl mesylates. Tetrahedron1996, 52, 5867–5880). 
3-Methyl-2-oxaadamantan-1-yl methanesulfonate (73): In 3 neck1 L round bottomed 
flask, provided with an inert atmosphere and magnetic stirrer, a solution of 
oxadamantanol (18.8 g, 112mmol) and freshly distilled Et3N (23.2 mL, 16.8 g, 166mmol) 
in anhydrous CH2Cl2 (525 ml) was prepared, cooled to -10ºC with an ice/NaCl bath, and 
treated dropwise with MsCl (13.8 mL,20.4 g, 178 mmol). Then the reaction mixture was 
stirred at -10 ºC for 30 mins. The resulting solution was poured onto an mixture 10% 
aq.HCl (228 mL) and crushed ice (58 mL) andextracted with CH2Cl2 (2×110mL). The 
combined organic layers were washed with staturedaq. NaHCO3 (178 mL) and H2O(178 
mL), dried with anhydrous Na2SO4, filtered,and evaporated under reduced pressure to 
give mesylate73 (23.6 g, 86% yield)as a brown solid.The 1H and 13C NMR data coincided 
with those previously reported (Camps, P.; 1996). 
7-Methylbicyclo[3.3.1]non-6-en-3-one (74): In 1 L round bottomed flask provided with 
magnetic stirrer, a suspension of mesylate 73 (11.8 g, 48.0mmol) and SiO2 (12 g) in 
CH2Cl2 (125 mL) was prepared, and then stirred at r. t. for 3 h. The resulting suspension 
wasevaporated under reduced pressure and the residue purified throughsilica gel column 
chromatography (hexane:EtOAc50:50),to give the enone74 (5.75g, 80% yield)as a 
colorless oil.The 1H and 13C NMR data coincided with those previously reported (Camps, 
P.; 1996). 
5,6,9,10- Tetrahydro-7-methyl-5,9- methanocycloocta[b] thieno[3,2-e] pyridin-4-
amine (75): In a triple neck 250 mL round bottomed flask equipped with an inert 
atmosphere, magnetic stirrer, a pressure equalizing dropping funnel and condenser, a 
suspension of 2-aminothiophene-3-carbonitrile (1.00 g; 8.05mmol) and AlCl3 (1.34 g; 
10.0 mmol) in 1,2-dichloroethane (15 mL) was prepared and treated with a solution of 
enone74(1.01 g; 6.72mmol) in anhydrous 1,2-dichloroethane (61 mL). The reaction 
mixture was stirred under reflux overnight. Then, it was allowed to cool to room 
temperature, diluted with water (35 mL), and THF (35 mL), then basified with 5N NaOH 
(15 mL), stirred for 30 min at room temperature, andextracted with CH2Cl2 (6 × 50 mL). 
The combined organic layers were dried with anhydrous Na2SO4, filtered, and evaporated 
under reduced pressure, to givea solid residue (1.92 g), which was purified by silica gel 
column chromatography, to afford the novel huprine 75 (1.37 g, 80% yield) as a yellow 
solid. 
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75·HCl: mp 227−228 °C;1H NMR (400 MHz, CD3OD) δ 1.58 (s, 3H, 7-CH3), 
superimposed in part 1.92 (dm, J=12.4 Hz, 1H, 12-Hsyn), 1.95 (br d, J=18.0 Hz, 1H, 6-
Hendo), 2.05 (dm, J=12.4 Hz, 1H, 12-Hanti), 2.50 (dd, J=17.6 Hz, J’= 4.4 Hz, 1H, 6-Hexo), 
2.76 (m, 1H, 9-H), 2.80 (br d, J=17.6 Hz, 1H, 10-Hendo), 3.17 (dd, J=17.6 Hz, J’=5.6 Hz, 
1H, 10-Hexo), 3.34 (m, 1H, 5-H), 4.86 (s, NH, +NH), 5.56 (br d, J=4.8 Hz, 1H, 8-H), 7.53 
(d, J=6.0 Hz, 1H, 3-H), 7.68 (d, J=6.0 Hz, 1H, 2-H); 13C NMR (100.6 MHz, CD3OD)δ 
23.5 (CH3, 7-CH3), 27.4 (CH, C5), 28.3 (CH, C9), 29.2 (CH2, C12), 35.5 (CH2, C10), 
35.9 (CH2, C6), 116.2 (C, C4a), 120.8 (CH, C3), 121.7 (C, C3a), 123.8 (CH, C2), 125.0 
(CH, C8), 134.7 (C, C7), 149.1 (C, C10a), 149.8 (C, C11a), 154.2 (C, C4); HRMS (ESI) 
calcd for (C15H16N2S + H+): 257.1107, found 257.1107. 
9-[(5,6,9,10-Tetrahydro-7-methyl-5,9-methanocycloocta[b]thieno[3,2-e]pyridin-4-yl) 
amino]nonanenitrile (76): In a tripleneck 50 mL round bottomed flask, provided with an 
inert atmosphere, magnetic stirrer, and 4Å molecular sieves, a suspension of the 
thienohuprine75 (1.00 g, 3.90 mmol) and powdered KOH (85% purity; 849mg; 
12.9mmol) in anhydrous DMSO (16.6 mL) was prepared and stirred, heating with a 
heatgun each 10 min during 1 h. Then it was stirredfor another 1 h at r. t., and treated with 
9-bromononanenitrile (935 mg; 4.29mmol). The reaction mixture was stirredat r. t. 
overnight.The resultingmixture was diluted with 2N NaOH (120 mL) and extracted with 
CH2Cl2 (4 × 100 mL). The combined organic layers werewashed with H2O (5 × 100 mL), 
dried with anhydrous Na2SO4, filtered, and evaporated under reduced pressure to give a 
dark brown oil, which was purified by column chromatography (hexane: EtOAc: Et3N50: 
50:0.2), to givenitrile 76 (760mg, 50% yield) as ayellow oil.  
76·HCl: mp 92−93 °C; 1H NMR (400 MHz, CD3OD) δ 1.36−1.54 (complex signal, 8H, 4-
H2, 5-H2, 6-H2, 7-H2), 1.59 (s, 3H, 7’-CH3), 1.64 (tt, J=J’=7.2 Hz, 2H, 3-H2), 1.81 (tt, 
J=J’=7.2 Hz, 2H, 8-H2), 1.89 (br d, J=17.2 Hz, 1H, 6’-Hendo), superimposed in part 1.91 
(dm, J=12.4 Hz, 1H, 12’-Hsyn), 2.07 (dm, J=12.4 Hz, 1H, 12’-Hanti), 2.43 (t, J=7.2 Hz, 
2H, 2-H2), 2.52 (dd, J=17.2 Hz, J’=4.8 Hz, 1H, 6’-Hexo), superimposed in part 2.75 (m, 
1H, 9’-H), 2.76 (br d, J=17.6 Hz, 1H, 10’-Hendo), 3.16 (dd, J=17.6 Hz, J’=5.6 Hz, 1H, 
10’-Hexo), 3.33 (m, 1H, 5’-H), 3.86 (tm, J= 7.2 Hz, 2H, 9-H2), 4.85 (s, NH, +NH), 5.57 (br 
d, J=4.8 Hz, 1H, 8’-H), 7.54 (d, J=5.6 Hz, 1H, 3’-H), 7.72 (d, J=5.6 Hz, 1H, 2’-H); 13C 
NMR (100.6 MHz, CD3OD)δ 17.4 (CH2, C2), 23.6 (CH3, 7’-CH3), 26.4 (CH2, C3), 27.1 
(CH, C5’), 27.7 (CH2, C7), 27.9 (CH, C9’), 29.5 (CH2, C12’), 29.6 (CH2), 29.7 (CH2), 
30.1 (CH2) (C4, C5, C6), 30.9 (CH2, C8), 35.5 (CH2, C10’), 35.9 (CH2, C6’), 46.7 (CH2, 
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C9), 117.3 (C, C4a’), 119.1 (C, C3a’), 121.3 (C, C1), 122.7 (CH, C3’), 123.5 (CH, C2’), 
125.0 (CH, C8’), 134.5 (C, C7’),  147.0 (C, C10a’), 152.4 (C, C11a’), 153.2 (C, C4’); 
HRMS (ESI) calcd for (C24H31N3S + H+): 394.2311, found 394.2313. 
N-(5,6,9,10-Tetrahydro-7-methyl-5,9-methanocycloocta[b]thieno[3,2-e]pyridin-4-yl) 
nonane- 1,9-diamine (77): In a 2 neck50 mL round bottomed flask equipped with an 
inert atmosphere and magnetic stirrer,a suspension ofnitrile76 (585 mg; 1.49mmol) in 
anhydrous Et2O (25 mL) wascooled to 0ºC with an ice bath and treated dropwise with a 
solution of LiAlH4 in Et2O (4M solution; 1.2 mL; 4.80mmol). The reaction mixture was 
stirred at room temperature overnight. Then it was cooled at 0 ºC with an ice bath, diluted 
dropwise with 1N NaOH (40 mL) and water (90 mL) and extracted with CH2Cl2 (3 × 100 
ml). The combined organic layers were dried with anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure to giveamine 77 (599 mg, quantitative yield) as 
ayellow oil, which was used for the next step without any further purification.  
77·2HCl: mp 86−87 ºC; 1H NMR (400 MHz, CD3OD) δ 1.36–1.54 (complex signal, 10H, 
3-H2, 4-H2, 5-H2, 6-H2, 7-H2), 1.58 (s, 3H, 7’-CH3), 1.66 (tt, J=J’=7.6 Hz, 2H, 8-H2), 
1.81 (tt, J=J’=7.6 Hz, 2H, 2-H2), 1.89 (br d, J=18.0 Hz, 1H, 6’-Hendo), superimposed in 
part 1.91 (dm, J=12.8 Hz, 1H, 12’-Hsyn), 2.07 (dm,  J=12.8 Hz, 1H, 12’-Hanti), 2.52 (dd, 
J=18.0 Hz, J’=4.8 Hz, 1H, 6’-Hexo), superimposed in part 2.76 (m, 1H, 9’-H), 2.77 (br d, 
J=17.6 Hz, 1H, 10’-Hendo), 2.91 (t, J=7.6 Hz, 2H, 9-H2), 3.16 (dd, J=17.6 Hz, J’=5.6 Hz, 
1H, 10’-Hexo), 3.34 (m, 1H, 5’-H), 3.86 (tm, J=7.6 Hz, 2H, 1-H2), 4.85 (s, NH, +NH), 5.57 
(br d, J=4.8 Hz, 1H, 8’-H), 7.54 (d, J=6.0 Hz, 1H, 3’-H), 7.72 (d, J=6.0 Hz, 1H, 2’-H); 
13C NMR (100.6 MHz, CD3OD) δ 23.5 (CH3, 7’-CH3), 27.2 (CH, C5’), 27.5 (CH2, C3), 
27.8 (CH2, C4), 28.0 (CH, C9’), 28.6 (CH2, C5), 29.4 (CH2, C12’), 30.1 (CH2), 30.3 
(CH2), 30.4 (CH2)(C6, C7, C8), 31.0 (CH2, C2), 35.5 (CH2, C10’), 35.9 (CH2, C6’), 40.8 
(CH2, C9), 46.6 (CH2, C1), 117.3 (C, C4a’), 119.2 (C, C3a’), 122.6 (CH, C3’), 123.5 
(CH, C2’), 125.0 (CH, C8’), 134.6 (C, C7’), 147.1 (C, C10a’), 152.5 (C, C11a’), 153.3 (C, 
C4’); HRMS (ESI) calcd for (C24H35N3S + H+) 398.2624, found 398.2629. 
9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-N-{9-[(5,6,9,10-tetrahydro-7-methyl-5,9-
methanocycloocta[b]thieno[3,2-e]pyridin-4-yl)amino]nonyl}anthracene-2-
carboxamide (28): In a 50 mL round bottomed flask provided with a magnetic stirrer, a 
suspension ofrhein (387 mg; 1.36mmol) in EtOAc (17.2 ml) and DMF (1.7 mL) was 
treated with EDC·HCl (356 mg; 1.86 mmol), Et3N (0.43 mL;312 mg; 3.09mmol) and 
HOBT (253 mg; 1.87mmol). The mixture was stirred for 1 h and treated with a solution 
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ofamine 77 (493 mg; 1.24mmol) in EtOAc (20 mL) and DMF (2 mL). The reaction 
mixture was stirred for 24h at r. t. and evaporated under reduced pressure to give a brown 
solid residue(1.53 g),which was purified by silica gel column chromatography 
(CH2Cl2:MeOH:50% aq. NH4OH 95:5:1)  to give the novel hybrid 28 (581 mg, 71% 
yield) as abrown solid . 
28·HCl: mp 174−175 °C; 1H NMR (400 MHz, CD3OD) δ 1.37−1.50 (complex signal, 
10H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2), 1.57 (s, 3H, 7”-CH3), 1.66 (tt, J=J’=6.8 Hz, 2H, 
2’-H2), 1.76 (tt, J=J’=7.2 Hz, 2H, 8’-H2), 1.86 (br d, J=17.2 Hz, 1H, 6”-Hendo), 
superimposed in part 1.87 (dm, J=11.6 Hz, 1H, 12”-Hsyn), 2.03 (dm, J=11.6 Hz, 1H, 12”-
Hanti), 2.49 (dm, J=17.2 Hz, 1H, 6”-Hexo), superimposed in part 2.71 (br d, J=17.6 Hz, 1H, 
10”-Hendo), 2.73 (m, 1H, 9”-H), 3.08 (dd, J=17.6 Hz, J’=5.6 Hz, 1H, 10”-Hexo), 3.26 (m, 
1H, 5”-H), 3.41 (t, J=6.8 Hz, 2H, 1’-H2), 3.72 (tm, J=7.2 Hz, 2H, 9’-H2), 4.85 (s, OH, 
NH, +NH), 5.54 (br d, J=4.8 Hz, 1H, 8”-H), 7.25 (d, J=8.0 Hz, 1H, 6-H), 7.40 (d, J=6.0 
Hz, 1H, 3”-H), 7.52 (d, J=6.0 Hz, 1H, 2”-H), 7.59 (br s, 1H, 3-H), superimposed in part 
7.60 (d, J=8.0 Hz, 1H, 8-H), 7.68 (dd, J=J’=8.0 Hz, 1H, 7-H), 7.99 (br s, 1-H); 13C NMR 
(100.6 MHz, CD3OD) δ 23.5 (CH3, 7”-CH3), 27.1 (CH, C5”), 27.7 (CH + CH2), 28.0 
(CH2) (C9”, C6’, C7’), 29.3 (CH2, C12”), 29.9 (CH2), 30.0 (CH2), 30.1 (CH2), 30.3 
(CH2) (C2’, C3’, C4’, C5’), 30.9 (CH2, C8’), 35.4 (CH2, C10”), 35.8 (CH2, C6”), 41.1 
(CH2, C1’), 46.7 (CH2, C9’), 116.8 (C, C10a), 117.2 (C, C4a”), 118.3 (C, C4a), 118.9 
(CH, C1), 119.0 (C, C3a”), 120.9 (CH, C8), 122.5 (CH, C3”), 123.3 (CH, C2”), 123.7 
(CH, C3), 125.0 (CH, C8”), 125.8 (CH, C6), 134.5 (C, C8a), 134.6 (C, C7”), 135.0 (C, 
C9a), 138.7 (CH, C7), 143.6 (C, C2), 147.0 (C, C10a”), 152.4 (C, C11a”), 153.2 (C, C4”), 
163.3 (C, C4), 163.5 (C, C5), 167.1 (C, CONH), 181.8 (C, C9), 193.4 (C, C10); HRMS 
(ESI) calcd for (C39H41N3O5S + H+) 664.2840, found 664.2838. 
6,7,10,11-Tetrahydro-2-methoxy-9-methyl-7,11-methanocycloocta[b]quinolin-12-
amine (78): The methoxyhuprine78 was prepared as described for 75. From 2-amino-5-
methoxybenzonitrile (223 mg, 1.51 mmol), enone74(188 mg, 1.25 mmol), and AlCl3 (250 
mg, 1.87 mmol), and stirring the reaction mixture under reflux for 3 days, a yellow solid 
residue (300 mg) was obtained and purified by silica gel column chromatography 
(CH2Cl2:MeOH:50% aq. NH4OH 99.8:0.2:0.4), to affordthe novel methoxyhuprine 78 
(150 mg, 43% yield)as a yellow solid. 
78·HCl: mp 285−286 °C; 1H NMR (400 MHz, CD3OD) δ 1.58 (s, 3H, 9-CH3), 
superimposed in part 1.95 (dm, J=12.4 Hz, 1H, 13-Hsyn), 1.99 (br d, J=17.6 Hz, 1H, 10-
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Hendo), 2.07 (dm, J=12.4 Hz, 1H, 13-Hanti), 2.51 (dd, J=17.6 Hz, J’=4.0 Hz, 1H, 10-Hexo), 
2.77 (m, 1H, 7-H), 2.87 (br d, J=17.6 Hz, 1H, 6-Hendo), 3.18 (dd, J=17.6 Hz, J’=5.6 Hz, 
1H, 6-Hexo), 3.40 (m, 1H, 11-H), 3.97 (s, 3H, 2-OCH3), 4.87 (s, NH, +NH), 5.57 (br d, 
J=4.8 Hz, 1H, 8-H), 7.47 (dd, J=9.2 Hz, J’=2.4 Hz, 1H, 3-H), 7.67 (d, J=9.2 Hz, 1H, 4-
H), 7.70 (d, J=2.4 Hz, 1H, 1-H); 13C NMR (100.6 MHz, CD3OD)δ 23.5 (CH3, 9-CH3), 
27.6 (CH, C11), 28.3 (CH, C7), 29.4 (CH2, C13), 35.7 (CH2), 36.0 (CH2) (C6, C10), 56.7 
(CH3, 2-OCH3), 102.8 (CH, C1), 114.7 (C, C12a), 117.9 (C, C11a), 121.7 (CH), 126.1 
(CH) (C3, C4), 125.0 (CH, C8), 134.2 (C), 134.9 (C) (C4a, C9), 150.4 (C, C5a), 155.4 (C, 
C12), 159.3 (C, C2); HRMS (ESI) calcd for (C18H20N2O + H+): 281.1648, found 
281.1650. 
9-[(6,7,10,11-Tetrahydro-2-methoxy-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl)amino]nonanenitrile (79): Nitrile 79 was prepared as described for 76. From 
huprine78 (260 mg, 0.93 mmol) and 9-bromononanenitrile (222 mg, 1.02 mmol), a brown 
oily residue (450 mg) was obtained and purified by silica gel column chromatography 
(CH2Cl2:MeOH:50% aq. NH4OH 99.8:0.2:0.2), to afford nitrile 79 (114 mg, 29% yield) 
as a yellow oil. 
79·HCl: mp 162−163 °C; 1H NMR (400 MHz, CD3OD) δ 1.32−1.50 (complex signal, 8H, 
4-H2, 5-H2, 6-H2, 7-H2), 1.58 (s, 3H, 9’-CH3), 1.62 (tt, J=J’=6.8 Hz, 2H, 3-H2), 
superimposed in part 1.88 (m, 2H, 8-H2), 1.94 (br d, J=17.6 Hz, 1H, 10’-Hendo), 
superimposed in part 1.96 (dm, J=12.8 Hz, 1H, 13’-Hsyn), 2.09 (dm, J=12.8 Hz, 1H, 13’-
Hanti), 2.43 (m, 2H, 2-H2), 2.56 (dm, J=17.6 Hz, 1H, 10’-Hexo), 2.77 (m, 1H, 7’-H), 2.88 
(br d, J=17.6 Hz, 1H, 6’-Hendo), 3.20 (dd, J=17.6 Hz, J’=5.6 Hz, 1H, 6’-Hexo), 3.48 (m, 
1H, 11’-H), 3.96 (s, 3H, 2’-OCH3), superimposed in part 3.98 (m, 2H, 9-H2), 4.85 (s, NH, 
+NH), 5.59 (br d, J=4.4 Hz, 1H, 8’-H), 7.53 (dd, J=9.2 Hz, J’=2.4 Hz, 1H, 3’-H), 7.66 (d, 
J=2.4 Hz, 1H, 1’-H), 7.72 (d, J=9.2 Hz, 1H, 4’-H); 13C NMR (100.6 MHz, CD3OD)δ 17.1 
(CH2, C2), 23.3 (CH3, 9’-CH3), 26.2 (CH2, C3), 27.3 (CH, C11’), 27.6 (CH2, C7), 27.8 
(CH, C7’), 29.3 (CH2, C13’), 29.4 (CH2), 29.6 (CH2), 29.9 (CH2) (C4, C5, C6), 31.7 
(CH2, C8), 35.8 (CH2, C6’), 36.4 (CH2, C10’), 48.9 (CH2, C9), 56.3 (CH3, 2’-OCH3), 
105.9 (CH, C1’), 117.2 (C), 118.6 (C) (C11a’, C12a’), 121.1 (C, C1), 121.6 (CH), 125.4 
(CH) (C3’, C4’), 125.0 (CH, C8’), 134.4 (C), 135.1 (C) (C4a’, C9’),  149.4 (C, C5a’), 
156.1 (C, C12’), 158.1 (C, C2’); HRMS (ESI) calcd for (C27H35N3O + H+): 418.2853, 
found 418.2862. 
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N-(6,7,10,11-Tetrahydro-2-methoxy-9-methyl-7,11-methanocycloocta[b]quinolin-12-
yl) nonane-1,9-diamine (80): Amine 80 was prepared as described for 77. From nitrile 79 
(60 mg, 0.14 mmol), amine 80 (34 mg, 58% yield) was obtained as a yellow oil, and 
directly used in the next step without further purification. 
80·2HCl:1H NMR (400 MHz, CD3OD) δ 1.28–1.48 (complex signal, 10H, 3-H2, 4-H2, 5-
H2, 6-H2, 7-H2), 1.58 (s, 3H, 9’-CH3), 1.66 (m, 2H, 8-H2), 1.88 (m, 2H, 2-H2), 1.93 (br d, 
J=17.6 Hz, 1H, 10’-Hendo), superimposed in part 1.96 (dm, J=12.8 Hz, 1H, 13’-Hsyn), 2.09 
(dm,  J=12.8 Hz, 1H, 13’-Hanti), 2.56 (dd, J=17.6 Hz, J’=4.0 Hz, 1H, 10’-Hexo), 2.77 (m, 
1H, 7’-H), superimposed in part 2.89 (d, J=18.0 Hz, 1H, 6’-Hendo), 2.91 (m, 2H, 9-H2), 
3.20 (dd, J=18.0 Hz, J’=5.6 Hz, 1H, 6’-Hexo), 3.49 (m, 1H, 11’-H), 3.96 (s, 3H, 2’-
OCH3), 3.97 (m, 2H, 1-H2), 4.86 (s, NH, +NH), 5.59 (br d, J=4.4 Hz, 1H, 8’-H), 7.53 (dd, 
J=9.2 Hz, J’=2.4 Hz, 1H, 3’-H), 7.66 (d, J=2.4 Hz, 1H, 1’-H), 7.73 (d, J=9.2 Hz, 1H, 4’-
H); 13C NMR (100.6 MHz, DMSO-d6) δ 23.1 (9’-CH3), 25.4, 25.8, 26.0, 26.1, 26.9, 27.9, 
28.4, 28.5, 28.7 (C3, C4, C5, C6, C7, C8, C7’, C11’, C13’), 30.1 (C2), 34.5, 35.6 (C6’, 
C10’), 38.7 (C9), 47.0 (C1), 55.8 (2’-OCH3), 104.7 (C1’), 115.4, 117.0 ( C11a’, C12a’), 
120.9, 123.9, 124.2 (C3’, C4’, C8’), 132.6, 133.4 (C4a’, C9’), 148.1 (C5a’), 153.7 (C, 
C12’), 156.0 (C, C2’); HRMS (ESI) calcd for (C27H39N3O + H+) 422.3166, found 
422.3181. 
9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-N-{9-[(6,7,10,11-tetrahydro-2-methoxy-9-
methyl-7,11-methanocycloocta[b]quinolin-12-yl)amino]nonyl}anthracene-2-
carboxamide (29): Hybrid 29 was prepared as described for 28. From rhein (74 mg, 0.26 
mmol) and amine 80 (100 mg, 0.24 mmol), a brown solid residue (425 mg) was obtained 
and purified by silica gel column chromatography (CH2Cl2: MeOH: 50% aq. NH4OH 
95:5:1), to afford the novel hybrid 29 (73 mg, 45% yield) as an orange solid. 
29·HCl:mp 137−138 °C; 1H NMR (400 MHz, CD3OD) δ 1.38−1.46 (complex signal, 
10H, 3’-H2, 4’-H2, 5’-H2, 6’-H2, 7’-H2), 1.60 (s, 3H, 9”-CH3), 1.67 (tt, J=J’=6.4 Hz, 2H, 
2’-H2), 1.85 (tt, J=J’=6.8 Hz, 2H, 8’-H2), 1.93 (br d, J=18.0 Hz, 1H, 10”-Hendo), 
superimposed in part 1.94 (dm, J=13.2 Hz, 1H, 13”-Hsyn), 2.07 (dm, J=13.2 Hz, 1H, 13”-
Hanti), 2.53 (dd, J=18.0 Hz, J’=5.2 Hz, 1H, 10”-Hexo), 2.75 (m, 1H, 7”-H), 2.80 (br d, 
J=17.6 Hz, 1H, 6”-Hendo), 3.14 (dd, J=17.6 Hz, J’=5.6 Hz, 1H, 6”-Hexo), 3.39 (m, 1H, 
11”-H), 3.43 (dt, J=J’=6.4 Hz, 2H, 1’-H2), 3.83 (s, 3H, 2”-OCH3), superimposed in part 
3.84 (m, 2H, 9’-H2), 4.85 (s, OH, NH, +NH), 5.59 (br d, J=5.2 Hz, 1H, 8”-H), 7.33 (dd, 
J=8.0 Hz, J’=1.2 Hz, 1H, 6-H), 7.37 (dd, J=9.2 Hz, J’=2.4 Hz, 1H, 3”-H), 7.41 (d, J=2.4 
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Hz, 1H, 1”-H), 7.50 (d, J=9.2 Hz, 1H, 4”-H), 7.65 (dd, J=7.6 Hz, J’=1.2 Hz, 1H, 8-H), 
7.69 (d, J=1.6 Hz, 1H, 3-H), 7.73 (dd, J=8.0 Hz, J’=7.6 Hz, 1H, 7-H), 8.12 (d, J=1.6 Hz, 
1H, 1-H); 13C NMR (100.6 MHz, CD3OD) δ 23.5 (CH3, 9”-CH3), 27.4 (CH, C11”), 27.5 
(CH2), 27.7 (CH2) (C6’, C7’), 27.9 (CH, C7”), 29.4 (CH2, C13”), 29.7 (CH2), 29.9 
(CH2), 30.0 (CH2), 30.1 (CH2) (C2’, C3’, C4’, C5’), 32.0 (CH2, C8’), 35.8 (CH2, C6”), 
36.3 (CH2, C10”), 41.0 (CH2, C1’), 49.1 (CH2, C9’), 56.3 (CH3, 2”-OCH3), 105.8 (CH, 
C1”), 116.7 (C, C10a), 117.1 (C), 118.2 (C), 118.3 (C) (C4a, C11a”, C12a”), 118.8 (CH, 
C1), 120.7 (CH, C8), 121.6 (CH), 125.2 (2CH) (C3”, C4”, C8”), 123.7 (CH, C3), 125.8 
(CH, C6), 134.4 (C), 134.9 (2C) (C9a, C4a”, C9”) C8”), 134.6 (C, C8a), 138.7 (CH, C7), 
143.6 (C, C2), 149.3 (C, C5a”), 155.7 (C, C12”), 157.9 (C, C2”), 163.3 (C, C4), 163.5 (C, 
C5), 167.1 (C, CONH), 181.8 (C, C9), 193.3 (C, C10); HRMS (ESI) calcd for 
(C42H45N3O6 + H+) 688.3381, found 688.3378. 
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Chapter 4. Epigenetic modifications and AD diseases 
 
Epigenetic processes, the changes in gene expression independent of any variation in the 
DNA coding sequence, are critical physiological mechanisms in the normal development 
and differentiation of the cells (Abel 2008, Portela 2010). Dysregulation of epigenetic 
processes are involved in different disorders of signal transduction pathways including 
cell differentiation, cell apoptosis, vascular remodeling, inflammation reaction and 
immune responses, (Portela 2010; Mihaylova 2013), synaptic plasticity and cognition 
(Abel 2008). Eukaryotic DNA is compressed through its unity histone octamers, each 
octameris composed of two recognizable copies of the four core histones (H2A, H2B, H3, 
and H4), which form nucleosomes that interconnected by sections of a linker DNA 
strands  formed by 147 base pairs (Allis, 2007); these structures are compressed together 
to form chromatin (Kouzarides 2007, Stein 1980). 
The main types of epigenetic modifications which can alter the chromatin structure and 
genome transcription include histone modifications (acetylation, phosphorylation, 
SUMOylation, methylation, ADP ribosylation, and ubiquitination), DNA methylation,  
nucleosome remodeling and RNA mediated pathways (Peterson 2004, Goldberg 2007, 
Portela 2010). 
 
• DNA methylation: DNA methylation emerges in high levels in the brain of mammals 
especially at CpG dinucleotide sites (Ehrlich, 1982); this process occurs by covalent 
addition of a methyl group from S-adenosyl methionine (SAM), to the 5-carbon of the 
cytosine residue to form 5-methylcytosine (5-mC) (Miranda 2007). This modification has 
important role in heterochromatin organization and long-term transcription silencing 
(Rottach 2009). 
 
• Histone modifications: Histone modifications includs acetylation, phosphorylation, 
SUMOylation, methylation, ADP ribosylation, and ubiquitination, affect chromatins 
structure by changing the level of attraction between the negatively-charged DNA and the 
positively-charged histone tails (Herranz 2007).  
Epigenetic studies have shown that histone acetylation is involved in the etiology of AD. 
It was suggested that abnormal histone acetylation can contribute to the development of 
AD. Dysregulation of gene transcription has shown to be associated with impairments in 
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learning and memory. Studies reported that changes in histone gene transcription related 
to aging in rodent models have shown downregulation of genes which are linked to 
synaptic function, as well as with mitochondrial function and DNA damage responses 
(Jiang 2001, Blalock 2003). 
The cellular and molecular processes that underlie learning and memory leading to 
transient changes in histone acetylation have become well established in the hippocampus, 
as well as in other brain regions (Levenson 2004, Fontan 2008). Studies showed that mice 
exposed to enriched environments exhibit increased acetylation of histones H3 and H4 in 
the hippocampus and cortex (Fischer 2007, Koseki 2012). Interestingly, aged mice show 
impairments in learning-promoted increases in histone acetylation levels.  
In basal conditions, it has not seen any difference in acetylation levels between 3-month 
old mice when compared to 16-month old mice. But after undergoing contextual fear 
conditioning, acetylation levels specifically at H4K12 in the brain were elevated in 3-
month old mice, but not in the 16-month old mice (Peleg 2010). The loss of acetylation at 
H4K12 for the 16-month old mice was correlated with hippocampus- dependent memory 
impairment. Other studies have shown that changes in certain histone acetylation marks 
are connected with the activity of specific HDAC proteins in the hippocampus. An 
increase in acetylation levels at H4K5 and H4K12 is correlated with loss of HDAC2 
protein function (Guan 2009) and rises in H4K8 acetylation levels associated with the loss 
of HDAC3 protein function (McQuown 2011). These studies suggest that learning and 
memory impairments may be due to the dysregulated expression of genes through 
epigenetic mechanisms. Dynamic regulation of gene transcription through acetylation of 
histone proteins has provided a therapeutic path, and with the development of HDAC 
inhibitors pharmacological modification of gene transcription can be achieved through 
this pathway. 
 
4.1 The biological role of Histone Acetylases and Histone Deacetylases 
 
Histone acetylation is regulated by the activities of two antagonistic enzymes: Histone 
Acetylases (HATs) and Histone Deacetylase (HDACs). 
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4.1.1 Histone Acetylases (HATs)  
HATs add acetyl groups on to ε-amino groups of lysine residues within the N-terminal tail 
of histones resulting in neutralization of the Histones positive charge (Yang 2007), which 
prevents interaction with the phosphate groups of the DNA leading to relaxed chromatin 
structure, and increase the ctivation of gene transcription (Herranz 2007). Acetylation is 
also implicated in remodelling and replication of chromatin, regulating microtubule 
dynamics and intracellular transport (Kouzarides 2007; Kazantsev 2007). 
 
4.1.2 Histone deacetylases (HDACs) 
Removing the acetyl groups from of lysine residues within the N-terminal tail of histones, 
results in transcription repression through leading to enhance the chromatin condensation 
and transcription silencing (Hanen 2008). 
In physiological conditions, the balance between HATs and HDACs is preserved to obtain 
normal cellular function. This equilibrium can be deranged in pathological circumstances. 
In neurodegenerative diseases HAT activity is greatly reduced (Saha 2006), conversely 
the activity of HDAC is increased (Saha 2006) which leads to histone hypoacetylation,  
transcriptionally inactive (Herranz 2007), decrease appearance of cell survival genes and 
enhances the appearance of apoptotic genes (Saha 2006). 
Therefore, dysregulation of the balance of HDACs is supposed to play important role in 
the progression of neurodegenerative diseases, and inhibiting of the HDACs activity 
would be a therapeutic approach through enhancing transcriptional activation of disease 
modifying genes to retrieve the damaged neurons during neurodegeneration diseases (Lu 
2006; Feinberg 2007; Hanen2008). These functions show that these classical HDACs 
have specific and extensive roles in memory formation, synaptic plasticity, neuronal 
growth and differentiation, which are essential for neuronal survival.  
HDACs are classified into four groups according to their yeast counter parts, including 
structure and cellular localization. Class I, II and IV are called classical HDACs which 
contain 11 enzymes sharing Zn2+ as a catalytic domain (Ruijter 2003, Chuang 2009). 
Class III HDACs are called sirtuins and have 7 members whose catalytic mechanism is 
Zn2+ independent and require nicotinamide adenine dinucleotide (NAD+) (Michishita. 
2005). 
 
• Class I HDACs: It Contains HDAC1, 2, 3, and 8, and these enzymes share the same 
homology to yeast transcriptional regulator RPD3 (Chuang 2009, Delcuve 2012), with 
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molecular weights range from 22 to 55 kDa (de Ruijteret al., 2003). The members of this 
class are primarily nuclearlocalized and ubiquitiously expressed, except HDAC3 which 
migrates between the nucleus and cytoplasm (Longworth 2006). 
Class I HDACs play distinct role in cell proliferation and have specific and important 
roles in neuronal survival, growth and differentiation, memory formation and synaptic 
plasticity.  
 
• Class II HDACs: Which are homologous to the yeast Hda1, is sub divided into Class 
IIa (HDAC 4, 5, 7 and 9) and Class IIb (HDAC6 and 10) (Chuang 2009, Delcuve 2012). 
Their molecular weightsprotein are in the range of 120 -135 kDa (Witt 2008). 
Class IIa HDACs: (4, 5, 7, and 9) localize to the nucleus and cytoplasm (Grozinger 2000) 
and their localization is regulated by the phosphorylation of key residues within the 14-3-
3 proteins which bind to conserved N-terminal sites of HDACs (Grozinger 2000-Kao, 
H.Y. 2001). This class is highly expressed in the heart, skeletal muscle and brain and 
plays important role in tissue-specific expression (Lucio2008). 
Class IIb HDACs: Contains HDAC 6 and 10, HDAC6 is a distinct enzyme within the 
classical HDACs because it contains two catalytic domains and this enzyme was 
identified as a microtubule-associated deacetylase as it regulates the microtubule 
dependent cell motility, (B. P. VAN 2003, Guardiola 2002). HADC 4 and 6 are involved 
in neurotoxic activity and their inhibition can lead to neurodegenerative therapeutics 
(Bolger 2005, Dompierre 2007, Bardai 2011). HDAC10 has a catalytic domain on its N-
terminus, and a second catalytic domain on the C-terminus (Tong, J.J 2002). Its function 
is still not well known but it has been shown that it has the ability to associate with other 
HDACs such as HDAC3 and to act as a recruiter not as a deacetylase (Andrea B. P. VAN 
2003). 
 
•  Class III HDACs: This class is known as Sirtuins consist of 7 enzymes depending on 
their amino acid sequence (Dryden S 2003) and has the same homology to yeast Sir2 
(Michan 2007). The members of this class differ in their localization: SIRT 1, 6 and 7 
localize to the nucleus, SIRT 2 to the cytoplasm, while SIRT 3, 4 and 5 to the 
mitochondria (Michishita. 2005). 
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• Class IV HDACs: This class contains only HDAC 11, is structurally related to class I 
and class II, it is highly expressed in kidney, heart, brain and skeletal muscle (Gao 2002), 
but its function is not largely known (Villagra. A 2009, Gao. L 2002). 
 
4.2 The role of HDAC in the development of AD 
 
Histone acetylation is implicated in gene expression through chromatin modification, and 
the acetylation was mainly in the N-terminal of histone H3 and H4. It was suggested that 
the cognitive deficit is one of key characteristics of AD patients. After the obtained results 
of an experiment performed on mice, it revealed that the deregulation of histone 
acetylation associated with age-dependent memory impairment. The aged mice display a 
deregulation of histone H4 lysine12 (H4K12) acetylation and fail to start a hippocampal 
gene expression which is implicate in memory consolidation, while the vorinostat-treated 
mice showed an increase of H4K12 acetylation and restore learning-induced gene 
expression (S. Peleg, 2010). Other studies showed that Histone acetylation H4 also is 
implicated in the pathology of AD, and applying HDAC inhibitors led to alteration in 
some important gene expression through regulating the histone acetylation. Another 
experiment includes applying class I HDAC inhibitors in a mouse model of AD such as 
sodium valproate, resulted in restore contextual memory (M. Kilgore 2010). The level of 
histone acetylation is affected by HDACs, and it was reported that using HDAC inhibitors 
led to alter the levels of the proteins like Aβ, GSK-3β, and tau hyperphosphorylation 
which have advantages in treating AD (J. Huang, 2010). 
HDAC2 is a negative regulator in learning and memory, it was reported that mice 
overexpressing HDAC2 showed decrease in synaptic plasticity and synapse number and 
memory formation, and the treatment of these mice with vorinostat resulted inrescue of 
synaptic number and learning impairments. 
Also HDAC6 protein level is significantly increased in cortex and hippocampus in AD 
brains compared with the normal brains, and application of Tubacin (a selective inhibitor 
of HDAC6) attenuates site-specific phosphorylation of tau, which indicated that HDAC6 
has a key rolein the AD. 
Another report by Gao et al. indicated that there is significant reduction of SirT1 in the 
parietal cortex of AD patients compared with the control, and the accumulation of Aβ and 
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tau in AD patients may be associated with the loss of SirT, which suggests the 
involvement of Sir2 in the pathology of AD. 
All of the these studies led the researches to suggest that HDAC proteins may be 
implicated in AD development, and regulate the level of histone acetylation which may 
alter the expression of some important genes involved in memory and cognition processes 
and in AD pathology . HDAC inhibitors could ameliorate cognitive deficits and memory 
impairment  in AD, through the inhibition of Aβ-induced hyperphosphorylation of tau 
protein; and through the regulation of the expression of important genes participating in 
the learning and memory. 
 
4.3 HDAC inhibitors in therapy 
 
During the last years, both academic and industrial laboratories have reported about new 
natural and synthetic compounds as HDAC inhibitors (HDACIs). In fact, HDAC are 
emerging as important target to treat different diseases such as immune disorders, cancer, 
diabetes, sickle-cell anemia and neurodegenerative disorders (Kazantsev 2008). 
Two HDACIs are currently in therapy for the treatment of cutaneous cell T lymphoma 
(CTCL) and they are SAHA and FK228. In particular, SAHA is a classic hydroxamate-
based HDACI and its structure, like most of the other HDACIs such as TSA, could be 
divided in three parts: hydrophobic cap region, and aliphatic linker and a Zinc-binding 
group. Both SAHA and TSA are highly potent HDACIs with an IC50 in the nanomolar 
range of concentration. This high activity could be explained analyzing the crystal 
structure between TSA, or SAHA, and the enzyme. Indeed, it could be observed that the 
aromatic moiety of TSA interacts with critical amino acids located at the entrance of a 
tunnel through hydrophobic interactions, and the aliphatic chain located between the cap 
group and the zinc-binding group establishes van der Walls interactions with amino acids 
located in the tunnel. At the bottom, the Zinc atom interacts with the two oxygen atoms of 
the hydroxamate function; this moiety interacts also with two His and  Tyr (Figure 50). 
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Figure 50: General structure of TSA and its binding with HDAC (E. Costa 2006) 
 
Based on the chemical structure and on the nature of the zinc-binding group, HDACIs 
could be divided in different chemical groups: hydroxamates, benzamide, aliphatic acids, 
electrophilic ketones and cyclic peptides. 
 
• Hydroxamates:  
Compounds belonging to this class have been the first to be developed and are highly 
active thanks to the hydroxamic acid able to interact with the zinc-binding group located, 
at the bottom of the tunnel of the active site. The importance of this group has been 
confirmed by SAR studies reporting that its replacement or its modification, such as 
methylation, induces a dramatic loss of the activity. The first discovered compound of this 
class was TSA in 1990: this is a natural product extracted from Streptomyces 
hygroscopicus strain and displayinga Ki value of 3.4 nM towards HDAC. As already 
reported, closely related to TSA is SAHA, which was the first HDAC I approved by the 
FDA and it showed an IC50 of about 1 nM towards HDAC (Wagner 2010). Structure-
actitvity relationships studies performed on SAHA reveal that the distance between the 
Cap and the zinc-binding group is optimal when is of six methylenes. At the opposite, the 
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capping group could be greatly modified by introducing different aryl substituent without 
any lost in activity. 
An example is compound XX in which the the benzyl group was replaced by an indole, 
without loss in activity (IC50 = 14 nM).  
Among the hydroxamate based compounds CBHA and its derivatives are very important 
since they demonstrated the possiblity to replace the aliphatic linker with an aromatic 
moiety without losing the activity. 
 
N
H
NH
O NHOH
O
XX
N
NHOH
O O
TSA
H
N
NHOH
O
O
SAHA
HOHN
O
NHOH
O
CBHA  
 
Figure 51: Structureof TSA and SAHA, XX, CBHA 
 
Over the years hundreds of interesting and promising hydroxamate-based HDACI have 
been reported either in patent or in scientific papers and many of them are currently 
evaluated in pre-clinical or clinical studies (Wagner 2010, Chuang 2009). 
 
• Benzamide:  
This class of compounds is characterized by the presence of a benzamide group in place 
of the hydroxamic acid for example butyric acid, valproic acid, MS-275and XXI in (figure 
52). It is hypothized that the aniline group is able to establish critical interactions with 
aminoacids located in the active site. Indeed, its acetylation as well as its replacement 
with other group induced a decrease in the inhibitory activity. In general, benzamides are 
less active than hydroxamic acids. Example of benzamides is MS-275 which is a specific 
inhibitor of HDAC1 and HDAC3 (IC50 = 0.5 and 1.7 μM) and currently it is in clinical 
trials for the treatment of various cancers (Grayson 2010). From SAR performed on this 
compound emerged that the substitution on position 3, 4 and 5 on the benzamide ring 
induced drop in the activity probably due to steric hindrance.  
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Figure 52: Structure of butyric acid, valproic acid, MS-275and XXI 
 
• Aliphatic acids:  
The carboxylic acids group is a well-known metal binding group and carboxylic acid 
characterized by asimple aliphatic chain possesses HDAC inhibitory activity. Examples of 
this class are butyric acid and valproic acid (Khan 2008, Grayson 2010). 
 
• Electrophilic ketones:  
Electrophilic ketones, such as trifluoromethyl ketones or α-keto amides, have been 
recently reported as weak HDAC inhibitors. The inhibitory activity seems to be due to the 
hydrated form of the ketones, which is able to coordinate the metal ion. SAR studies 
conducted on this class of derivatives showed that the linker could be replaced with other 
groups, even if the best activity is obtained with aliphatic chain constituted by five or six 
methylenes, and the replacement of the trifluoromethyl group led to a drop of the activity. 
 
• Cyclic peptides:  
Compounds belonging to this class possess a macrocycle containing hydrophobic 
aminoacids as capping group. The first inhibitors belonging to this group were discovered 
through screening of natural products and examples are Trapoxin A and Chlamydocin and 
Cyl-2 (Grayson 2010, Furumai2002, Grayson 2010).  
 
 
130 
 
OO
HN
HN O
N
NH
O
R1
O R2
R3
n
9 10
Trapoxin A (R1=R2=benzyle, R3=H,n=2)
Trapoxin B (R1=R2=benzyle, R3=H,n=1)
Chlamydocin (R1=benzyle, R2=R3=Me,n=1)
HC-Toxin (R1=R2=Me,R3=H,n=1)
Cyl-2 (R1=Bu, R2=H, R3=4-MeObenzyle,n=2)
WF-3161 (R1=Bu, R2=H, R3=Benzyle,n=2)  
 
Figure 53: Structure of chlamydocin and trapoxin A and B 
 
These compounds showed an epoxyketone moiety, which is essential to obtain an 
irreversible inhibition; indeed, the replacement of this group led to a reduction of the 
activity. These compounds are very interesting because they displayed great activity and 
selectivity: for instance, Trapoxin A, Chlamydocin and Cyl-2 are 640 to 57000-fold 
selectivefor HDAC1 versus HDAC6 (Khan2008). Among cyclic peptides, the only one 
under clinical investigation is FK228, called Romidepsin, which is a natural compound 
isolated from Chromobacteriumviolaceum. 
 
 
Figure 54: Structure of FK 228 
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 The mechanism of action of this compound has been deeply investigated and seems that 
the disulphide bridge is reduced in vivo by the glutathione reductase and the obtained 
thiol group is able to chelate the zinc atom present in the enzyme. 
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4.4 Drug Design 
 
As discussed in the introduction, the development of new MTDLs potentially useful in the 
treatment of multifactorial diseases represents an exciting research filed. In particular, 
MTDLs are particularly useful to treat diseases such as cancer and AD. Indeed, today one 
of the most used drugs in the anticancer therapy is Imatinib: this compound, used for the 
treatment of acute myeloid leukemia, exerts its antiproliferative action by interacting with 
different biological targets, in this case kinases, involved in the development of the 
disease. 
Similarly, also in the field of anti-AD drug discovery, one of the most promising agents 
currently in clinical trial exerts its therapeutic potential interacting with different targets; 
Ladostigil is, indeed, able to simultaneously inhibit two targets responsible for the 
development of AD, the enzymes AChE and mono amino oxidase.  
One of the most useful design strategy for MTDLs consists of identifying two molecules 
that simultaneously administered are able toact synergistically in order to potentiate the 
biological activityof both compounds. Then, fragments of these molecules responsible for 
the biological actions are selected and combined in a unique chemical entity to provide 
hybrid. 
The aim of this work has been the development of new MTDLs able to simultaneously 
target two proteins responsible for the development of AD, namely GSK3β and HDAC, as 
neuroprotective agents.  
Indeed, it was recently reported that combination of lithium, a GSK-3β inhibitor, and 
valproic acid, a HDAC inhibitor, results in a synergistic neuroprotective effect against 
glutamate excitotoxicity. In particular, when the two drugs were administered singularly 
did not show any protective effects against glutamate-induce neurotoxicity in Cerebellar 
granule cells. From the analysis of the mechanism of action, it appears that responsible of 
this effect is the potentiation of GSK-3β inhibition induced by the combination of lithium 
and valproic acid. Importantly, the potentiation of lithium-induced neuroprotection is 
achieved also combining lithium with other HDAC inhibitor such as TSA (Leng Y 2008). 
Moreover, Sharma et al reported that sub-effective dose combination of lithium chloride 
and Valproic acid produced a synergistic neuroprotection against streptozotocin-induced 
cognitive deficits in rats (Leng Y 2008). 
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Furthermore, it is reported that HDAC3 is directly phosphorylated by GSK3β and 
inhibition of GSK-3β protects against HDAC3-induced neurotoxicity (F. H. Bardai 2011). 
These studies provide a strong rationale for the design of MTDLs able to simultaneously 
interact with GSK-3β and HDAC. On these bases, we have designed and synthesized a 
series of MTDLs by coupling the two pharmacophoric fragments responsible for GSK-3β 
and HDAC inhibition, namely the immide and the hydroxamic acid functions, 
respectively. In order to evaluate the best distance between these two fragments, four 
derivatives have been synthesized endowed with an aliphatic linker characterized by a 
different length (Figure 55). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Drug design for GSK-3β – HDAC as MTDLs for AD 
 
  
GSK-3β HDAC 
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4.5 Methods 
 
Synthesis: 
The compounds (24-27) were synthesized by following the procedure in (Scheme 3). 
Compound 82 was synthesized starting from 4-Nitrophtalimide which was reduced in 
acidic condition and using ultra sonic for 2 hours, to give compound 81. Amine function 
was then transformed into isothiocyanate group using thiocarbonyl dipyridine, to give the 
compound 82. 
The hydroxamic acid chains were synthesized through reaction of the corresponding 
bromo carboxylic acid with sodium azide, to give through nucleophilic substitution the 
corresponding azido acids 83-86. The carboxylic function was transformed in a protected 
hydroxamic acid one. Then the azide group was reducedto amine group through 
Staudinger reaction to give the compounds 91-94.  
Reaction of compound 82 with the amine (91-94) gave, respectively, compounds 95-98.  
The final acid hydrolysis allowed the removal of all protecting groups, leading to the 
formation of the final products 24-27.  
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Scheme 1: 
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Conditions: (i) Reduction, (ii) TCP, DCM anhydrous, room temperature 
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Conditions: (i) NaN3, DMF, Reflex, 16 h; (ii) o-tritylhydroxylamine, IBCF, NMM, THF, 2h, room 
temperature (iii) PPh3, DCM, overnight, room temperature 
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Scheme 3: 
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Conditions: (i) DMF, Et3N, 2h, room temperature (ii) TFA, Et3SiH, room temperature, 30 min. 
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4.6 Results and discussion  
 
Target compounds have been evaluated for their ability to inhibit GSK-3β, by using a 
luminescence assay, and HDAC1, by using fluorimetric assay (Table 9). 
As reported in Table 9, all the synthesized compounds turned out to be good GSK-3β 
inhibitors with an IC50 in the micromolar range of concentration. In particular, the 
inhibitory activity is strictly related to the length of the spacer. The best compound of the 
serie was 27, characterized by a five methylene spacer, with an IC50 of 2.69 ± 0.01 μM. 
Interesting, reducing the length of the spacer we observed a parallel decrease of the 
inhibitory activity, in particular compound  24, characterized by the shorter linker, was the 
least active of the series (IC50 = 19.96 ± 1.76 μM). Considering HDAC1 inhibitory 
activity, the most interesting compound of the series is again 27, which induced, at 5μM, 
an almost completely abolishing of the enzymatic activity. Compounds characterized by 
shorter linkers, such as 24-26, were less potent than compound 27. It is worth to note that 
compound 27 is slightly more active than SAHA (residual activity at 5 μM, 13.49 vs 
27.74). 
 
Table 9: Inhibitory activity of compounds 24-27 against GSK-3β and HDAC1 
Compound GSK-3β IC50 (μM) 
HDAC1 
% residual activity at 5 
μM 
24 19.96 ± 1.76 54.96 
25 n.d. 55.80 
26 4.11 ± 0.01 53.37 
27 2.69 ± 0.01 13.49 
SAHA n.a.a 27.74 
10 20.22 ± 0.40 n.db 
    a not active up to 50 μM; 
  b n.d. not determined. 
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Compound 27 turned out to be the best of the series in terms of inhibition of both targets. 
For this reason, it was selected for further biological evaluations. In particular, to 
investigate its HDAC inhibitory potential in cell, Western blotting analyses were 
performed in neuroblastoma (SH-SY5Y) cell lines. Cells were treated with compound 27 
and its parent compound, SAHA and 10, for 30 h at three different concentrations (0.1, 1 
and 5 μM). From (Figure 56), it could be observed that compound 27 was able to induce 
hyperacetylation of both histone H3 in lysine residues 9 and 14 (H3K9K14ac) and α-
tubulin (Tub-ac), compared to control, although in a less extent compared to the well-
known HDAC inhibitor, SAHA. It is worth to note that such effects are already visible at 
the concentration of 0.1 μM.  
By a closer look to (Figure 56), it appears that compound 27 induces a more significant 
increase of α-tubulin acetylation level compared to H3K9–14ac signal. Since α-tubulin is 
a substrate of HDAC6 and acetylated α-tubulin levels function as a biochemical marker 
for HDAC6 cellular activity, the increase in the level of acetyl-α-tubulin compared to 
H3K9K14ac could be ascribed to an intrinsic selectivity of compound 27 for HDAC6.  
 
 
 
Figure 56: Western blot analyses carried out for the indicated target compounds in SHSY-5Y 
cells after 30 h of treatment. 
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Studies are currently ongoing in order to evaluate the potential toxicity of compound 27, 
its neuroprotective active against different toxic stress (such as ROS and β-amyloid) and 
its effect on neurite outgrowth and synaptic activity in SH-SY5Y neuronal cells. 
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4.7 Conclusion 
 
This study allowed us to discover of new GSK-3 β-HDAC inhibitor as MTDLs endowed 
with different biological activities as anti Alzehimer agents. All the synthesized 
compounds indicated to be good GSK-3β inhibitors with an IC50 in the micromolar range 
of concentration. In particular, the inhibitory activity is strictly related to the length of the 
spacer.The best compound of the serie was 27, characterized by a five methylene spacer, 
with an IC50 of 2.69 ± 0.01 μM. Considering HDAC1 inhibitory activity, the most 
interesting compound of the series is compound 27, which induced, at 5μM, an almost 
completely abolishing of the enzymatic activity. The activity of compound 27 HDAC 
inhibitor is slightly more active than SAHA (residual activity at 5 μM, 13.49 vs 27.74). 
The compound 27 was subsjected for further biological evaluations. In particular, to 
investigate its HDAC inhibitory potential in neuroblastoma (SH-SY5Y) cell lines and the 
results showed that the compound 27 could be ascribed to an intrinsic selectivity of 
compound 27 for HDAC6.  
The compound 27 Studies are currently ongoing in order to evaluate the potential toxicity 
of compound 27, its neuroprotective active against different toxic stress (such as ROS and 
β-amyloid) and its effect on neurite outgrowth and synaptic activity in SH-SY5Y neuronal 
cells. 
The promising results in this study may represent a new GSK-3 β-HDAC inhibitor as 
MTDLs hopefully useful for the Alzehimer treatment, therefore more biological 
investigations for the compound 27 are currently ongoing to evaluate its potential toxicity, 
its neuroprotective active against different toxic stress and its effect on neurite outgrowth 
and synaptic activity in SH-SY5Y neuronal cells. 
 
 
 
  
141 
 
4.8 Experimental Section 
 
Chemistry: 
Melting points were taken in glass capillary tubes on a Buchi SMP-20 apparatus and are 
uncorrected. ESI-MS spectra were recorded on Perkin-Elmer 297 and WatersZQ 4000. 1H 
NMR and 13C NMR were recorded on Varian VRX 200 and 300 instruments. Chemical 
shift are reported in parts per millions (ppm) relative to peak of tetramethylsilane (TMS) 
and spin multiplicities are given as s (singlet), br s (broad singlet), d (doublet), t (triplet), q 
(quartet) or m (multiplet) Although IR spectral data are not included (because of the lack 
of unusual features), they were obtained for all compounds reported, and they were 
consistent with the assigned structures. Chromatographic purifications were performed on 
silica gel columns by flash (Kieselgel 40, 0.040-0.063 mm, Merck) or gravity (Kieselgel 
60, 0.063-0.200 mm, Merck) column chromatography. Reactions were followed by thin 
layer chromatography (TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates 
(60 F254) and then visualized in an iodine chamber or with a UV lamp.The term “dried” 
refers to the use of anhydrous sodium sulfate. 
 
5-Aminoisoindoline-1, 3-dione (81): To a suspension of 4 Nitrophtalimide (5g, 0.026 
mol) in a mixture of glacial acetic acid (20 mL), ethanol (20 mL) and water (10 mL) was 
added reduced iron powder (7.28 g, 0.13 mol). The resulting suspension was exposed to 
ultrasonic irradiation for 2 h at 30 °C monitoring with TLC analysis the progress of 
reaction. The reaction mixture was filtered to remove the iron residue, which was washed 
with ethyl acetate (30 mL). The filtrate was partitioned with 2M KOH and the basic layer 
was further extracted with ethyl acetate (3 x 200 mL). The combined organic extracts 
were washed with brine (2 x 200 mL) and water (3 x 200 mL), dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was finally purified by flash silica 
gel column chromatography, using DCM: MeOH: Ammonium hydroxide (90:10:1) as 
mobile phase. 1H NMR (400 MHz, DMSO-d6, ppm): δ 6.35 (s, 2H), 6.75 (d, J= 8 Hz, 
1H), 6.82 (s, 1H), 7.38 (d, J = 8 Hz, 1H). 
5-Thiocyanatoisoindoline-1, 3-dione (82): In a flask, provided with an inert atmosphere, 
we placed compound 70 (3g; 0.018 mol) dissolved in DCM anhydrous. The resulting 
solution was treated dropwise with a solution of thiocarbonyl dipyridine (4.29 g, 0.018 
mol) in DCM anhydrous. The resulting mixture was left stirring overnight at room 
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temperature, after that it was concentrated under reduced pressure.The crude residue was 
purified by flash silica gel column chromatography using petrolum ether : ethyl acetate 
(70:30) as mobile phase. 1H NMR (400 MHz, CDCl3) δ: 7.600 (d, J = 8.4 Hz, 1H), 7.410 
(d, J = 2.4 Hz, H1), 7.281(q, J = 10 Hz, H1); 13C NMR (101 MHz, CDCl3) δ 168.121, 
167.865, 136.289, 135.509, 134.395, 131.712, 130.011, 124.614, 120460. MS (ESI+)m/z = 
205 (M+H)+. 
General procedure for the synthesis of compounds 83-86: To a suspension of 
appropriate carboxylic acid (3-bromopropanoic acid, 4-bromobutanoic acid, 5-
bromopentanoic acid) 1eq n dimethylformamide, sodium azide (4eq) was added and the 
reaction mixture was stirred at 60 ° C for 16 hours, the mixture was diluted with water and 
acidified with 2N HCl. The acidic layer was further extracted with dichloromethane (3 x 
200 mL). The organic phase was washed with saturated solution of sodium chloride, the 
combined organic extracts were dried (MgSO4) and concentrated under reduced pressure 
to give a yellow oil crude residue. 
General procedure for the synthesis of compounds 87-90: Methylmorpholine was 
added to the appropriate amount of compounds 83-86 dissolved in THF anhydrous. The 
resulting mixture was cooled to -5 °C for 5 minutes before adding isobutyl 
chloroformate.The resulting mixture was left at 0 °C for 10 minutes, then o-
tritylhydroxylamine and N-methylmorpholine were added. The resulting mixture was 
stirred at room temperature for 2 hours. After this time the mixture was poured into 2N 
HCl. The organic layer was washed with water, solution of sodium bircarbonato 5%, 
saturated solution of sodium chloride. The combined organic extracts were dried 
(MgSO4) and concentrated under reduced pressure The crude residue was then purified by 
flash silica gel column chromatography using ethyl acetate, hexane (2.5 : 7.5) as mobile 
phase. 
3-Azido-N-(trityloxy) propanamide (87):1 H NMR (400 MHz, DMSO-d6) δ 7.31(s, 
15H), 2.41 (t, 2H), 1.81 (m, 2H). 
4-Azido-N-(trityloxy) propanamide (88): 1 H NMR (400 MHz, DMSO-d6) δ 7.30 (s, 
15H), 2.32 (t, 2H), 1.6 (m, 2H), 1.43 (m, 2H). 
5-Azido-N-(trityloxy) pentanamide (89):1 H NMR (400 MHz, DMSO-d6) δ 7.29, (s, 
15H), 2.53 (t, 2H), 1.61 (m, 4H), 1.51 (m, 2H).  
6-Azido-N-(trityloxy) hexanamide (90):1 H NMR (400 MHz, DMSO-d6) δ 7.33 (s, 
15H), 2.71 (t, 2H), 1.51 (m, 6H), 1.34 (m, 2H). 
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General procedure for the synthesis of compounds 91-94: The appropriate azide 87-90 
was dissolved in methanol then some drops of water and triphenylphosphine were added. 
The resulting mixture was stirred at room temperature for 16 hours, then concentrated 
under reduced pressure The crude residue was then purified by flash silica gel column 
chromatography, using DCM :MeOH : ammonia aq (90: 10: 1) as mobile phase. 
3-Amino-N-(trityloxy) propanamide (91): 1 H NMR (400 MHz, DMSO-d6) δ 7.28 (dd, 
J =10.3, 3.6 Hz, 15H), 2.35 (t, J = 7.0 Hz, 2H), 1.74 (t, J =7.3 Hz, 2H), 1.26-1.15 (m, 2H), 
1.09-1.00 (m, 2H); 13C NMR (101 MHz, CDCl3) δ: 141.8, 140.8, 129.0, 128.2, 127.8, 
93.2, 38.9, 31.5, 30.2, 26.3. 
4-Amino-N-(trityloxy) propanamide (92): 1 H NMR (400 MHz, DMSO-d6) δ 7.29 (s, 
15H), 2.67 (t, 2H), 2.31 (t, 2H), 1.9 (m, 2H); 13C NMR (101 MHz, CDCl3) δ168.09, 
147.92, 147.52, 146.99, 129.2, 127.98, 126.03, 99.34, 43.87, 31.15, 29.94. 
5-Amino-N-(trityloxy) pentanamide (93):1 H NMR (400 MHz, DMSO-d6) δ 7.30 (s, 
15H), 2.43 (t, J = 6.8 Hz, 2H), 1.75 (t, J = 7.0 Hz, 2H), 1.27-1.02 (m, 6H), 0.98-0.87 (m, 
2H); 13C NMR (101 MHz, DMSO-d6) δ 170.7, 142.9, 129.4, 127.9, 127.8, 92.1, 41.9, 
33.3, 32.4, 28.7, 26.5, 25.3. 
6-Amino-N-(trityloxy)hexanamide (94):1 H NMR (400 MHz, DMSO-d6) δ 7.38-7.15 
(m, 15H), 2.46 (t, J = 5.3 Hz, 2H), 1.75 (t, J = 7.2 Hz, 2H), 1.32-1.21 (m, 2H), 1.20-1.01 
(m, 6H), 0.99-0.88 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ: 170.6, 143.0, 129.4, 128, 
127.8, 92.1, 55.4, 42.0, 33.6, 29.1, 28.8, 26.7, 25.2. 
General procedure for the synthesis of compounds 95-98: To a solution of compound 
82 (150 mg, 0.734 mmol) in dichloromethane 0.734 mmol of appropriate amine (91-94) 
were added, and 0.734 mmol of triethylamine. The resulting mixture was stirred at room 
temperature for 16 hours, then concentrated under reduced pressure The crude residue was 
purified by flash silica gel column chromatography using ethyl acetate: petroleum ether 
(8: 2), as mobile phase. 
3-(3-(1,3-Dioxoisoindolin-5-yl) thioureido)-N-(trityloxy) propanamide (95): 1H-NMR 
(400 MHz, DMSO-d6) δ 11.43 (s, 1H), 10.32 (d, 1H), 8.19 (d, 2H), 7.95 (t, 1H), 7.29 (s, 
15H), 6.97 (s, 1H), 3.57 (t, 2H), 2.61 (t, 2H). 
4-(3-(1,3-Dioxoisoindolin-5-yl) thioureido)-N-(trityloxy) butanamide (96): 1H-NMR 
(400 MHz, DMSO-d6) δ 11.54 (s, 1H), 10.6 (s, 1H), 8.38 (d, 2H), 7.78 (t, 1H), 7.34 (s, 
15H), 7.56 (s, 1H), 3.8 (d, 2H), 2.54 (t, 2H), 1.87-1.93 (m, 2H). 
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5-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-(trityloxy) pentanamide (97): 1H-NMR 
(400 MHz, DMSO-d6) δ 12.01 (s, 1H), 11.1 (s, 1H), 8.26 (d, 2H), 7.69(t, 1H), 7.27 (s, 
15H), 7.49 (s, 1H), 3.68 (d, 2H), 2.48 (t, 2H), 1.57-1.54 (m, 4H). 
6-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-(trityloxy) hexanamide (98): 1H-NMR 
(400 MHz, DMSO-d6) δ 11.19 (s, 1H), 10.10 (d, 1H), 8.16 (t, 2H), 7.72 (t, 1H), 7.26 (s, 
15H), 3.36 (d, 2H), 1.80(d,2H), 1.42(m, 4H), 1.1(m,2H). 
General procedure for the synthesis of compounds 24-27: The appropriate compound 
(95-98) was dissolved in dichloromethane then trilfuoroacetic acid was added; the mixture 
was stirred at room temperature for few minutes then trietilsilan dropwise was added. The 
resulting mixture was stirred at room temperature for 12 hours, then concentrated under 
reduced pressure The crude residue was purified by flash silica gel column 
chromatography, using DCM:MeOH (9.5:0.5) as mobile phase. 
3-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-hydroxypropanamide (24): 1H-NMR 
(400 MHz, DMSO-d6) δ 11.45 (s, 1H), 10.77 ( s, 1H), 9.08 (s. 1H), 8.12 (s, 2H), 7.65 (t, 
1H), 7.23 (s, 1H), 7.03 (s, 1H), 3.86 (t, 2H), 2.13 (t, 2H);  13C NMR (101 MHz, DMSO-
d6) δ 178.32, 171.21, 167.19, 167.03, 140.72, 131.9, 130.65, 127.45, 126.92, 123.29, 
43.87, 34.8; MS (ESI+) m/z = 308.3 (M+H)+. 
4-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-hydroxybutanamide (25): 1H-NMR (400 
MHz, DMSO-d6) δ 11.43 (s, 1H), 10.57 ( s, 1H), 10.1 (s. 1H), 8.23 (s, 2H), 7.76 (t, 1H), 
7.19 (s, 1H), 7.0 (s, 1H), 3.59 (t, 2H), 3.25 (t, 2H), 1.86- 1.76 (m, 2H);  13C NMR (101 
MHz, DMSO-d6) δ 179.42, 170.31, 167.24, 167.17, 139.82, 133.64, 131.35, 127.35, 
127.02, 122.52, 45.19, 31.48, 26.71; MS (ESI+) m/z = 322.34 (M+H)+. 
5-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-hydroxypentanamide (26): 1H-NMR 
(400 MHz, DMSO-d6) δ 11.76 (s, 1H), 10.32 ( s, 1H), 9.98 (s. 1H), 8.27 (s, 2H), 7.9 (t, 
1H), 7.25 (s, 1H), 7.13(s, 1H), 3.74 (t, 2H), 2.65-2.54 (m, 2H), 1.61- 1.59 (m, 4H);  13C 
NMR (101 MHz, DMSO-d6) δ 178.92, 169.48, 166.28, 166.08, 140.19, 132.94, 130.95, 
127.85, 126.92, 121.92, 43.17,32.98, 29.71, 23.8; MS (ESI+) m/z = 336.37 (M+H)+. 
6-(3-(1,3-Dioxoisoindolin-5-yl)thioureido)-N-hydroxyhexanamide (27): 1H-NMR (400 
MHz, DMSO-d6) δ 12.06 (s, 1H), 11.12 ( s, 1H), 10.65 (s. 1H), 8.37 (s, 2H), 7.53 (t, 1H), 
7.47 (s, 1H), 7.24(s, 1H), 3.64 (t, 2H), 2.75-2.64 (m, 2H), 1.53- 1.39 (m, 6H);  13C NMR 
(101 MHz, DMSO-d6) δ 179.32, 168.51, 167.47, 166.17, 141.67, 134.83, 131.18, 127.37, 
127.1, 121.92, 45.96,33.04, 29.83, 27.8, 23.84; MS (ESI+) m/z = 350.38 (M+H)+. 
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Chapter 5. DNA as target: Topoisomerases structures 
 
5.1 Introduction to cancer therapy  
 
Cancer is the name given to a collection of related diseases when some of the body’s cells 
begin to divide without stopping and spread rapidly into surrounding tissues. These 
abnormal cells able to grow beyond their usual boundaries pervade adjoining parts of the 
body and spreading to other tissues. Cancer developed in different tissues of the body and 
has many distinct types which differ substantially in their behavior and response to 
treatments. 
Cancer is one of the central causes of death worldwide, besides infectious diseases, 
malnutrition and cardiac diseases; the global cancer burden is continuously rising, mainly 
due to the permanent growth of the world’s population and the proceeding ageing, 
especially in more developed countries. Another reason is the increasing adoption of 
cancer associated behaviors particularly smoking, physical inactivity, and unhealthy diets. 
In 2008, about 12.7 million cancer cases and 7.6 million cancer deaths were estimated to 
have occurred worldwide, there of 3.4 million incidences and 1.8 million deaths in 
Europe, it is expected that cancer related deaths will at least double by 2030 (World 
Cancer Report 2008). 
Cancer developments associated with multiple genetic changes, losing the control over a 
number of processes and mutations which may be produced in any cell division event due 
to faulty DNA replication or repair. Cells become abnormal and lose its monitoring on 
growth, old or damaged cells survive when they should die, and new cells form when they 
are not needed. These extra cells can divide uncontrollably forming growths called 
tumors. There are two different types of tumor: benign and malignant.  
Benign tumors: This type can form in different part of the body but remain confined in the 
initial location, unlike malignant ones, do not spread into or invade nearby tissues, they 
can form in different part of the body and grow slowly When removed, they usually do 
not grow back, (Cooper M.G 2000).  
Malignant tumors:  These tumers are able to spread into and invade nearby tissues. These 
tumors grow in different body sites from the primary tumor, they can pass more easily to 
distant places in the body through bloodstream or lymphatic channels and form new 
147 
 
tumors far from the original tumor, these secondary tumors may grow, invade and damage 
nearby tissues, and spread again, forming the so called “metastasis”. 
Due to the abundance of diverse cancer types, there are different treatment options, based 
on the location, stage of the cancer, the presence of metastases, and also the patient’s 
general health state. Among the most common methods currently in uses are: surgery, 
radiation therapy, chemotherapy, bone-marrow transplantation, immune and hormonal 
therapy. 
Chemotherapy is the most common form of cancer treatment and includes the use of 
chemical entities able to alter the cell division process, through the infliction of serious 
damages to DNA or proteins triggering the apoptosis process or stopping their 
proliferation. Chemotherapeutics are classified into four different categories based on 
their target or the nature of their composition. These groups include: cytotoxics, 
biological, targeted therapeutics, and hormonal therapeutics. Cytotoxics were discovered 
primarily due to their abilities to kill cells. The cytotoxic targets include: DNA 
(intercalating, alkylating and cross-linking agents); DNA synthesis pathway enzymes 
(antimetabolites); tubulin (antimictrotubule and tubulin polymerizing agents); and 
topoisomerases (topoisomerases I and II). 
Topoisomerases are the major enzymes that maintain the topology and the integrity of 
DNA. Inhibition of topoisomerase interferes with all central DNA processing steps such 
as replication, transcription, translation and recombination. 
 
5.2 DNA-Topoisomerases  
 
DNA topoisomerases are crucial enzymes found in all living organisms. The first 
topoisomerase was discovered in 1971 (Wang 1971), and it was described by its ability in 
eliminating the negative superhelical coils from DNA. The functions of topoisomerase 
enzymes are related with DNA processingand are commonin all living cells. 
Topoisomerases control the steady-state level of DNA supercoiling, which in role 
facilitate DNA-protein interaction and block the damaging excess of supercoils. These 
DNA associated enzymes have fundamental role in replication, transcription, 
recombination and other various cellular processes (Wang 2002, Gellert 1981, Nitiss, 
1994, Postow 1999). Topoisomerase enzymes are able to modify the conformation of 
DNA by a complex catalytic action includes DNA strand cleavage, strand passage and 
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relegation of the DNA strands. Topoisomerases are classified mainly in two distinct 
classes, characterized by their mechanistic and physical properties (Champoux 2001). 
Type I topoisomerase makes transient single strand breaks in DNA, facilitating regulated 
rotation about the nick before rejoining; this action does not need an energy cofactor, 
instead this energy can be obtained from that stored in the supercoiled DNA.  
Depending on the type of DNA adduct these topoisomerases can be classified in type I 
and type II. The type I enzymes are further subdivided into type IA and type IB. 
Type IA topoisomerases (containing eukaryotic topoisomerase IIIa and IIIb) establish a 
transient covalent phosphotyrosine attach to the 5' end of DNA; this type has the ability to 
relax only negatively supercoiled DNA and for this reaction needs magnesium and a 
single stranded stretch of DNA. Type IB topoisomerases (including eukaryotic 
topoisomerase I and mitochondrial topoisomerase I) linkage to the 3' DNA terminus and 
this type is able to relax both positively and negatively supercoiled DNA with the same 
effectiveness and the reaction does not demand a single-stranded region of DNA or metal 
(Wang 1996, Champoux 1998). 
The type II enzymes modify the topology by causing an intact helix pass through a 
transient double-stranded break in the DNA backbone (Berger 1998). It requires ATP for 
the catalytic function. During cleavage, two tyrosines attack opposite stands of the DNA 
duplex establishing covalent 5'-phosphotyrosine linkages to DNA in a four base pair 
stagger. 
Topoisomerases I and II have become main targets for cancer therapy and they have been 
extensively studied over the past three decades for the rational drug design of novel anti-
cancer drugs. In this introduction, we will describe briefly the role of the different types of 
these enzymes and their pharmacological significance. 
 
5.2.1 DNA topoisomerases I 
Topoisomerases I are enzymes that involve DNA topology by transiently cleaving one 
DNA strand at a time. The gene for human topoisomerase I has been mapped to 
chromosome 20q12-13.2 (Juanet al 1988). The topoisomerase I gene is 100 kD a 
monomeric protein, it needs phosphorylation for full activity. This protein is abundant in 
the nucleus and also exists in nucleoplasm and mitochondria (Fleischmann 1984, Zhang 
2001m Christensen 2002). 
Stewart has revealed by proteolysis studies that the enzyme consists of four main 
domains: a highly charged 24kDa NH2-terminal domain, a positively charged 56 kDa core 
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domain, 7kDa linker domain, and 6 kDa COOH-terminal domain which includes the 
catalytic Tyr-723. Recently, the determination of X-ray crystal structure of human 
topoisomerase I explained the mechanism of action of this enzyme on DNA (Stewart 
1998, Redinbo 1998), and helped in understanding the structure-activity relationships for 
several topoisomerases inhibitors (Staker2002). 
 
 
 
Figure 57: The domain structure of human TopI (a) Ribbon diagram of the co-crystal structure of 
humanTop1 containing a 22 base pair duplex oligonucleotide (pdb entry 1K4T) (b) The domain 
structure of human Top1 is depicted on a linear representation of the protein (Staker 2002). 
 
Based on the polarity of the strand cleavage, topoisomerase I is divided into 
topoisomerase IA and IB (Wang 2002). Topoisomerase IA composes a transient 5-
phospho-tyrosine covalent intermediate, results a free 3-OH strand and enhances passage 
of the intact strand through the broken strand; topoisomerase IB gives a 3-phospho-
tyrosine covalent intermediate, forms a free 5-OH strand and leaves the broken strand free 
to rotate around the intact strand. The two types have the same chemistry function in 
breaking the phosphodiester bond, the enzyme attacks a phosphodiester bond of the DNA 
with a tyrosyl group building a covalent bond on one side of the break and forming a free 
hydroxylated strand on the other side. And the reverse reaction through attacking the 
phosphotyrosine by the free hydroxylated strand retrieves the phosphodiester bond and 
releases the enzyme for next catalytic cycle.  
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Topoisomerase I exists throughout the cell cycle and its function differs less 
thantopoisomerase II during the cell cycle (Heck 1988, Romig 1990), therefore, 
topoisomerase I emerged as an attractive target for drug design in anticancer therapy. 
 
5.2.2 DNA topoisomerases II 
Topoisomerase II has main role in DNA replication and transcription. Topoisomerase II 
also plays a major role in chromosome condensation and separation during mitosis. 
Studies have revealed that topoisomerase II partly involves in forming chromosome 
scaffold and nuclear matrix. (Adolphs 1977). Topoisomerases II insert double-strand 
breaks in a DNA duplex and impose the passing of another duplex through this break 
before resealing it. The cleavage-religation reaction is similar to those carried out by type 
I topoisomerases with the formation of a covalent bond between a tyrosine from the 
enzyme and the DNA phosphate, but the transient link is exclusively formed with the 5’-
end of the DNA breaks. These enzymes have different function in cell cycle regulation 
and nuclear isolation (Austin 1995).  
 
 
 
 
Figure 58: Topoisomerase II organization and structure (a) Linear domain map, from N- to C-
terminus (top to bottom), highlighting the relative position of conserved functional elements (b) 
Top2 ATP as a domain and DNA binding and cleavage (Classen 2003, Schmidt 2010). 
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Topoisomerase IIα is expressed in the proliferating compartments of all tissues and is 
detectable in both the cell nucleus and cytoplasm, whereas topoisomerase IIβ is a 180 kDa 
protein localized ubiquitously and is centralize in the nucleoli and nucleoplasm (Turley 
1997). During mitosis, topoisomerase IIα links completely to the mitotic chromatin, while 
topoisomerase IIβ distributes into the cytosol (Meyer 1997). The levels of topoisomerase 
IIβ are stable over the cell cycle and topoisomerase IIα levels are closely associated to the 
proliferation state of the cell, being increased 2-3 fold during G2/M phases and in rapidly 
proliferating cells (Turley 1997). All types of topoisomerases II are ATP-dependent 
multimeric enzymes with a dyad symmetry. Each unit of the enzyme is consisted of an 
ATP-binding domain and a catalytic breakage- religation domain including covalent 
bond-forming tyrosine residue. 
 
5.3 Topoisomerases as Targets for Cancer Chemotherapy 
 
Several anticancer agents currently in clinical use are known to exert their cytotoxic 
function partly by targeting DNA topoisomerase enzymes. Since cancer cells in several 
cases are highly proliferative cells, and topoisomerases are implicated in replication and 
proliferation processes, the levels of these enzymes are higher in growing cancer cells 
comparing to normal cells, making these enzymes an important target for potential 
selective anticancer drugs. 
Topoisomerase levels are increased in several haematological malignancies and solid 
tumours comparing to normal cells. Studies revealed that the levels of topoisomersase1 
are 14-16 folds higher in cancerous colon tissue than in normal tissue (Giovanella 1989). 
Overexpression of topoisomerase isoforms has been found in human cervix, lung and 
colon cancers; furthermore, it was reported a content of l0-fold more elevate in 
topoisomerase I and topoisomerase II in ovarian tumors tissues compared to the 
corresponding normal tissues (McLeod 1994, Vander Zee 1991). The inhibition of 
topoisomerases in tumour cells will result in unwinding, strand separation and inhibition 
of the reproduction of DNA. Concerning drugs which selectively interact with the 
topoisomerase enzymes, the increased levels of these enzymes were found in many 
tumors and this finding could provide a higher level of tumor cell selectivity that would 
reduce the DNA damage to normal tissue and minimize side effects. 
The interaction of topoisomerases with DNA can be broken down into several key steps: 
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1. Enzyme-DNA-binding; 
2. Cleavage of DNA by transesterification from the phosphodiester DNA backbone to an 
enzyme catalytic tyrosine resulting in a covalent bond between the protein and one 
terminus of the DNA nick (3' terminus in the case of topo I and 5' terminus of a double-
strand break in the case of topoisomerase II); 
3. DNA strand passage; 
4. Resealing of the DNA break concerted with the release of the topoisomerase enzyme; 
5. ATP hydrolysis (topoisomerase II only). 
Topoisomerase targeting agents can function at any of the above steps resulting in 
inhibition or poisoning of the enzyme leading to cell death. Topoisomerase inhibitors are 
classified based on the mechanism of action into two classes: catalytic inhibitors and 
topoisomerase poisons.  
Topoisomerase poisons stabilize the drug-DNA-enzyme ternary complex, inhibiting 
religation of the cleaved strand(s). Subsequent with a cut in the replication complexes, 
transient topoisomerase mediated breaks become permanent double-stranded breaks, 
triggering apoptosis cascade (cell death syndrome) (Fortune 2000). 
Catalytic inhibitors act by binding directly to topoisomerases, binding to DNA modifing 
its structure so that it can no longer be recognized by the topoisomerases or by trapping 
topoisomerase II in a closed clamp form prohibiting the enzyme turnover (Roca 1994). 
 
5.3.1 Anticancer topoisomerase I-targeted drugs 
The potent anticancer activity of Camptothecin was known before the discovery of 
Topoisomerase Ias its molecular target. It was studied extensively in the Cancer 
Chemotherapy National Service Center of the National Cancer Institute during the 1960s 
(DeWys 1968). Camptothecin sodium salt proved remarkable activity and enhances the 
survival time in mice bearing several lymphocytic leukemias (Gallo 1971). Camptothecin 
sodium salt was demonstrated to be efficient in patients with advanced disseminated 
melanoma or gastrointestinal malignancies (Gottlieb 1970, Moertel 1972). Unfortunately, 
its use was discontinued in the 1970s because of severe side effects (Wall 1995), included 
myelo-suppression, vomiting, diarrhea, and hemorrhagic cystitis, and currently it is used 
as reference for clinical investigation for Topoisomerase I-targeted agents. 
Camptothecin derivatives such as topotecan (Hycamtin®) and irinotecan (Camptosar®, 
Campto®) are water-soluble and endowed with fewer side effects. All the camptothecin 
derivatives are potent topoisomerase I poisons by stabilizing the transient covalent DNA-
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topoisomerase I cleavage complex and prohibition religation of the cleaved DNA strand. 
Although camptothecins proved to be potent anticancer, all of them suffer from clear 
limitation (Pommier 2009) in addition to their dose-limiting toxicity, which prohibits the 
use of curative doses (Giovanella BC 1989). Camptothecins are rapidly inactivated due 
totheinstability of the six-membered lactone ring; indeed, at physiological pH 
camptothecins are in equilibrium with their inactive (carboxylate) form.  
Topotecan (Hycamtin) received FDA approval in 1996 for the treatment of advanced 
metastatic ovarian carcinoma and since then it has been approved for the use in the 
treatment of small cell lung cancer. This drug has the shortest plasma half-life of any 
camptothecin reported to date and requires repeated daily administration or continuous 
infusion over several days or even weeks (Takimoto 1998). Irinotecan, (CPT-11, 
Camptosar), was approved by FDA for the treatment of colorectal and gastro esophageal 
malignancies (Makeyev 2012). 
 
 
 
Figure 59: Chemical structures of Topisomerase I inhibitors 
 
Homocamptothecin family resulted from modulating the metabolically liable 
camptothecin lactone ring from a six-membered α-hydroxylactone to a seven-membered 
α-hydroxylactone ring (Troconiz 2006). Diflomotecan BN80915 is the 
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difluorohomocamptothecin derivative, which is one of the most potent topoisomerase 
inhibitors (Lansiaux 2001). In preclinical safety studies, the dose-limiting toxicity of 
diflomotecan was myelosuppression (Troconiz2006). Currently diflomotecan is under 
Phase II clinical trial for advanced metastatic cancer, SCLC malignancy. 
Gimatecan (ST1481) is a seven-position modified lipophilic camptothecin derivative 
developed to provide rapid uptake and increase accumulation and stabilize the 
Topoisomerase I-DNA-drug ternary complex compared with conventional camptothecins 
(Perego 2006), Gimatecan showed good tolerability in Phase I clinical trial. Gimatecan 
has undergone Phase II clinical study in advanced epithelial ovarian, fallopian tube, and 
peritoneal cancers, advanced breast cancer, malignant glioma, and metastatic colorectal 
cancer (Mariani 2006, Hu 2009); these studies have demonstrated that gimatecan is active 
as a single agent with bone marrow suppression as serious side effect. 
Edotecarin from Indolocarbazolesgroup, is a derivative of NB-506 that as a 
Topoisomerase Iinhibitor enhances single-strand DNA cleavage more efficiently than NB-
506 or camptothecin (Long 2002, Yamada 2006, Hurwitz 2007). 
The indenoquinoline NSC314622 was found as a potential Topoisomerase inhibitor by 
COMPARE analysis from 48-h cytotoxicity screening of the NCI 60-cell line panel (Long 
2000). 
Other indenoisoquinoline derivatives, such as LMP400 (NSC 743400) and LMP776 (NSC 
725776), have been developed (Pommier 2009) and are currently in Phase 1 of clinical 
trial for Lymphomas Malignancy. 
Nitidine and fagaronine are benzo- phenanthridine alkaloids, they are active as 
Topoisomerase I inhibitors (Zee 1975, Janin 1993). An extensive structure-activity 
relationship was proceeded around the dibenzo[c,h][1,6]naphthyridin-6-one family of 
compounds, which displayeda potent Top1-targeting activity and suitable pharmaceutical 
properties (Zhu 2006, Satyanarayana 2008), Many of these compounds that had unique 
DNA cleavage site selectivity were potent cytotoxic agents in cancer cell lines. 
 
5.3.2 Anticancer topoisomerase II-targeted drugs  
Topoisomerase II catalyzes the transient breaking and rejoining of two strands of double 
helix allowing the strands to pass through one to another. With this mechanism 
topoisomerase II monitors and changes the topologic state of DNA in nucleus. 
Topoisomerase II inhibitors act by inhibiting the catalytic activity of the enzyme, thus 
blocking its action. Such ligands can inhibit religation of broken DNA by stabilizing 
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topoisomerase II DNA cleavage complex while others can act by accelerating the enzyme 
rate to produce more DNA cleavage and inhibition of ligation. (Baldwin 2005) These 
mechanisms of topoisomerase II inhibitors lead to permanent double strand cuts in DNA 
and promote apoptotic signals resulting in efficient death of cancer cells. The mechanism 
of action of topoisomerase II is summarized in Figure 61. 
 
 
 
Figure 60: Chemical structures of FDA-approved drugs targeting topoisomerase II. 
 
Anthracyclines (Figure 60) is the largest group of approved topoisomerase II targeting 
agents including doxorubicin (approved in 1974), daunomycin (approved in 1979), 
idarubicin, aclarubicin and Mitoxantrone. Several earlier clinical studies with 
anthracyclines revealed that anthracyclines target topoisomerase II and produce free 
radicals that damage DNA and other cellular structures, as well as acting as DNA 
intercalating agents. Some anthracyclines have substantial antitumor activity, but they 
also have significant toxicity, including cardiotoxicity. Aclarubicin is distinct among 
approved anthracyclines because it is topoisomerase II catalytic inhibitor. Mitoxantrone, 
is a potent intercalating agent that has been approved for leukemia and advanced hormone 
refractory prostate cancer, and it is the only topoisomerase II poison that has been 
approved for a non-cancer indication, such as multiple sclerosis (Giovannoni 2011). 
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Similar to the other anthracyclines, mitoxantrone can lead to substantial cardiotoxicity, 
albeit to a lesser extent than antracyclines (Hamzehloo 2006). 
Etoposide is an effective antimitotic and antineoplastic agent which has been in clinical 
use for over two decades; it was derived from Podophyllotoxins. After preclinical studies 
and clinical trials for over 20 years, Food and Drug Administration (FDA) approved its 
use in clinics for cancer chemotherapy (Baldwin 2005). 
 
 
 
Figure 61: Mechanism of action of topoisomerase II: (1) Topoisomerase II-DNA binding (2) pre-
strand passage DNA cleavage-religation equilibrium (3) ATP binding and DNA strand passage (4) 
post-strand passage DNA cleavage-religation equilibrium (5) ATP hydrolysis and gate opening (6) 
DNA release and enzyme turnover (Baldwin 2005).  
 
Studies revealed that the main mechanism of action of etoposide is astopoisomerase II 
inhibitors and it is considered a DNA poison.  The binding of etoposide to topoisomerase 
II is reversible; hence the longevity of the efficiency of etoposide is due to the exposure 
time (Hainsworth 1995). Beside topoisomerase II inhibition action, some metabolic 
products of etoposide bind directly to DNA leading to single strand cuts (Baldwin 2005). 
Teniposide is another topoisomeraseII inhibitor, which is almost 10-fold more cytotoxic 
than etoposide.It is usedin thetreatment of refractory childhood acute lymphoblastic 
leukaemia, even ifits used is limited,due to a higher incidence of hypersensitivity 
reactions.The appearance of myelosuppression represents the dose limiting toxicity for 
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this compound and some studies reported of acute non-lymphocytic leukaemia with l1q23 
chromosomal abnormalities in patients treated with teniposide (Stine 1997). 
Doxorubicin (Adriamycine®) is isolated from Streptomyces peucetiusvar. 
caesius,(Arcamone 1969), it acts with three direct mechanisms:the first mechanism of 
action is intercalation between base pairs interfering with DNA and RNA synthesis. 
Doxorubicin also acts as a topoisomerase II inhibitor. Similar to Etoposide, through 
stabilizing the enzyme DNA cleavage complex, leading to the accumulation of double 
strand breaks which are signals for programmed cell death (Swift 2006), another 
mechanism for doxorubicin is the interaction with cell membrane, by binding to 
negatively charged phospholipids, result in modification of the membrane dynamics and 
fluidity (Speelmans 1994). Doxorubicin is a widely used chemotherapeutic in clinic in 
various cancers, such as breast, ovarian, bladder, lung, thyroid and gastric cancers, as well 
as neuroblastoma, lymphoma, leukemia, Kaposi's sarcoma and in the treatment of breast 
cancer. 
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5.4 Drug design  
 
Tryptanthrin (indolo-[2, 1-b]-quinazoline-6, 12-Dione) is a weakly basic alkaloid which 
consists of a quinazoline ring fused to an indole moiety with carbonyl groups in the 6- and 
12-positions. Tryptanthrin has been isolated from numerous natural sources; in particular, 
it was first isolated from Isatistinctoria and it also produced by culture of the yeast 
Candida lipolytica, fungi such as Schizophyllum communeand Leucopaxilluscerealisand 
from various plants such as Polygonumtinctorium. A number of biological actions have 
been associated to tryptanthrin and its derivatives. For instance, tryptanthrin is reported to 
have antifungal, antimicrobial (Honda, G  2010), tuberculostatic and antimalaria activity 
(Bhattacharjee, A. K 2002). Furthermore, it is able to inhibit enzymes such as COX-2, 5-
lipooxigenase (5-LOX)and nitric oxide (NO) synthase.It is worth to note that tryptanthrin 
showsantiproliferative effects in leukemia cell lines and in vivo in intestinal and lung 
cancers. Indeed, tryptanthrin targetsindoleamine 2,3-dioxygenase (IDO-1) and suppresses 
angiogenesis by reducing the expression of angiogenic factors. 
Recently, Liang and coworkers reported about a tryptanthrin derivative, 
benzo[b]tryptanthrin, as Topoisomerase inhibitor. In particular, this compound is able to 
inhibit both topoisomerase I and II and shows cytotoxic activity in colon cancer cell lines 
(Liang JL 2012). Further studies on this compound revealed that it behaves as 
topoisomerase II inhibitor by binding to the ATP-binding pocket in competition with ATP 
(Kyu 2015). Moreover, benzo[b]tryptanthrin is able to induce a down-regulation of 
multidrug resistance protein 1 (MDR1) inadriamycin resistant breast cancer cell line 
(MCF7) and induces apoptosis through activation of caspase-3 and PARP. 
Aim of the present work was the development of 7- and 9-substitued Tryptanthrin 
derivatives with the aim of increasing the affinity towards topoisomerase II and the 
cytotoxic activity. 
In particular, we chose to introduce different substituents characterized by different 
chemical physical properties, such as: 
- morpholine: compounds 30 and 36; 
- N,N-dimethylehtlendiamine: compound 31 and 37;  
- diethylenamine: compounds 32 and 38; 
- N-methylpiperazine: compounds 33 and 39; 
- aminoethanol: compounds 34 and 40; 
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- piperidine: compounds 35 and 41. 
In particular, all these substituents are characterized by a basic function which can 
contribute to improve the water solubility of tryptanthrin derivatives as well as their 
ability to interact with the targets reported above through ionic bonds of the protonated 
amine functions with ionized acidic residues, located in target structures. 
 
 
 
Figure 62: Drugs design leading to compounds 30-41. 
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5.5 Methods 
 
5.5.1 Synthesis:  
Bromoisatin 101 and 102 were synthesized following the procedure reported in literature 
(Panagiotis 2004). (Scheme 1) The Bromotryptanthrin 103 and 104 were synthesized by 
reaction of 101 and 102 with isatoicanhydrinein toluene followed by 
addition of Et 3 N and stirring under reflux for 5 hours (Scheme 2 and 3). 
The compound  30-41 were obtained by the reaction of the two isomers of Bromoisatine 
(101-102) (Scheme 1) with isatoic anhydride, to provide the trypthantrine derivatives 103 
and 104 (Scheme 2). These bromo derivatives were reacted with different amines (scheme 
4 and 5). By dissolving 103 and 104 in DMF then adding the corresponding amine, and 
leave the reaction stirring under reflux for 3 hours. 
 
5.5.2 Biology: 
The synthesized compounds are currently under biological evaluation towards 
topoisomerases I  and II. 
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Scheme 5: 
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5.6 Conclusion 
 
In this work we designed and synthesised 12 new compounds as potentionl 
topoisomerases inhibitors for cancer treatment.The new compounds were acheived by 
linking several different positively charged chains on tryptanthrin, with the aim of 
increasing the affinity towards topoisomerases. The synthesized compounds are currently 
under biological evaluation towards topoisomerases I and II. 
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5.7 Experimental Section 
 
Chemistry: 
Melting points were taken in glass capillary tubes on a Buchi SMP-20 apparatus and are 
uncorrected. ESI-MS spectra were recorded on Perkin-Elmer 297 and WatersZQ 4000. 1H 
NMR and 13C NMR were recorded on Varian VRX 200 and 300 instruments. Chemical 
shift are reported in parts per million (ppm) relative to peak of tetramethylsilane (TMS) 
and spin multiplicities are given as s (singlet), br s (broad singlet), d (doublet), t (triplet), q 
(quartet) or m (multiplet) Although IR spectral data are not included (because of the lack 
of unusual features), they were obtained for all compounds reported, and they were 
consistent with the assigned structures. Chromatographic separations were performed on 
silica gel columns by flash (Kieselgel 40, 0.040-0.063 mm, Merck) or gravity (Kieselgel 
60, 0.063-0.200 mm, Merck) column chromatography. Reactions were followed by thin 
layer chromatography (TLC) on Merck (0.25 mm) glass-packed precoated silica gel plates 
(60 F254), and then visualized in an iodine chamber or with a UV lamp.The term “dried” 
refers to the use of anhydrous sodium sulfate. 
 
General procedure for the synthesis of (101-102): compounds1 01-102 have been 
synthesized following the procedure reported in literature (Panagiotis 2004). 
4-Bromoindoline-2,3-dione (100): Solid orange,1H NMR (400 MHz, CDCl3) δ 11.17 (s, 
1 H), 7.46 (dd, 1 H), 7.22 (dd, 1 H), 6.89 (dd, 1 H). 
6-Bromoindoline-2,3-dione (101): Red solid, 1H NMR (400 MHz, CDCl3) δ 11.10 (s, 
1H), 7.47 (d, 1 H), 7.26 (dd, 1 H), 7.08 (d, 1 H). 
General procedure for the synthesis of (103-104): A solution of Bromoisatin 101-102 
(1 mmol), isatoic anhydride (1 mmol), and Et3N (5mmol) in toluene (5 mL) was refluxed 
for 5 hand concentrated under reduced pressure. The crude residue was then purified by 
flash silica gel column chromatography with DCM/ MeOH, (97:3), as mobile phase. 
8-Bromo-6H-indeno[2,1-b]quinoline-6,11(10bH)-dione (103): yellow solid, 1H NMR 
(400 MHz, CDCl3) δ 7.84 (d, 1H), 7.56- 7.49 (m, 2H), 7.32- 7.26 (m, 4H), 4.21 (s, 1H). 
9-Bromo-6H-indeno[2,1-b]quinoline-6,11(10bH)-dione (104): Dark yellow solid, 1H 
NMR (400 MHz, CDCl3) δ 7.76 (t, 1H), 7.89- 7.69 (m, 4H), 7.43- 7.32 (m, 2H), 4.27 (s, 
1H). 
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General procedure for the synthesis of (30-35): To a solution of appropriate 103-104 
(0.611 mmol) in DMF, the appropriate amine (0.611 mmol) was added, The resulting 
mixture was stirred at room temperature for 3 hours, then concentrated under reduced 
pressure The crude residue was then purified by flash silica gel column chromatography 
using DCM:MeOH,(98:2) as mobile phase. 
7-Morpholinoindolo[2,1-b]quinazoline-6,12-dione (30): 1H NMR (400 MHz,DMSO), δ 
8.39 ( d, J = 8 Hz, 1H), 7.96 (d, J = 8 Hz, 1H), 7.97(d, J = 8 Hz, 1H), 7.80 (t, J = 8  Hz, 
1H), 7.62 (t, J = 8 Hz, 1H), 7.54 (t, J = 8 Hz, 1H), 6.81 (d, J = 8 Hz, 1H), 3.98-3.95 (m, 
4H), 3.48-3.42 (m, 4H);  13C NMR (101 MHz, DMSO) δ 178.33, 158.08, 151.53, 147.18 
,146.81, 145.05, 139.08, 134.85, 130.22, 129.46, 127.38, 123.34, 115.28, 110.51, 108.73, 
66.69, 51.07. ESI-MS (m/z): 334 [M +H].+ 
7-((2-(Dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione (31): 1H 
NMR (400 MHz, DMSO), δ 8.277 (d, J = 7.6 Hz, 1H), 7.911(d, J = 6 Hz, 1H), 7.69 (t, J = 
7.6 Hz, 1H), 7.623 (t, J = 9.6 Hz, 2H), 7.545 (t, J = 6.8 Hz, 1H), 6.769 (d, J = 8.8 Hz, 1H), 
3.497-3.467 (m, 2H), 2.611-2.504 (m, 2H), 2.301 (s, 6H ); 13C NMR (101 MHz, DMSO) δ 
178.4, 152.9, 144.47, 142.8, 140.7, 107.04, 138.57, 129.04, 127.12, 121.76, 120.57, 
115.05, 113.39, 104.5, 57.83, 44.49, 44.39, 43.87; ESI-MS (m/z): 335.15 [M +H].+ 
7-(Diethylamino)indolo[2,1-b]quinazoline-6,12-dione (32): 1H NMR (400 MHz, 
DMSO), δ 8.337 (d, J =8 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H),7.732 (t, J = 9.6 Hz, 1H), 7.595 
(d, J = 7.6 Hz, 1H), 7.533 (t, J = 8 Hz, 1H), 7.386 (t, J = 8.8 Hz, 1H), 6.512 (d, J = 8.4 Hz, 
1H), 3.383- 3.329 (m , 4H), 1.318- 1.237 (m, 6H); 13C NMR (101 MHz, DMSO) δ 181.3, 
147.31, 146.97, 146.14 , 145.77, 144.56, 141.73, 132.45, 131.69, 123.12, 123.009, 116.09, 
115.31, 113.45, 109.62,45.87, 43.76, 11.6, 10.9,  ESI-MS (m/z): 320 [M +H].+ 
7-(4-Methylpiperazin-1-yl) indolo[2,1-b]quinazoline-6,12-dione (33): 1H NMR (400 
MHz, DMSO), δ 8.42 (d, J = 8 Hz, 1H), 8.14 (d, J = 8 Hz, 1H), 7.99 (d, J = 8 Hz, 1H), 
7.98 (t, J = 8 Hz, 1H), 7.64-7.60 (m, 2H), 6.81 (d, J = 8 Hz, 1H), 3.66-3.49 (m, 4H), 3.06 
(s, 4H), 2.64 (s, 3H); 13C NMR (101 MHz, DMSO) δ 179.87, 153.84, 145.32, 145.19, 
141.34, 139.41, 129.87, 127.97, 127.12, 122.35, 121.05, 115.23, 114.36, 108.62, 108.13, 
54.89, 53.92, 50.12, 49.75, 44.32, ESI-MS (m/z): 347 [M +H].+  
7-((2-Hydroxyethyl)amino)indolo[2,1-b]quinazoline-6,12-dione (34): 1H NMR (400 
MHz, DMSO), δ 8.244 (d, J = 7.6 Hz, 1H), 8.88 (d,  J= 6.4 Hz, 2H), 7.786 (t,  J = 8 Hz, 
1H), 7.588 (t, J = 6 Hz, 1H),  7.507 (t, J = 7.6 Hz, 1H), 751 (d, J = 7.6 Hz, 1H), 4.981 (t, J 
= 8 Hz, 1H), 3.648-3.609 (m, 2H), 3.449-3.329 (m, 2H); 13C NMR (101 MHz, DMSO) δ 
180.729, 158 .086 ,149.509 ,146.936 ,146.453 ,144.847 ,139.943 ,135.274 ,129.974 
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,129.644 ,127.218 ,123.282 ,110.850 ,105.579 ,103.878 ,59.853 ,44.826; ESI-MS (m/z): 
308 [M +H].+ 
7-(Piperidin-1-yl)indolo[2,1-b]quinazoline-6,12-dione (35): 1H NMR (400 MHz, 
DMSO) δ 8.24 (d, 1H), 7.91-7.76 (m, 2H), 7.63- 7.53 (m, 3H), 6.9 (t, 1H), 4.13 (t, 2H), 
2.98 (s, 3H), 1.64- 1.53 (m, 2H), 1.12 (t, 3H); 13C NMR (101 MHz, DMSO) δ 181.86, 
161.47, 152.6, 152, 148.53, 146.7, 136.87, 133.62, 128.12, 127.9, 126.43, 121.33, 119.86, 
114.65, 113.96, 59.54, 43.94, 20.86, 12.74;  ESI-MS (m/z): 319.14 [M +H]+ 
9-Morpholinoindolo[2,1-b] quinazoline-6,12-dione (36): 1H NMR (400 MHz, DMSO) 
δ 8.409 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8 Hz, 1H), 7.89-7.82 (m, 2H), 7.69 (t, J = 8.4 Hz, 
1H), 7.73 (d, J = 8 Hz, 1H), 3.94-3.88 (m, 4 H), 3.59- 3.50 (m , 4H); 13C NMR (101 MHz, 
DMSO) δ 179.45, 154.56, 148.84, 145.36, 142.93, 140.15, 133.88, 127.53, 126,44, 
122,63, 121.63, 120.73, 115.93, 102.42, 103.14, 63.88, 62.74, 51.20, 50.96;  ESI-MS 
(m/z): 334 [M +H].+ 
9-((2-(Dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione (37): 1H NMR 
(400 MHz, DMSO) δ 8.32 (t, 1H), 7.96- 7.65 (m, 2H), 7.65 (d, 1H), 7.43 (s, 1H), 6.85 (s, 
1H), 6.74 (d, 1H), 6.12 (s, 1H), 3.61 (t, 2H), 2.78 (t, 2H), 2.31 (s, 6H); 13C NMR (101 
MHz, DMSO) δ 187.5, 162.55, 155.86, 152.09, 148.75, 146.7, 135.8, 133.65, 128.98, 
128.21, 120, 108.76, 106.87, 105.98, 62.9, 48.12, 47.97, 47.64; ESI-MS (m/z): 334.38 [M 
+H].+ 
9-(Diethylamino)indolo[2,1-b]quinazoline-6,12-dione (38): 1H NMR (400 MHz, 
DMSO) δ 8.309 (d, J = 7.6 Hz, 1H), 7.937 (d, J = 7.6 Hz, 1H), 7.734 (t, J = 8 Hz, 1H), 
7.66 (t, J = 9.2 Hz, 2H),7.53 (t, J = 7.2 Hz, 1H), 6.485 (d, J = 11.2 Hz, 1H), 3.526-3.472 
(m, 4H), 1.270-1.222 (m , 6H); 13C NMR (101 MHz, DMSO) δ: 181.65, 155.46, 151.32, 
145.42, 1441.68, 143.21, 129.72, 127.31, 122.08, 124.32, 121.03, 115.90, 103.37, 101.46, 
102.66, 44.37, 43.96, 12.98, 12.01; ESI-MS (m/z): 320 [M +H].+ 
9-(4-Methylpiperazin-1-yl)indolo[2,1-b]quinazoline-6,12-dione (39): Red solid, 1H 
NMR (400 MHz, DMSO) δ 8.39 (d, J = 7.6 Hz, 1H), 8.051 (t, J = 8.4 Hz, 1H), 7.84 (d, J = 
7.6 Hz, 1H), 7.744 (d, J = 8.8 Hz, 1H), 7.651 (t, J = 14.8 Hz, 1H), 7.00 (t, J = 8 Hz,1H), 
6.702 (d, J = 8.4 Hz, 1H), 3.641- 3.541 (m, 4H), 2.60- 2.55 (m, 4H), 2.38 (s, 3H); 13C 
NMR (101 MHz, DMSO) δ: 179.85, 155.32, 151.43, 147.79, 142.13, 141.35, 129.89, 
127.45, 122.97, 122.76, 121.28, 115.50, 103.65, 102.66, 102.17, 52.11, 51.90, 47.44, 
46.53, 42.59; ESI-MS (m/z): 347 [M +H].+ 
9-((2-Hydroxyethyl)amino)indolo[2,1-b]quinazoline-6,12-dione (40): Red solid; 1H 
NMR (400 MHz, CDCl3) δ 10.01 (s, 1H), 8.23 (d, 1H), 7.75-7.87 (d, 2H), 7.71 (d, 1H), 
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7.43 (t, 1H), 6.87 (s, 1H), 5.73 (t, 1H), 4.8 (s, 1H), 3.51- 3.65 (m, 4H); 13C NMR (101 
MHz, CDCl3) δ: 188.01, 161.86, 153.97, 150.76, 146.96, 145.92, 133.52, 129.94, 127, 
126.86, 126.21, 121, 109.87, 107,12, 105.67, 62.03, 43.90; ESI-MS (m/z): 307.31 [M 
+H].+ 
9-(Piperidin-1-yl)indolo[2,1-b]quinazoline-6,12-dione (41): Red solid (71%);1 H NMR 
(400 MHz, CDCl3) δ 8.34 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 7.8 Hz, 2H), 7.79 (d, J = 7.4 
Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.59 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 8.6 Hz, 1H), 3.57 
(s, 4H), 1.71 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 177.7; 158.6,  156.8, 149.1, 146.9, 
134.8, 130.1, 129.2, 127.7, 127.1, 123.3, 110.8, 110.2, 100.5, 48.6, 25.5, 24.2; ESI-MS 
(m/z): 331.1321[M +H].+ 
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